WO2018067618A1 - Hpv-specific binding molecules - Google Patents

Hpv-specific binding molecules Download PDF

Info

Publication number
WO2018067618A1
WO2018067618A1 PCT/US2017/055005 US2017055005W WO2018067618A1 WO 2018067618 A1 WO2018067618 A1 WO 2018067618A1 US 2017055005 W US2017055005 W US 2017055005W WO 2018067618 A1 WO2018067618 A1 WO 2018067618A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
cdr
amino acid
tcr
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/055005
Other languages
English (en)
French (fr)
Inventor
James SISSONS
Cameron Brandt
Alexandra CROFT
Allen Ebens
Haley PEPER
Dean Y. TOY
Brian Belmont
Stephen Goldfless
Yue Jiang
Timothy Johnstone
David KOPPSTEIN
Hieu Nguyen
Blythe SATHER
Sonia TIMBERLAKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Juno Therapeutics Inc
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020197012569A priority Critical patent/KR20190062505A/ko
Priority to US16/338,452 priority patent/US11072660B2/en
Priority to EP17787729.7A priority patent/EP3519433A1/en
Priority to CN201780065335.3A priority patent/CN110139873A/zh
Priority to JP2019517952A priority patent/JP2019536437A/ja
Priority to CA3037086A priority patent/CA3037086A1/en
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Priority to AU2017338827A priority patent/AU2017338827B2/en
Priority to MX2019003768A priority patent/MX2019003768A/es
Publication of WO2018067618A1 publication Critical patent/WO2018067618A1/en
Anticipated expiration legal-status Critical
Priority to US17/384,589 priority patent/US20210363258A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Definitions

  • the present disclosure relates in some aspects to binding molecules, such as those that recognize or bind a peptide epitope of human papilloma virus (HPV) 16 E6 or E7 in the context of a major histocompatibility complex (MHC) molecule.
  • the present disclosure relates to T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize a peptide epitope of HPV 16 E6 or E7.
  • TCRs T cell receptors
  • the present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.
  • HPV Human papillomavirus
  • HPV 16 is a common virus among human subjects that, in some cases, can be transmitted by skin-to-skin contact and is a common sexually transmitted virus.
  • Certain subtypes of HPV, such as HPV 16 can lead to certain cancers, such as cervical and other cancers.
  • cancer can be associated with expression of the HPV oncoproteins E6 and/or E7.
  • HPV E6 and/or E7 may contribute to cancer progression by targeting tumor suppressor signaling pathways that are involved in cellular growth control.
  • Certain therapeutic agents targeting HPV 16-expressing cells or cancers are available, but improved agents against HPV 16 are needed. Provided are embodiments that meet such needs.
  • a binding molecule containing a first variable region containing a complementarity determining region 3 (CDR-3) containing an amino acid sequence set forth in any of SEQ ID NOs: 138, 144, 147, 153, 159, 163, 167, 173, 175, 301, 304, 308, 478, 493, 505, 511, 523, 539, 555, 572, 588, 600, 612, 624, 638, 650, 662, 679, 694, 712, 729, 744, 762, 776, 788, 802, 818, 832, 846, 858, 870, 882, 896, 911, 926, 940, 952, 964, 976, 988, or 1002, or a CDR3 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 117, 119, 121, 123, 125, 127, 295, 297, 2
  • the first variable region further contains a complementarity determining region 1 (CDR-1) containing an amino acid sequence set forth in any of SEQ ID NOs: 136, 142, 151, 157, 161, 165, 171, 302, 306, 537, 570, 677, 692, 710, 727, 742, 760, 800, 816, 909, 938, or 1000, or a CDR-1 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 117, 119, 121, 123, 125, 127, 295, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, 676, 691, 709, 726, 741, 759, 775, 787, 799, 815, 830, 845, 857, 869, 881, 895
  • CDR-1 complementarity
  • the second variable region contains a
  • CDR-1 complementarity determining region 1
  • CDR-1 complementarity determining region 1
  • a CDR-1 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 118, 120, 122, 124, 126, 128, 296, 298,300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, 685, 700, 718, 735, 750, 768, 781, 793, 808, 824, 839, 851, 863, 875, 887, 901, 917, 931, 945, 957, 969, 981, 993, or 1008; and/or a complementarity determining region 2 (CDR-2) containing an amino acid sequence set
  • the binding molecule is an antibody or antigen- binding fragment thereof. In some of any such embodiments, the binding molecule is a T cell receptor (TCR) or antigen-binding fragment thereof.
  • TCR T cell receptor
  • TCR T cell receptor
  • Va variable alpha
  • ⁇ variable beta
  • said Va region contains the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 117, 119, 121, 123, 125, 127, 295, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, 676, 691, 709, 726, 741, 759, 775, 787, 799, 815, 830, 845, 857, 869, 881, 895, 908, 925, 937, 951, 963, 975, 987, or 999, or an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 9
  • said Va region contains a complementarity determining region 3 (CDR-3) containing the amino acid sequence
  • said Va region contains a complementarity determining region 1 (CDR-1) containing the amino acid sequence ⁇ 2 ⁇ 3 ⁇ 4 ⁇ 5 ⁇ 6 ⁇ 7 (SEQ ID NO: 243), wherein Xi is T, D, N, or V; X 2 is I or S; X 3 is S, D, A, P, or M; X 4 is G, Q, P, or null; X5 is T, S, I, or F; X 6 is D, Y,Q, T, or S; and X 7 i s Y, G, N, or Q; or a complementarity determining region 2 (CDR-2) containing the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 X 7 X 8 (SEQ ID NO: 247), wherein Xi is G, Q, I, V, or M; X 2 is L, S, Q, Y, F, T, or G; X 3
  • CDR-1 complementarity determining region
  • the binding molecule or TCR or antigen-binding fragment thereof binds to or recognizes a peptide epitope of human papillomavirus (HPV) 16 E6 or E7 in the context of an MHC molecule. In some aspects, the binding molecule or TCR or antigen-binding fragment thereof binds to or recognizes a peptide epitope of human
  • HPV papillomavirus
  • the peptide epitope derived from HPV 16 E6 is or contains the amino acid sequence set forth in any of SEQ ID NOs: 232-234.
  • the peptide epitope derived from HPV 16 E6 is or contains E6(29-38)
  • TIHDIILECV (SEQ ID NO:233).
  • said Va region contains a complementarity determining region 3 (CDR-3) containing the amino acid sequence
  • said Va region contains a complementarity determining region 1 (CDR-1) containing the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 X 7 (SEQ ID NO: 240), wherein Xi is T, D, or N; X 2 is I, or S; X 3 is S, D, or A; X 4 is G, Q, P, or null; X 5 is T, S, or I; X 6 is D, Y, or Q; and X 7 i s Y, G, N, or Q; or a complementarity determining region 2 (CDR-2) containing the amino acid sequence X 1 X 2 X 5 X 4 X 5 X 5 X 7 X 8 (SEQ ID NO: 244), wherein Xi is G, Q, I, or V; X 2 is L, S, Q, or Y; X 3 is T, G, or S; X 4 is Y, S
  • XiX 2 HX 4 X 5 (SEQ ID NO: 252), wherein Xi is S or M; X 2 is G, E, D, or N; X 4 is V, N, or E; and X 5 is S, R, N, or Y; or a complementarity determining region 2 (CDR-2) containing the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 (SEQ ID NO: 255), wherein Xi is F or S; X 2 is Q, Y, or V; X 3 is N, D, or G; X 4 is E or V; X 5 is A, K, or G; and X 6 is Q, M, or T.
  • CDR-2 complementarity determining region 2
  • said Va region contains a complementarity determining region 3 (CDR-3) containing an amino acid sequence set forth in any of SEQ ID NOs: 138, 144, 147, 163, 167 173, 304, 308, 478, 493, 505, 511, 523, 539, 555, 572, 588, 600, 612, 624, 638, 650, 662, or 679, or a CDR3 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, or 676; and/or a Vp region containing a CDR-3 (CDR-3) containing an amino acid sequence set forth in any of SEQ ID NOs: 138, 144, 147, 163, 167 173, 304, 308, 478,
  • CDR-3 complementarity determining region 3 containing an amino acid sequence set forth in any of SEQ ID NOs: 141, 146, 150, 164, 170, 174, 305, 309, 486, 499, 517, 531, 548, 563, 581, 594, 606, 618, 630, 644, 656, 670, or 686, or a CDR3 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 122, 124 126, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, or 685.
  • CDR-3 complementarity determining region 3
  • the Va region further contains a complementarity determining region 1 (CDR-1) containing an amino acid sequence set forth in any of SEQ ID NOs: 136, 142, 161, 165, 171, 302, 306, 537, 570, or 677, or a CDR- 1 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123, 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, or 676; and/or a complementarity determining region 2 (CDR-2) containing an amino acid sequence set forth in any of SEQ ID NOs: 137, 143, 162, 166, 172, 303, 307, 538, 571, or 678, or a CDR-2 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113,
  • the ⁇ region contains a complementarity determining region 1 (CDR-1) containing an amino acid sequence set forth in any of SEQ ID NOs: 139, 145, 148, 168, 484, 546, 561, 579, or 668, or a CDR-1 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 122, 124, 126, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, or 685; and/or a CDR-1 containing an amino acid sequence set forth in any of SEQ ID NOs: 139, 145, 148, 168, 484, 546, 561, 579, or 668, or a CDR-1 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 122, 124, 126, 298, 300, 483, 498, 498
  • CDR-2 complementarity determining region 2 containing an amino acid sequence set forth in any of SEQ ID NOs: 140, 149, 169, 485, 547, 562, 580, or 669, or a CDR-2 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 122, 124, 126, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, or 685.
  • CDR-2 complementarity determining region 2
  • said Va region contains a complementarity determining region 1 (CDR-1) containing an amino acid sequence set forth in any of SEQ ID NOs: 136, 142, 161, 165, 171, 302, 306, 537, 570, or 677; a complementarity determining region 2 (CDR-2) containing an amino acid sequence set forth in any of SEQ ID NOs: 137, 143,
  • CDR-3 complementarity determining region 3 containing an amino acid sequence set forth in any of SEQ ID NOs: 138, 144, 147,
  • said ⁇ region contains a complementarity determining region 1 (CDR-1) containing an amino acid sequence set forth in any of SEQ ID NOs: 139, 145, 148, 168, 484, 546, 561, 579, or 668; a complementarity determining region 2 (CDR-2) containing an amino acid sequence set forth in any of SEQ ID NOs: 140, 149 or 169; and/or a complementarity determining region 3 (CDR-3) containing an amino acid sequence set forth in any of SEQ ID NOs: 141, 146, 150, 164, 170, 174, 305, 309, 486, 499, 517, 531, 548, 563, 581, 594, 606, 618, 630, 644, 656, 6
  • said Va region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 136, 137, and 138, respectively, and said ⁇ region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 139, 140, and 141, respectively; said Va region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 142, 143, and 144, respectively, and said ⁇ region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 145, 140, and 146, respectively; said Va region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 136, 137, and 147, respectively, and said ⁇ region contains a CDR-1, CDR-2,
  • said Va region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively containing the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123, 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, or 676; and/or said Vp region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively containing the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a ⁇ region amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 122, 124, 126, 298, 300, 483, 498,
  • the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 111 and 112, respectively; the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 113 and 114, respectively; the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 115 and 116, respectively; the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 121 and 122, respectively; the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 123 and 124, respectively; the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 125 and 126, respectively; the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 297 and 298, respectively; the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 299 and 300, respectively.
  • the binding molecule or TCR or antigen-binding fragment thereof binds to or recognizes a peptide epitope of human papillomavirus (HPV) 16 E7 in the context of an MHC molecule.
  • a T cell receptor (TCR) or antigen-binding fragment thereof containing an alpha chain containing a variable alpha (Va) region and a beta chain containing a variable beta ( ⁇ ) region, wherein the TCR or antigen-binding fragment thereof binds to or recognizes a peptide epitope of human papillomavirus (HPV) 16 E7 in the context of an MHC molecule.
  • the peptide epitope derived from HPV 16 E7 is or contains the amino acid sequence set forth in any of SEQ ID NOs: 235-239. In some aspects, the peptide epitope derived from HPV 16 E7 is or contains E7(l l-19) YMLDLQPET (SEQ ID NO:236).
  • said Va region contains a complementarity determining region 3 (CDR-3) containing the amino acid sequence X1X2SX X5X6X7X8 9 10 11 (SEQ ID NO: 249), wherein Xi is A or V; X 2 is E or V; X 4 is I or R; X 5 is R or D; X 6 is G or N; X 7 is F or Y; X 8 is N or Q; X9 is V or N; X10 is L or F; and Xn is H or V; and/or said ⁇ region contains a complementarity determining region 3 (CDR-3) containing the amino acid sequence AX2TX 4 RX 6 X 7 YX 9 XioXii (SEQ ID NO: 259), wherein X 2 is S or I; X 4 is T or D; X 6 is S or T; X 7 is S or N; X9 is E or G; X10 is Q
  • said Va region contains a complementarity determining region 1 (CDR-1) containing the amino acid sequence XiSX 3 X 4 X5X6 (SEQ ID NO: 241), wherein Xi is D or V; X 3 is S, or P; X 4 is S or F; X5 is T or S; and X 6 i s Y or N; or a complementarity determining region 2 (CDR-2) containing the amino acid sequence
  • XiX 2 X 3 X 4 X 5 X 6 X7 (SEQ ID NO: 245), wherein Xi is I or M; X 2 is F or T; X 3 is S or F; X 4 is N or S; X5 is M or E; X 6 is D or N; and X 7 is M or T; and/or said ⁇ region contains a
  • CDR-1 complementarity determining region 1
  • CDR-2 complementarity determining region 2
  • said Va region contains a complementarity determining region 3 (CDR-3) containing the amino acid sequence set forth in any of SEQ ID NOs: 153, 159, 301, 694, 712, 729, 744, 762, 776, 788, 802, 818, 832, 846, 858, 870, 882, 896, 911, 926, 940, 952, 964, 976, 988, or 1002, or a CDR3 contained within the amino acid sequence set forth in any of SEQ ID NOs: 117, 119, or 295; and/or said ⁇ region contains a complementarity determining region 3 (CDR-3) containing an amino acid sequence set forth in any of SEQ ID NOs: 156, 160, 703, 721, 736, 753, 769, 782, 794, 809, 825, 840, 852, 864, 876, 888, 902, 919, 932, 946, 958, 970,
  • CDR-2 complementarity determining region 2
  • the ⁇ region contains a complementarity determining region 1 (CDR-1) containing the amino acid sequence set forth in SEQ ID NO: 154; and/or a complementarity determining region 2 (CDR-2) containing the amino acid sequence set forth in SEQ ID NO: 155.
  • CDR-1 complementarity determining region 1
  • CDR-2 complementarity determining region 2
  • said Va region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 151, 152, and 153, respectively, and said ⁇ region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 154, 155, and 156, respectively; said Va region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 157, 158, and 159, respectively, and said ⁇ region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 154, 155, and 160, respectively; or said Va region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 151, 152, and 301, respectively, and said ⁇ region contains a CDR-1, CDR
  • said Va region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively containing the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in any of SEQ ID NOs: 117, 119, or 295; and/or said ⁇ region contains a
  • CDR-1 complementarity determining region 1
  • CDR-2 complementarity determining region 2
  • CDR-3 complementarity determining region 3
  • the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 117 and either 118 or 296, respectively; the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 119 and 120, respectively; or the Va and ⁇ regions include the amino acid sequences of SEQ ID NOs: 295 and either 118 or 296, respectively.
  • the peptide epitope derived from HPV16 E7 is or contains E7(86-93) TLGIVCPI (SEQ ID NO:235).
  • said Va region contains a complementarity determining region 3 (CDR-3) containing the amino acid sequence set forth in SEQ ID NO: 175; and/or said ⁇ region contains a complementarity determining region 3 (CDR-3) containing the amino acid sequence set forth in any of SEQ ID NO: 178.
  • the Va region contains a complementarity determining region 1 (CDR-1) containing the amino acid sequence set forth in SEQ ID NO: 142; and/or a complementarity determining region 2 (CDR-2) containing the amino acid sequence set forth in SEQ ID NO: 143.
  • said ⁇ region contains a complementarity determining region 1 (CDR-1) containing an amino acid sequence set forth in SEQ ID NOs: 176; and/or a complementarity determining region 2 (CDR-2) containing an amino acid sequence set forth in SEQ ID NOs: 177
  • said Va region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 142, 143, and 175, respectively
  • said ⁇ region contains a CDR-1, CDR-2, and CDR-3, containing the amino acid sequences of SEQ ID NOs: 176, 177, and 178, respectively.
  • said Va region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively containing the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in SEQ ID NO: 127; and/or said ⁇ region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively containing the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a ⁇ region amino acid sequence set forth in SEQ ID NO: 128.
  • CDR-1 complementarity determining region 1
  • CDR-2 CDR-2
  • a CDR-3 respectively containing the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a ⁇ region amino acid sequence set forth in SEQ ID NO: 128.
  • Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 127 and 128, respectively.
  • the alpha chain further contains an alpha constant (Ca) region and/or the beta chain further contains a beta constant ⁇ ) region.
  • the Ca and C ⁇ regions are mouse constant regions.
  • said Ca region contains the amino acid sequence set forth in SEQ ID NO: 262, or a sequence of amino acids that has at least 90% sequence identity thereto; and/or said CP region contains the amino acid sequence set forth in SEQ ID NO: 263, or a sequence of amino acids that has at least 90% sequence identity thereto.
  • the Ca and CP regions are human constant regions.
  • said Ca region contains the amino acid sequence set forth in any of SEQ ID NOs: 212, 213, 215, 217, 218, 220, or 524, or a sequence of amino acids that has at least 90% sequence identity thereto; and/or said CP region contains the amino acid sequence set forth in any of SEQ ID NOs: 214, 216, 631, or 889, or a sequence of amino acids that has at least 90% sequence identity thereto.
  • the TCR or antigen-binding fragment thereof containing one or more modifications in the a chain and/or ⁇ chain such that when the TCR or antigen-binding fragment thereof is expressed in a cell, the frequency of mispairing between the TCR a chain and ⁇ chain and an endogenous TCR a chain and ⁇ chain is reduced, the expression of the TCR a chain and ⁇ chain is increased and/or the stability of the TCR a chain and ⁇ chain is increased.
  • the one or more modifications is a replacement, deletion, or insertion of one or more amino acids in the Ca region and/or the C ⁇ region.
  • the one or more modifications contain replacement(s) to introduce one or more cysteine residues that are capable of forming one or more non-native disulfide bridges between the alpha chain and beta chain.
  • the TCR or antigen-binding fragment thereof contains a Ca region containing a cysteine at a position corresponding to position 48 with numbering as set forth in SEQ ID NO: 212, 213, 215, 217, 218, 220, or 524, and/or a C ⁇ region containing a cysteine at a position corresponding to position 57 with numbering as set forth in SEQ ID NO: 214, 216, 631, or 889.
  • said Ca region contains the amino acid sequence set forth in any of SEQ ID NOs: 196, 198, 200, 201, 203, or 525, or a sequence of amino acids that has at least 90% sequence identity thereto containing one or more cysteine residues capable of forming a non-native disulfide bond with the beta chain; and/or said C ⁇ region contains the amino acid sequence set forth in any of SEQ ID NOs: 197, 199, 632, or 890, or a sequence of amino acids that has at least 90% sequence identity thereto that contains one or more cysteine residues capable of forming a non-native disulfide bond with the alpha chain.
  • the TCR or antigen-binding fragment thereof is encoded by a nucleotide sequence that has been codon-optimized.
  • a) said alpha chain contains the amino acid sequence set forth in any of SEQ ID NOs: 18, 28, 38, 68, 78, 88, 287, 291, 473, 488, 500, 506, 518, 532, 550, 565, 583, 595, 607, 619, 633, 645, 657, or 672, a sequence of amino acids that has at least 90% sequence identity thereto; or an amino acid sequence encoded by the nucleotide sequence set forth in any of SEQ ID NOs: 20, 30, 40, 70, 80, 90, 100, 202, 219, 389, 430, 1019, 1021, 1023, 1025, 1027, 1029, 1031, 1033, 1035, 1037, 1039, 1041, 1043, 1045 or a nucleotide sequence that has at least 90% sequence identity thereto; and/or said beta chain contains an amino acid sequence set forth in any of SEQ ID NOs: 22, 32, 42, 72,
  • the alpha and beta chains contain the amino acid sequences of SEQ ID NOs: 78 and 82, respectively; the alpha and beta chains contain the amino acid sequences of SEQ ID NOs: 88 and 92, respectively, the alpha and beta chains contain the amino acid sequences of SEQ ID NOs: 287 and 289, respectively, or the alpha and beta chains contain the amino acid sequences of SEQ ID NOs: 291 and 293, respectively.
  • a) said alpha chain contains the amino acid sequence set forth in any of SEQ ID NOs: 19, 29, 39, 69, 89, 288, 292, 474, 489, 501, 507, 519, 533, 551, 566, 584, 596, 608, 620, 634, 646, 658, or 673, a sequence of amino acids that has at least 90% sequence identity thereto that contains one or more cysteine residues capable of forming a non-native disulfide bond with the beta chain; or an amino acid sequence encoded by the nucleotide sequence set forth in any of SEQ ID NOs: 10, 11, 21, 31, 41, 71, 81, 91, 101, 1097, 1099, 1101, 1103, 1105, 1107, 1109, 1111, 1113, 1115, 1117, 1119, 1121, 1123, 1125, 1127, or a nucleotide sequence that has at least 90% sequence identity thereto and encodes an alpha chain that
  • a) said alpha chain contains the amino acid sequence set forth in SEQ ID NOs: 48, 58, 283, 687, 705, 722, 737, 755, 771, 783, 795, 811, 826, 841, 853, 865, 877, 891, 904, 921, 933, 947, 959, 971, 983, or 995, a sequence of amino acids that has at least 90% sequence identity thereto; or an amino acid sequence encoded by the nucleotide sequence set forth in any of SEQ ID NOs: 50, 60, 183, 1049, 1051, 1055, 1057, 1059, 1061, 1063, 1065, 1067, 1069, 1071, 1073, 1075, 1077, 1079, 1081, 1083, 1085, 1087, 1089, 1091, 1093, 1095, 1225, 1226, or a nucleotide sequence that has at least 90% sequence identity thereto; and/or said beta chain contains
  • a) said alpha chain contains the amino acid sequence set forth in SEQ ID NOs: 49, 59, 284, 688, 706, 723, 738, 756, 772, 784, 796, 812, 827, 842, 854, 866, 878, 892, 905, 922, 934, 948, 960, 972, 984, or 996, a sequence of amino acids that has at least 90% sequence identity thereto that contains one or more cysteine residues capable of forming a non-native disulfide bond with the beta chain; or an amino acid sequence encoded by the nucleotide sequence set forth in any of SEQ ID NOs: 12, 51, 61, 1129, 1131, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147, 1149, 1151, 1153, 1155, 1157, 1159, 1161, 1163, 1165, 1167, 1169, 1171, 1173, 1175, 11
  • alpha and beta chains contain the amino acid sequences of SEQ ID NOs: 59 and 63, respectively; or the alpha and beta chains contain the amino acid sequences of SEQ ID NOs: 284 and 286, respectively.
  • a) said alpha chain contains the amino acid sequence set forth in SEQ ID NO: 98, a sequence of amino acids that has at least 90% sequence identity thereto; or an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 100, or a nucleotide sequence that has at least 90% sequence identity thereto; and/or said beta chain contains an amino acid sequence set forth in SEQ ID NO: 102, a sequence of amino acids that has at least 90% sequence identity thereto; or an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 104, or a nucleotide sequence that has at least 90% sequence identity thereto; or b) the alpha and beta chains contain the amino acid sequences of SEQ ID NO:
  • a) said alpha chain contains the amino acid sequence set forth in SEQ ID NO: 99, a sequence of amino acids that has at least 90% sequence identity thereto that contains one or more cysteine residues capable of forming a non-native disulfide bond with the beta chain; or an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 101, or a nucleotide sequence that has at least 90% sequence identity thereto and encodes an alpha chain that contains one or more cysteine residues capable of forming a non-native disulfide bond with the beta chain; and/or said beta chain contains an amino acid sequence set forth in SEQ ID NO: 103, a sequence of amino acids that has at least 90% sequence identity thereto that contains one or more cysteine residues capable of forming a non-native disulfide bond with the alpha chain; or an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 105, or
  • the TCR or antigen-binding fragment thereof further contains a signal peptide.
  • the signal peptide contains the amino acid sequence set forth in any of SEQ ID NOs: 181, 184, 187, 189, 190, 192, 193, 310, 311, 182, 185, 186, 188, 191, 194, 487, 540, 549, 564, 573, 582, 671, 680, 695, 704, 713, 730, 745, 754, 763, 770, 803, 810, 819, 834, 903, 912, 920, 1003, or 1011.
  • the binding molecule or TCR or antigen-binding fragment thereof is isolated or purified or is recombinant. In some of any such embodiments, the binding molecule or TCR or antigen-binding fragment thereof is human. [0049] In some of any such embodiments, the binding molecule or TCR or antigen-binding fragment thereof is monoclonal. In some of any such embodiments, the binding molecule or TCR or antigen-binding fragment thereof is single chain. In some of any such embodiments, the binding molecule or TCR or antigen-binding fragment thereof contains two chains.
  • the antigen- specificity is at least partially CD8- independent.
  • the MHC molecule is an HLA-A2 molecule.
  • nucleic acid molecule encoding the binding molecule or the TCR or antigen-binding fragment thereof according to any one of the embodiments described above.
  • the nucleic acid molecule containing a nucleotide sequence encoding an alpha chain and/or a nucleotide sequence encoding a beta chain wherein said nucleotide sequence encoding an alpha chain contains the sequence selected from the group consisting of residues 61-816 of SEQ ID NO: 20, residues 58-804 of SEQ ID NO: 30, residues 61-825 of SEQ ID NO: 40, residues 64-813 of SEQ ID NO: 50, residues 64-816 of SEQ ID NO: 60, residues 58-807 of SEQ ID NO: 70, residues 61-825 of SEQ ID NO: 80, residues 67-831 of SEQ ID NO: 90, residues 58-801 of SEQ ID NO: 100, or a sequence having at least 90% sequence identity thereto;
  • the nucleic acid molecule containing a nucleotide sequence encoding an alpha chain and/or a nucleotide sequence encoding a beta chain contains the sequence selected from the group consisting of residues 67-825 of SEQ ID NO: 10, residues 58-813 of SEQ ID NO: 11, residues 64-822 of SEQ ID NO: 12 residues 61-825 of SEQ ID NO: 21, residues 58-813 of SEQ ID NO: 31, residues 61-834 of SEQ ID NO: 41, residues 63-822 of SEQ ID NO: 51, residues 64-825 of SEQ ID NO: 61, residues 58-816 of SEQ ID NO: 71, residues 61-834 of SEQ ID NO: 81, residues 67-840 of SEQ ID NO: 91, residues 58-810 of SEQ ID NO: 101, or a sequence having at least 90% sequence identity
  • the nucleotide sequence encoding the alpha chain and the nucleotide sequence encoding the beta chain are separated by a nucleotide sequence encoding an internal ribosome entry site (IRES) or a peptide sequence that causes ribosome skipping.
  • the nucleotide sequence encoding the alpha chain and the nucleotide sequence encoding the beta chain are separated by a peptide sequence that causes ribosome skipping.
  • the peptide that causes ribosome skipping is a P2A or T2A peptide and/or contains the sequence of amino acids set forth in SEQ ID NO: 204 or 211.
  • nucleic acid containing the nucleotide sequence set forth in any of SEQ ID NOs: 13, 14, 15, 26, 36, 46, 56, 66, 76, 86, 96, 106, 432-472, or a nucleotide sequence having at least 90% sequence identity thereto.
  • the nucleic acid is synthetic.
  • the nucleic acid is cDNA.
  • the vector is an expression vector.
  • the vector is a viral vector.
  • the viral vector is a retroviral vector.
  • the viral vector is a lentiviral vector.
  • the lentiviral vector is derived from HIV- 1.
  • an engineered cell containing the vector according to any one of the embodiments described above is provided herein.
  • an engineered cell containing the binding molecule or the TCR or antigen-binding fragment thereof according to any one of the embodiments described above is heterologous to the cell.
  • an engineered cell containing a heterologous TCR or antigen- binding fragment thereof that binds to or recognizes a peptide epitope of human papillomavirus (HPV) 16 E6 in the context of an MHC molecule, wherein the TCR or antigen-binding fragment thereof does not bind to or recognize the epitope E6(29-38) containing the amino acid sequence TIHDIILECV (SEQ ID NO: 233).
  • the TCR or antigen-binding fragment thereof that binds to or recognizes a peptide epitope of human papillomavirus (HPV) 16 E6 in the context of an MHC molecule is or contains the sequence set forth in SEQ ID NO: 232 or SEQ ID NO: 234.
  • HPV human papillomavirus
  • the peptide derived from HPV16 E7 is or contains the sequence set forth in any of SEQ ID NOs: 235-239.
  • the peptide derived from HPV16 E7 is or contains the sequence set forth in SEQ ID NO: 236.
  • the TCR or antigen-binding fragment thereof is a TCR or antigen-binding fragment thereof according to any one of the embodiments described above.
  • the peptide derived from HPV16 E7 is or contains the sequence set forth in SEQ ID NO:235.
  • the TCR or antigen-binding fragment thereof is a TCR or antigen-binding fragment thereof according to any one of the embodiments described above.
  • the engineered cell is a T cell.
  • the T cell is CD8+. In some aspects, the T cell is CD4+.
  • the engineered cell is a cell line. In some embodiments, the engineered cell is a primary cell obtained from a subject. In some embodiments, the subject is a mammalian subject. In some embodiments, the subject is a human.
  • the provided engineered cells contain a genetic disruption of a T cell receptor alpha constant (TRAC) gene and/or a T cell receptor beta constant (TRBC) gene.
  • the TRBC gene is one or both of a T cell receptor beta constant 1 (TRBC1) or T cell receptor beta constant 2 (TRBC2) gene.
  • the vector is a viral vector and the introducing is carried out by transduction.
  • the methods provided herein include introducing into the cell one or more agent, wherein each of the one or more agent is independently capable of inducing a genetic disruption of a T cell receptor alpha constant (TRAC) gene and/or a T cell receptor beta constant (TRBC) gene.
  • the one or more agent capable of inducing a genetic disruption comprises a DNA binding protein or DNA-binding nucleic acid that specifically binds to or hybridizes to the target site.
  • the one or more agent capable of inducing a genetic disruption comprises (a) a fusion protein containing a DNA- targeting protein and a nuclease or (b) an RNA-guided nuclease.
  • the DNA-targeting protein or RNA-guided nuclease comprises a zinc finger protein (ZFP), a TAL protein, or a clustered regularly interspaced short palindromic nucleic acid (CRISPR)-associated nuclease (Cas) specific for a target site within the TRAC and/or TRBC gene.
  • ZFP zinc finger protein
  • TAL protein a TAL protein
  • CRISPR clustered regularly interspaced short palindromic nucleic acid
  • Cas clustered regularly interspaced short palindromic nucleic acid-associated nuclease specific for a target site within the TRAC and/or TRBC gene.
  • the one or more agent comprises a zinc finger nuclease (ZFN), a TAL-effector nuclease (TALEN), or and a CRISPR-Cas9 combination that specifically binds to, recognizes, or hybridizes to the target site.
  • ZFN zinc finger nuclease
  • TALEN TAL-effector nuclease
  • CRISPR-Cas9 CRISPR-Cas9 combination that specifically binds to, recognizes, or hybridizes to the target site.
  • the each of the one or more agent comprises a guide RNA (gRNA) having a targeting domain that is complementary to the at least one target site.
  • the one or more agent is introduced as a ribonucleoprotein (RNP) complex containing the gRNA and a Cas9 protein.
  • RNP ribonucleoprotein
  • the RNP is introduced via electroporation, particle gun, calcium phosphate transfection, cell compression or squeezing.
  • the RNP is introduced via electroporation.
  • the one or more agent is introduced as one or more polynucleotide encoding the gRNA and/or a Cas9 protein.
  • a method for producing a cell according to any one of the embodiments described above including transducing a cell in vitro or ex vivo with a vector according to any one of the embodiments described above.
  • the TCR or antigen-binding fragment thereof binds to or recognizes a peptide epitope of HPV 16 in the context of an MHC molecule that is at least partially CD8-independent.
  • the CD8+ cell and CD4+ cell are engineered with the same TCR or antigen-binding fragment thereof and/or are each engineered with a TCR or antigen-binding fragment thereof that binds to or recognizes the same peptide epitope of HPV 16 in the context of an MHC molecule.
  • compositions according to any one of the embodiments described above further containing a pharmaceutically acceptable excipient.
  • a method of treatment including administering the engineered cell according to any one of the embodiments described above to a subject having a disease or disorder associated with HPV.
  • a method of treatment including administering the composition according to any one of the embodiments described above to a subject having a disease or disorder associated with HPV.
  • the disease or disorder is associated with HPV16.
  • the disease or disorder is cancer.
  • the subject is a human.
  • compositions such as any of the compositions described herein, for use in treating a disease or disorder associated with HPV.
  • compositions such as any of the compositions provided herein, for the manufacture of a medicament for treating a disease or disorder associated with HPV.
  • the disease or disorder is associated with HPV16.
  • the disease or disorder is cancer.
  • the subject is a human.
  • FIG. 1 shows lytic activity of monoclonal T cell lines expressing exemplary TCRs incubated with SiHa cells or Caski target cells based on the percent of caspase positive target cells at various assessed time points. Specifically, results are shown for T cell lines expressing the modified version of TCR 5 and the modified version of TCR 12.
  • FIG. 2A and FIG. 2B show flow cytometry results for tetramer binding by a CD4+ Jurkat-derived cell line (Neg Ctrl CD4+), the CD4+ Jurkat-derived cell line expressing various E6(29-38)-specific TCRs (CD4+ TCR-E6(29)), the CD4 + Jurkat-derived cell line that also expresses exogenous CD8 (CD8), or the CD4 + Jurkat-derived cell line that also expresses exogenous CD8 and various E6(29-38)-specific TCRs (CD8+ TCR-E6(29)).
  • results are shown for a reference TCR, the modified version of TCR 5, the modified version of TCR 4, the modified version of TCR 3 and the modified version of TCR 8.
  • FIG. 3 shows flow cytometry results for tetramer binding by CD4+ Jurkat-derived cell line (Neg Ctrl CD4+), the CD4+ Jurkat-derived cell line expressing various E7(l l-19)- specific TCRs (CD4+ TCR- E7(l 1-19)), the CD4 + Jurkat-derived cell line that also expresses exogenous CD8 (CD8), or the CD4 + Jurkat-derived cell line that also expresses exogenous CD8 and various E7(l l-19)-specific TCRs (CD8+ TCR- E7(l l-19)). Specifically, results are shown for the modified version of TCR 7 and the modified version of TCR 12.
  • FIG. 4 shows flow cytometry results for tetramer binding by CD4+ Jurkat-derived cell line (Neg Ctrl CD4+), the CD4+ Jurkat-derived cell line expressing various E7(86-93)- specific TCRs (CD4+ TCR- E7(86-93)), the CD4 + Jurkat-derived cell line that also expresses exogenous CD8 (CD8), or the CD4 + Jurkat-derived cell line that also expresses exogenous CD8 and various E7(86-93)-specific TCRs (CD8+ TCR- E7(86-93)). Specifically, results are shown for the modified version of TCR 11.
  • FIGS. 5A-5C show flow cytometry results for tetramer binding and in Jurkat-derived cell line that also expresses exogenous CD8 and various E6(29-38)-specific TCRs, in CD8+ cells. Results are shown for TCR 9, TCR13, TCR14, a reference TCR capable of binding to HLA-A2/E6(29-38) (Reference TCR) and cells that had been mock transfected (mock) (FIG. 5A); TCR 17, TCR 21, TCR 22, Reference TCR and Mock (FIG. 5B); and TCR 18, TCR 23, TCR 24 and TCR 27 (FIG. 5C).
  • FIGS. 5D-5F show flow cytometry results for tetramer binding and in Jurkat-derived cell line that also expresses exogenous CD8 and various E6(29-38)-specific TCRs. Results are shown for TCR 15, TCR 16, TCR 17, TCR 19, TCR 20 and TCR 21 (FIG. 5D); TCR 18, TCR 23, TCR 24, TCR 27 and TCR 28 (FIG. 5E); and TCR 25, TCR 26, TCR 29 and TCR 30 (FIG. 5F).
  • FIGS. 6A-6F show flow cytometry results for tetramer binding and in Jurkat-derived cell line that also expresses exogenous CD8 and various E7(l l-19)-specific TCRs. Results are shown for TCR 12 and cells that had been mock transfected (mock) (FIG. 6A); TCR 31, TCR 32, TCR 33 and TCR 34 (FIG. 6B); TCR 12, TCR 49, TCR 50 and TCR 51 (FIG. 6C);TCR 35, TCR 36, TCR 37, TCR 38, TCR 53 and TCR 54 (FIG. 6D); TCR 39, TCR 40, TCR 41, TCR 42, TCR 43 and TCR 44 (FIG. 6E); and TCR 45, TCR 46, TCR 47, TCR 48, TCR 54 and TCR 55 (FIG. 6F).
  • binding molecules such as those that bind or recognize a peptide epitope of human papillomavirus (HPV) 16, e.g., a peptide epitope of HPV 16 E6 or E7, in the context of an MHC molecule.
  • binding molecules include T cell receptors (TCRs) and antigen-binding fragments thereof and antibodies and antigen binding fragments thereof that exhibit antigenic specificity for binding or recognizing a peptide epitope of HPV 16 E6 or HPV 16 E7.
  • TCRs T cell receptors
  • nucleic acid molecules encoding the binding molecules, engineered cells containing the binding molecules, compositions and methods of treatment involving administering such binding molecules, engineered cells or compositions.
  • HPV is a causative organism in most cases of cervical cancer and has been implicated in anal, vaginal, vulvar, penile, and oropharyngeal cancers, and other cancers.
  • the HPV genome contains an early region containing six open reading frames (El, E2, E4, E5, E6 and E7), which encode proteins involved in cell transformation and replication, and a late region containing two open reading frames (LI and L2), which encode proteins of the viral capsid.
  • E6 and E7 are oncogenes that can affect cell cycle regulation and contribute to the formation of cancers.
  • the E6 gene product can cause p53 degradation and the E7 gene product can cause retinoblastoma (Rb) inactivation.
  • a provided HPV 16 binding molecule including a TCR or antigen binding fragment thereof or an anti-HPV 16 antibody, e.g., antibody fragments thereof, and proteins such as chimeric molecules containing one or more of the foregoing, such as the chimeric receptors, e.g., TCR-like CARs, and/or engineered cells expressing the TCRs or CARs, bind to a peptide epitope derived from HPV16 E6 protein.
  • a provided HPV 16 binding molecule including a TCR or antigen binding fragments thereof or anti-HPV 16 antibody, e.g., antibody fragments and proteins containing the same, such as the chimeric receptors, e.g., TCR-like CARs, and/or engineered cells expressing the TCRs or CARs, binds to a peptide epitope derived from HPV 16 E7 protein.
  • the binding molecule recognizes or binds HPV 16 E6 or E7 epitopes in the context of an MHC molecule, such as an MHC Class I molecule.
  • the MHC Class I molecule is an HLA-A2 molecule, including any one or more subtypes thereof, e.g. HLA-A*0201, *0202, *0203, *0206, or *0207.
  • HLA-A*0201 e.g. HLA-A2 positive Caucasian population
  • HLA-A*0201 more than 95% of the HLA-A2 positive Caucasian population
  • the frequency has been reported to be approximately 23% HLA-A*0201, 45% HLA-A*0207, 8% HLA-A*0206 and 23% HLA-A*0203.
  • the MHC molecule is HLA-A*0201.
  • the TCR or antigen-binding fragment thereof recognizes or binds to an epitope or region of HPV 16 E6 or HPV 16 E7, such as a peptide epitope containing an amino acid sequence set forth in any of SEQ ID NOs: 232-239, and as shown below in Table 1.
  • the binding molecule e.g., TCR or antigen-binding fragment thereof or antibody or antigen-binding fragment thereof, is isolated or purified or is recombinant.
  • the binding molecule e.g., TCR or antigen-binding fragment thereof or antibody or antigen-binding fragment thereof, is human.
  • the binding molecule is monoclonal.
  • the binding molecule is a single chain.
  • the binding molecule contains two chains.
  • the binding molecule, e.g., TCR or antigen— binding fragment thereof or antibody or antigen-binding fragment thereof is expressed on the surface of a cell.
  • the provided binding molecules have one or more specified functional features, such as binding properties, including binding to particular epitopes, and/or particular binding affinities as described.
  • TCRs T Cell Receptors
  • the binding molecule that recognizes or binds an epitope or region of HPV 16 is a T cell receptor (TCR) or an antigen -binding fragment thereof.
  • TCR T cell receptor
  • a "T cell receptor” or “TCR” is a molecule that contains a variable a and ⁇ chains (also known as TCRa and TCRp, respectively) or a variable ⁇ and ⁇ chains (also known as TCRy and TCR5, respectively), or antigen-binding portions thereof, and which is capable of specifically binding to a peptide bound to an MHC molecule.
  • the TCR is in the ⁇ form.
  • TCRs that exist in ⁇ and ⁇ forms are generally structurally similar, but T cells expressing them may have distinct anatomical locations or functions.
  • a TCR can be found on the surface of a cell or in soluble form.
  • TCR is found on the surface of T cells (or T lymphocytes) where it is generally responsible for recognizing antigens bound to major histocompatibility complex (MHC) molecules.
  • MHC major histocompatibility complex
  • the term "TCR" should be understood to encompass full TCRs as well as antigen-binding portions or antigen-binding fragments thereof.
  • the TCR is an intact or full-length TCR, such as a TCR containing the a chain and ⁇ chain.
  • the TCR is an antigen-binding portion that is less than a full- length TCR but that binds to a specific peptide bound in an MHC molecule, such as binds to an MHC-peptide complex.
  • an antigen-binding portion or fragment of a TCR can contain only a portion of the structural domains of a full-length or intact TCR, but yet is able to bind the peptide epitope, such as MHC-peptide complex, to which the full TCR binds.
  • an antigen-binding portion contains the variable domains of a TCR, such as variable a (V a ) chain and variable ⁇ (V ) chain of a TCR, or antigen-binding fragments thereof sufficient to form a binding site for binding to a specific MHC-peptide complex.
  • variable domains of the TCR contain complementarity determining regions (CDRs), which generally are the primary contributors to antigen recognition and binding capabilities and specificity of the peptide, MHC and/or MHC-peptide complex.
  • CDRs complementarity determining regions
  • a CDR of a TCR or combination thereof forms all or substantially all of the antigen-binding site of a given TCR molecule.
  • the various CDRs within a variable region of a TCR chain generally are separated by framework regions (FRs), which generally display less variability among TCR molecules as compared to the CDRs (see, e.g., Jores et al, Proc. Nat'l Acad. Sci. U.S.A.
  • CDR3 is the main CDR responsible for antigen binding or specificity, or is the most important among the three CDRs on a given TCR variable region for antigen recognition, and/or for interaction with the processed peptide portion of the peptide-MHC complex.
  • the CDR1 of the alpha chain can interact with the N-terminal part of certain antigenic peptides.
  • CDR1 of the beta chain can interact with the C-terminal part of the peptide.
  • CDR2 contributes most strongly to or is the primary CDR responsible for the interaction with or recognition of the MHC portion of the MHC-peptide complex.
  • the variable region of the ⁇ -chain can contain a further hypervariable region (CDR4 or HVR4), which generally is involved in superantigen binding and not antigen recognition (Kotb (1995) Clinical Microbiology Reviews, 8:411-426).
  • the a-chain and/or ⁇ -chain of a TCR also can contain a constant domain, a transmembrane domain and/or a short cytoplasmic tail (see, e.g., Janeway et al, Immunobiology: The Immune System in Health and Disease, 3 Ed., Current Biology Publications, p. 4:33, 1997).
  • each chain (e.g. alpha or beta) of the TCR can possess one N-terminal immunoglobulin variable domain, one immunoglobulin constant domain, a transmembrane region, and a short cytoplasmic tail at the C-terminal end.
  • a TCR for example via the cytoplasmic tail, is associated with invariant proteins of the CD3 complex involved in mediating signal transduction.
  • the structure allows the TCR to associate with other molecules like CD3 and subunits thereof.
  • a TCR containing constant domains with a transmembrane region may anchor the protein in the cell membrane and associate with invariant subunits of the CD3 signaling apparatus or complex.
  • the intracellular tails of CD3 signaling subunits e.g. CD3y, CD35, CD3s and CD3 ⁇ chains
  • the exact locus of a domain or region can vary depending on the particular structural or homology modeling or other features used to describe a particular domain. It is understood that reference to amino acids, including to a specific sequence set forth as a SEQ ID NO used to describe domain organization of a TCR are for illustrative purposes and are not meant to limit the scope of the embodiments provided. In some cases, the specific domain (e.g. variable or constant) can be several amino acids (such as one, two, three or four) longer or shorter.
  • residues of a TCR are known or can be identified according to the International Immunogenetics Information System (IMGT) numbering system (see e.g. www.imgt.org; see also, Lefranc et al. (2003) Developmental and Comparative
  • IMGT International Immunogenetics Information System
  • the CDR1 sequences within a TCR Va chains and/or ⁇ chain correspond to the amino acids present between residue numbers 27-38, inclusive
  • the CDR2 sequences within a TCR Va chain and/or ⁇ chain correspond to the amino acids present between residue numbers 56-65, inclusive
  • the CDR3 sequences within a TCR Va chain and/or ⁇ chain correspond to the amino acids present between residue numbers 105-117, inclusive.
  • the a chain and ⁇ chain of a TCR each further contain a constant domain.
  • the a chain constant domain (Ca) and ⁇ chain constant domain ⁇ ) individually are mammalian, such as is a human or murine constant domain.
  • the constant domain is adjacent to the cell membrane.
  • the extracellular portion of the TCR formed by the two chains contains two membrane-proximal constant domains, and two membrane-distal variable domains, which variable domains each contain CDRs.
  • each of the Ca and C ⁇ domains is human.
  • the Ca is encoded by the TRAC gene (IMGT nomenclature) or is a variant thereof.
  • the Ca has or comprises the sequence of amino acids set forth in SEQ ID NO: 213 or 220 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 213 or 220.
  • the Ca has or comprises the sequence of amino acids set forth in SEQ ID NO: 212, 215 or 217 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 212, 215 or 217.
  • the Ca has or comprises the sequence of amino acids set forth in any of SEQ ID NOS: 212, 213, 215, 217, 220, or 524.
  • the C is encoded by TRBC1 or TRBC2 genes (IMGT nomenclature) or is a variant thereof.
  • the CP has or comprises the sequence of amino acids set forth in SEQ ID NO:214, 216, 631, or 889 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 214, 216, 631, or 889.
  • the CP has or comprises the sequence of amino acids set forth in SEQ ID NO: 214, 216, 631, or 889.
  • any of the provided TCRs or antigen-binding fragments thereof can be a human/mouse chimeric TCR.
  • the TCR or antigen-binding fragment thereof comprises an alpha chain and/or a beta chain comprising a mouse constant region.
  • the Ca is a mouse constant region that is or comprises the sequence of amino acids set forth in SEQ ID NO: 262, 317, 833, 1012, 1014, 1015, 1017 or 1018 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 262, 317, 833, 1012, 1014, 1015, 1017 or 1018 .
  • the Ca is or comprises the sequence of amino acids set forth in SEQ ID NO: 262, 317, 833, 1012, 1014, 1015, 1017 or 1018 .
  • the CP is a mouse constant region that is or comprises the sequence of amino acids set forth in SEQ ID NO: 263, 109, 1013 or 1016 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 263, 109, 1013 or 1016.
  • the CP is or comprises the sequence of amino acids set forth in SEQ ID NO: 263, 109, 1013 or 1016.
  • the Ca is or comprises the sequence of amino acids set forth in SEQ ID NO: 262 or 1014 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 262 or 1014 and/or the CP is or comprises the sequence of amino acids set forth in SEQ ID NO: 263 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 263.
  • the Ca and/or CP is or comprises any Ca and/or C described in WO 2015/184228, WO 2015/009604 and WO 2015/009606.
  • the TCR or antigen-binding fragment thereof herein comprises a variant of an alpha chain and/or a beta chain, e.g., an alpha and/or beta chain that comprises a mouse constant region.
  • the variant comprises the amino acid sequence of any of the TCRs described herein with one, two, three, or four or more amino acid substitution(s) in the constant region of the alpha or beta chain.
  • the variant comprises the amino acid sequence of any of the constant regions described herein with one, two, three, or four or more amino acid substitution(s) in the constant region.
  • the TCRs (or functional portions thereof) comprising the substituted amino acid sequence(s) advantageously provide one or more of increased recognition of HPV 16 targets, increased expression by a host cell, and increased anti-tumor activity as compared to the parent TCR comprising an unsubstituted amino acid sequence.
  • the substituted amino acid sequences of the mouse constant regions of the TCR a and ⁇ chains, SEQ ID NOs: 1015 and 1016, respectively correspond with all or portions of the unsubstituted mouse constant region amino acid sequences SEQ ID NOs: 1014 and 263, respectively, with SEQ ID NO: 1015 having one, two, three, or four amino acid substitution(s) when compared to SEQ ID NO: 1014 and SEQ ID NO: 1016 having one amino acid substitution when compared to SEQ ID NO: 263.
  • a variant of a TCR comprises the amino acid sequences of (a) SEQ ID NO: 1015 (constant region of alpha chain), wherein (i) X at position 48 is Thr or Cys; (ii) X at position 112 is Ser, Gly, Ala, Val, Leu, lie, Pro, Phe, Met, or Trp; (iii) X at position 114 is Met, Gly, Ala, Val, Leu, He, Pro, Phe, Met, or Trp; and (iv) X at position 115 is Gly, Ala, Val, Leu, lie, Pro, Phe, Met, or Trp; and (b) SEQ ID NO: 1016 (constant region of beta chain), wherein X at position 56 is Ser or Cys.
  • the Ca is or comprises the sequence of amino acids set forth in SEQ ID NO: 1015 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 1015 and/or the C is or comprises the sequence of amino acids set forth in SEQ ID NO: 1016 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 1016.
  • the TCR may be a heterodimer of two chains a and ⁇ that are linked, such as by a disulfide bond or disulfide bonds.
  • the constant domain of the TCR may contain short connecting sequences in which a cysteine residue forms a disulfide bond, thereby linking the two chains of the TCR.
  • a TCR may have an additional cysteine residue in each of the a and ⁇ chains, such that the TCR contains two disulfide bonds in the constant domains.
  • each of the constant and variable domains contains disulfide bonds formed by cysteine residues.
  • the TCR can contain an introduced disulfide bond or bonds.
  • the native disulfide bonds are not present.
  • the one or more of the native cysteines (e.g. in the constant domain of the a chain and ⁇ chain) that form a native interchain disulfide bond are substituted to another residue, such as to a serine or alanine.
  • an introduced disulfide bond can be formed by mutating non- cysteine residues on the alpha and beta chains, such as in the constant domain of the a chain and ⁇ chain, to cysteine.
  • the presence of non-native cysteine residues (e.g. resulting in one or more non-native disulfide bonds) in a recombinant TCR can favor production of the desired recombinant TCR in a cell in which it is introduced over expression of a mismatched TCR pair containing a native TCR chain.
  • cysteines can be introduced or substituted at a residue corresponding to Thr48 of the Ca chain and Ser57 of the C ⁇ chain, at residue Thr45 of the Ca chain and Ser77 of the C ⁇ chain, at residue TyrlO of the Ca chain and Serl7 of the C ⁇ chain, at residue Thr45 of the Ca chain and Asp59 of the C ⁇ chain and/or at residue Serl5 of the Ca chain and Glul5 of the C ⁇ chain with reference to numbering of a Ca set forth in any of SEQ ID NOS: 212, 213, 217, or 524, or C ⁇ set forth in SEQ ID NO: 214 or 216.
  • the variant of the TCR is a cysteine- substituted, chimeric TCR in which one or both of the native Thr48 of SEQ ID NO: 1014 and the native Ser56 of SEQ ID NO: 263 is substituted with Cys.
  • the Ca is or comprises the sequence of amino acids set forth in SEQ ID NO: 1017 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 1017 and/or the C is or comprises the sequence of amino acids set forth in SEQ ID NO: 1016 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 1013.
  • any of the provided cysteine mutations can be made at a corresponding position in another sequence, for example, in the mouse Ca and CP sequences described above.
  • corresponding residues can be determined by alignment of a reference sequence with the Ca sequence set forth in any of SEQ ID NOS: 212, 213, 215, 217, 220, or 524, or the Cp sequence set forth in SEQ ID NO: 214, 216, 631, or 889, by structural alignment methods as described herein. By aligning the sequences, one skilled in the art can identify corresponding residues, for example, using conserved and identical amino acid residues as guides.
  • the variant includes substitutions of one, two, or three amino acids in the transmembrane (TM) domain of the constant region of one or both of the a and ⁇ chains with a hydrophobic amino acid to provide a hydrophobic amino acid-substituted TCR.
  • the hydrophobic amino acid substitution(s) in the TM domain of the TCR may increase the hydrophobicity of the TM domain of the TCR as compared to a TCR that lacks the hydrophobic amino acid substitution(s) in the TM domain.
  • the variant of the TCR comprises one, two, or three of the native Ser 112, Met 114, and Gly 115 of SEQ ID NO: 1014 may, independently, be substituted with Gly, Ala, Val, Leu, He, Pro, Phe, Met, or Trp; for example with Leu, He, or Val.
  • the Ca is or comprises the sequence of amino acids set forth in SEQ ID NO: 1018 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 1018 and/or the C is or comprises the sequence of amino acids set forth in SEQ ID NO: 263 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 263.
  • the variant includes substitutions cysteine substitutions in the constant region of one or both of the a and ⁇ chains in combination with the substitution(s) of one, two, or three amino acids in the transmembrane (TM) domain of the constant region of one or both of the a and ⁇ chains with a hydrophobic amino acid.
  • the variant has the native Thr48 of SEQ ID NO: 1014 substituted with Cys; one, two, or three of the native Ser 112, Met 114, and Gly 115 of SEQ ID NO: 1014, independently, substituted with Gly, Ala, Val, Leu, He, Pro, Phe, Met, or Trp; for example with Leu, He, or Val; and the native Ser56 of SEQ ID NO: 19 substituted with Cys.
  • the Ca is or comprises the sequence of amino acids set forth in SEQ ID NO: 833 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 833 and/or the C is or comprises the sequence of amino acids set forth in SEQ ID NO: 1013 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 1013.
  • the TCR is a full-length TCR. In some embodiments, the TCR is an antigen-binding portion. In some embodiments, the TCR is a dimeric TCR (dTCR). In some embodiments, the TCR is a single-chain TCR (sc-TCR). A TCR may be cell-bound or in soluble form. In some embodiments, the TCR is in cell-bound form expressed on the surface of a cell.
  • a dTCR contains a first polypeptide wherein a sequence corresponding to a provided TCR a chain variable region sequence is fused to the N terminus of a sequence corresponding to a TCR a chain constant region extracellular sequence, and a second polypeptide wherein a sequence corresponding to a provided TCR ⁇ chain variable region sequence is fused to the N terminus a sequence corresponding to a TCR ⁇ chain constant region extracellular sequence, the first and second polypeptides being linked by a disulfide bond.
  • the bond can correspond to the native interchain disulfide bond present in native dimeric ⁇ TCRs.
  • the interchain disulfide bonds are not present in a native TCR.
  • one or more cysteines can be incorporated into the constant region extracellular sequences of dTCR polypeptide pair.
  • both a native and a non-native disulfide bond may be desirable.
  • the TCR contains a transmembrane sequence to anchor to the membrane.
  • a dTCR contains a provided TCR a chain containing a variable a domain, a constant a domain and a first dimerization motif attached to the C-terminus of the constant a domain, and a provided TCR ⁇ chain comprising a variable ⁇ domain, a constant ⁇ domain and a first dimerization motif attached to the C-terminus of the constant ⁇ domain, wherein the first and second dimerization motifs easily interact to form a covalent bond between an amino acid in the first dimerization motif and an amino acid in the second dimerization motif linking the TCR a chain and TCR ⁇ chain together.
  • the TCR is a scTCR, which is a single amino acid strand containing an a chain and a ⁇ chain that is able to bind to MHC-peptide complexes.
  • a scTCR can be generated using methods known to those of skill in the art, See e.g., International published PCT Nos. WO 96/13593, WO 96/18105, W099/18129, WO 04/033685,
  • a scTCR contains a first segment constituted by an amino acid sequence corresponding to a sequence of a provided TCR a chain variable region, a second segment constituted by an amino acid sequence corresponding to a provided TCR ⁇ chain variable region sequence fused to the N terminus of an amino acid sequence corresponding to a TCR ⁇ chain constant domain extracellular sequence, and a linker sequence linking the C terminus of the first segment to the N terminus of the second segment.
  • a scTCR contains a first segment constituted by an amino acid sequence corresponding to a provided TCR ⁇ chain variable region, a second segment constituted by an amino acid sequence corresponding to a provided TCR a chain variable region sequence fused to the N terminus of an amino acid sequence corresponding to a TCR a chain constant domain extracellular sequence, and a linker sequence linking the C terminus of the first segment to the N terminus of the second segment.
  • a scTCR contains a first segment constituted by a provided a chain variable region sequence fused to the N terminus of an a chain extracellular constant domain sequence, and a second segment constituted by a provided ⁇ chain variable region sequence fused to the N terminus of a sequence ⁇ chain extracellular constant and
  • a scTCR contains a first segment constituted by a provided TCR ⁇ chain variable region sequence fused to the N terminus of a ⁇ chain extracellular constant domain sequence, and a second segment constituted by a provided a chain variable region sequence fused to the N terminus of a sequence a chain extracellular constant and
  • transmembrane sequence and, optionally, a linker sequence linking the C terminus of the first segment to the N terminus of the second segment.
  • the a and ⁇ chains must be paired so that the variable region sequences thereof are orientated for such binding.
  • Various methods of promoting pairing of an a and ⁇ in a scTCR are well known in the art.
  • a linker sequence is included that links the a and ⁇ chains to form the single polypeptide strand.
  • the linker should have sufficient length to span the distance between the C terminus of the a chain and the N terminus of the ⁇ chain, or vice versa, while also ensuring that the linker length is not so long so that it blocks or reduces bonding of the scTCR to the target peptide-MHC complex.
  • the linker of a scTCRs that links the first and second TCR segments can be any linker capable of forming a single polypeptide strand, while retaining TCR binding specificity.
  • the linker sequence may, for example, have the formula -P-AA-P-, wherein P is proline and AA represents an amino acid sequence wherein the amino acids are glycine and serine.
  • the first and second segments are paired so that the variable region sequences thereof are orientated for such binding.
  • the linker has a sufficient length to span the distance between the C terminus of the first segment and the N terminus of the second segment, or vice versa, but is not too long to block or reduces bonding of the scTCR to the target ligand.
  • the linker can contain from or from about 10 to 45 amino acids, such as 10 to 30 amino acids or 26 to 41 amino acids residues, for example 29, 30, 31 or 32 amino acids.
  • the linker has the formula -PGGG-(SGGGG) n -P-, wherein n is 5 or 6 and P is proline, G is glycine and S is serine (SEQ ID NO: 266).
  • the linker has the sequence
  • a scTCR contains a disulfide bond between residues of the single amino acid strand, which, in some cases, can promote stability of the pairing between the a and ⁇ regions of the single chain molecule (see e.g. U.S. Patent No. 7,569,664).
  • the scTCR contains a covalent disulfide bond linking a residue of the immunoglobulin region of the constant domain of the a chain to a residue of the
  • the disulfide bond corresponds to the native disulfide bond present in a native dTCR. In some embodiments, the disulfide bond in a native TCR is not present. In some embodiments, the disulfide bond is an introduced non-native disulfide bond, for example, by incorporating one or more cysteines into the constant region extracellular sequences of the first and second chain regions of the scTCR polypeptide. Exemplary cysteine mutations include any as described above. In some cases, both a native and a non-native disulfide bond may be present.
  • a scTCR is a non-disulfide linked truncated TCR in which heterologous leucine zippers fused to the C-termini thereof facilitate chain association (see e.g. International published PCT No. WO99/60120).
  • a scTCR contain a TCRa variable domain covalently linked to a TCRP variable domain via a peptide linker (see e.g., International published PCT No. W099/18129).
  • any of the provided TCRs can be linked to signaling domains that yield an active TCR on the surface of a T cell.
  • the TCR is expressed on the surface of cells.
  • the TCR does contain a sequence corresponding to a transmembrane sequence.
  • the transmembrane domain is positively charged.
  • the transmembrane domain can be a Ca or CP transmembrane domain.
  • the transmembrane domain can be from a non-TCR origin, for example, a transmembrane region from CD3z, CD28 or B7.1.
  • the TCR does contain a sequence corresponding to cytoplasmic sequences.
  • the TCR contains a CD3z signaling domain.
  • the TCR is capable of forming a TCR complex with CD3.
  • the TCR is a soluble TCR.
  • the soluble TCR has a structure as described in WO99/60120 or WO 03/020763.
  • the TCR does not contain a sequence corresponding to the transmembrane sequence, for example, to permit membrane anchoring into the cell in which it is expressed.
  • the TCR does not contain a sequence corresponding to cytoplasmic sequences. /. Exemplary TCRs
  • the provided -TCRs or antigen-binding fragment thereof that bind or recognize a peptide epitope of HPV 16 in the context of an MHC e.g. a peptide epitope of HPV 16 E6 or a peptide epitope of HPV 16 E7
  • the provided anti-HPV 16 TCR or antigen-binding fragment thereof e.g.
  • anti-HPV 16 E6 or anti-HPV 16 E7 TCRs contains a V a region sequence or sufficient antigen- binding portion thereof that contains a CDR-1, CDR-2 and/or CDR-3 as described.
  • the provided anti-HPV 16 TCR or antigen-binding fragment thereof e.g., anti- HPV 16 E6 or anti-HPV 16 E7 TCRs
  • the anti-HPV 16 TCR or antigen-binding fragment thereof contains a V a region sequence that contains a CDR-1, CDR-2 and/or CDR-3 as described and contains a ⁇ region sequence that contains a CDR-1, CDR-2 and/or CDR-3 as described.
  • the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such a sequence.
  • the TCR contains a Va region that contains a
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a V a region containing a complementarity determining region 3 (CDR-3) comprising an amino acid sequence set forth in any of SEQ ID NOs: 138, 144, 147, 153, 159, 163, 167, 173, 175, 301, 304, 308, 478, 493, 505, 511, 523, 539, 555, 572, 588, 600, 612, 624, 638, 650, 662, 679, 694, 712, 729, 744, 762, 776, 788, 802, 818, 832, 846, 858, 870, 882, 896, 911, 926, 940, 952, 964, 976, 988, or 1002, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a V a region containing a CDR3 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 117, 119, 121, 123, 125, 127, 295, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, 676, 691, 709, 726, 741, 759, 775, 787, 799, 815, 830, 845, 857, 869, 881, 895, 908, 925, 937, 951, 963, 975, 987, or 999, or a sequence at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical with such a sequence.
  • the TCR contains a ⁇ region that contains a
  • CDR-3 complementarity determining region 3
  • Xi is A or S
  • X 2 is S, I, or V
  • X 3 is S, T, or V
  • X 4 is H, P, L, Y, T, D, or Q
  • X 5 is L, G, W, F, S, or R
  • X 6 is A, G, L, S, or T
  • X 7 is G, E, A, T, R, or null
  • X 8 is null or G
  • X9 is null or G
  • X 10 is null, F, G, T, S, or A
  • Xn is T, N, H, A, S, or F
  • X 12 is G, T, Q, D, Y, or L
  • X 13 is E, P, T, G or W
  • X 14 is L, A, Q, Y, or K
  • Xi 5 is F, H, Y, or
  • the TCR contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising an amino acid sequence set forth in any of SEQ ID NOs: 141, 146, 150, 156, 160, 164, 170, 174, 178, 305, 309, 486, 499, 517, 531, 548, 563, 581, 594, 606, 618, 630, 644, 656, 670, 686, 703, 721, 736, 753, 769, 782, 794, 809, 825, 840, 852, 864, 876, 888, 902, 919, 932, 946, 958, 970, 982, 994, or 1010, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-3 complementarity determining region 3
  • the TCR contains a ⁇ region containing a CDR3 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 118, 120, 122, 124, 126, 128, 296, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, 685, 700, 718, 735, 750, 768, 781, 793, 808, 824, 839, 851, 863, 875, 887, 901, 917, 931, 945, 957, 969, 981, 993, or 1008 or a sequence at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical with such a sequence.
  • the Va region further contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence XiX 2 X X 4 X 5 X 6 X 7 (SEQ ID NO: 243), where Xi is T, D, N, or V; X 2 is I or S; X 3 is S, D, A, P, or M; X 4 is G, Q, P, or null; X 5 is T, S, I, or F; X 6 is D, Y, Q, T, or S; and X 7 is Y, G, N, or Q.
  • CDR-1 complementarity determining region 1
  • the Va region further contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 X 7 X 8 (SEQ ID NO: 247), where Xi is G, Q, I, V, or M; X 2 is L, S, Q, Y, F, T, or G; X 3 is T, G, S, or F; X 4 is Y, S, N, I, or null; X 5 is null or D; X 6 is null, E, Q, S, M, or K; X 7 is S, Q, R, G, D, or N; and X 8 is N, E, M, T, or K.
  • CDR-2 complementarity determining region 2
  • the V a region contains a complementarity determining region 1 (CDR-1) comprising an amino acid sequence set forth in any of SEQ ID NOs: 136, 142, 151, 157, 161, 165, 171, 302, 306, 537, 570, 677, 692, 710, 727, 742, 760, 800, 816, 909, 938, or 1000, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-1 complementarity determining region 1
  • the V a region contains a CDR-1 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 117, 119, 121, 123, 125, 127, 295, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, 676, 691, 709, 726, 741, 759, 775, 787, 799, 815, 830, 845, 857, 869, 881, 895, 908, 925, 937, 951, 963, 975, 987, or 999, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the V a region contains a complementarity determining region 2 (CDR-2) comprising an amino acid sequence set forth in any of SEQ ID NOs: 137, 143, 152, 158, 162, 166, 172, 303, 307, 538, 571, 678, 693, 711, 728, 743, 761, 801, 817, 831, 833, 910, 939, or 1001, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-2 complementarity determining region 2
  • the V a region contains a CDR-2 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 117, 119, 121, 123, 125, 127, 295, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, 676, 691, 709, 726, 741, 759, 775, 787, 799, 815, 830, 845, 857, 869, 881, 895, 908, 925, 937, 951, 963, 975, 987, or 999, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the ⁇ region further contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence XiX 2 X 3 X 4 Xs (SEQ ID NO: 254), where Xi is S, M, or L; X 2 is G, E, D, N, or Q; X 3 is H or V; X 4 is V, N, E, L, or T; and X 5 is S, R, N, Y, A, or M.
  • CDR-1 complementarity determining region 1
  • the ⁇ region further contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence ⁇ 2 ⁇ 3 ⁇ 4 ⁇ 5 ⁇ 6 ⁇ 7 (SEQ ID NO: 257), where Xi is F, Y, S, or A; X 2 is Q, Y, V, or N; X 3 is N, D, G, F, or Q; X 4 is null or G; X 5 is E, V, N, K, or S; X 6 is A, K, G, or E; and X 7 is Q, M, T, I, or A.
  • CDR-2 complementarity determining region 2
  • the ⁇ region contains a complementarity determining region 1 (CDR-1) comprising an amino acid sequence set forth in any of SEQ ID NOs: 139, 145, 148, 154, 168, 176, 484, 546, 561, 579, 668, 701, 719, or 751, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-1 complementarity determining region 1
  • the ⁇ region contains a CDR-1 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 118, 120, 122, 124, 126, 128, 296, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, 685, 700, 718, 735, 750, 768, 781, 793, 808, 824, 839, 851, 863, 875, 887, 901, 917, 931, 945, 957, 969, 981, 993, or 1008, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the ⁇ region contains a complementarity determining region 2 (CDR-2) comprising an amino acid sequence set forth in any of SEQ ID NOs: 140, 149, 155, 169, 177, 485, 547, 562, 580, 669, 702, 720, 752, 918, or 1009, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-2 complementarity determining region 2
  • the ⁇ region contains a CDR-2 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 118, 120, 122, 124, 126, 128, 296, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, 685, 700, 718, 735, 750, 768, 781, 793, 808, 824, 839, 851, 863, 875, 887, 901, 917, 931, 945, 957, 969, 981, 993, or 1008, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Va region contains the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 117, 119, 121, 123, 125, 127, 295, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, 676, 691, 709, 726, 741, 759, 775, 787, 799, 815, 830, 845, 857, 869, 881, 895, 908, 925, 937, 951, 963, 975, 987, or 999, or an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto.
  • the ⁇ region contains the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 118, 120, 122, 124, 126, 128, 296, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, 685, 700, 718, 735, 750, 768, 781, 793, 808, 824, 839, 851, 863, 875, 887, 901, 917, 931, 945, 957, 969, 981, 993, or 1008, or an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto.
  • the TCR contains an alpha chain comprising any of such Va chain sequences and any of such ⁇ chain sequences.
  • the alpha chain of the TCR or antigen-binding fragment thereof further contains an alpha constant (Ca) region or portion thereof.
  • the beta chain further contains a beta constant (CP) region or portion thereof.
  • the TCR e.g., the HPV 16 E6 or E7 TCR or antigen-binding fragment thereof, contains an alpha chain comprising a variable alpha (Va) region and an alpha constant (Ca) region or portion thereof and/or a beta chain comprising a variable beta ( ⁇ ) region and a beta constant region (CP) or portion thereof.
  • the Ca and CP regions are mouse constant regions.
  • the Ca region contains the amino acid sequence set forth in SEQ ID NO: 262 or 317, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the CP region contains the amino acid sequence set forth in SEQ ID NO: 263 or 109, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Ca and CP regions are human constant regions.
  • the Ca region comprises the amino acid sequence set forth in any of SEQ ID NOs: 212, 213, 215, 217, 218, 220, or 524, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the CP region contains the amino acid sequence set forth in SEQ ID NO: 214, 216, 631, or 889, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Ca and/or CP regions are modified, for example, by incorporation of one or more non-native cysteine residues.
  • the constant region is a modified form of a human constant region (e.g. modified compared to a Ca region set forth in any of SEQ ID NOs: 212, 213, 215, 217, 218, 220, or 524, and/or a Cp region set forth in SEQ ID NO:214, 216, 631, or 889.
  • the modification is by introduction of cysteine at residue Thr48 of the Ca chain and/or Ser57 of the CP chain, at residue Thr45 of the Ca chain and/or Ser77 of the CP chain, at residue TyrlO of the Ca chain and/or Serl7 of the CP chain, at residue Thr45 of the Ca chain and Asp59 of the CP chain and/or at residue Serl5 of the Ca chain and Glul5 of the CP chain with reference to numbering of a Ca set forth in any of SEQ ID NOS: 212, 213, 217, 218 or 524 or Cp set forth in SEQ ID NO: 214 or 216.
  • Corresponding residues can be identified by aligning a reference sequence to any of SEQ ID NOS: 212, 213, 217, 218 or 524 or 214 or 216.
  • Thr48 in the Ca chain aligns with or corresponds to Thr49 in the sequence set forth in SEQ ID NO: 215 or 220 and Ser57 in the CP chain aligns with or corresponds to Ser58 in the sequence set forth in SEQ ID NO:631 or 889.
  • the Ca region contains a non-native cysteine at residue 48 (or at a corresponding residue, e.g.
  • residue 49 and comprises the amino acid sequence set forth in any of SEQ ID NOs: 196, 198, 200, 201, 203, 525, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence and that contains the introduced non-native cysteine residue or residues.
  • the CP region contains a non-native cysteine at residue 57 (or at a corresponding residue, e.g.
  • residue 58 and contains the amino acid sequence set forth in SEQ ID NO: 197, 199, 632, or 890, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94,
  • the TCR or antigen-binding fragment thereof comprises an alpha chain comprising the sequence of amino acids set forth in SEQ ID NO: 18, 28, 38, 48, 58,
  • a sequence of amino acids that has at least 90% sequence identity thereto such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence and/or a beta chain comprising the sequence of amino acids set forth in SEQ ID NO: 22, 32, 42, 52, 62, 72, 82, 92, 102, 285, 289, 293, 479, 494, 512, 526, 541, 556, 574, 589, 601, 613, 625, 639, 651, 663, 681, 696, 714, 731, 746, 764, 777, 789, 804, 820, 835, 847, 859, 871, 883, 897, 913, 927, 941, 953, 965, 977, 989, or 1004 or a sequence of amino acids that has at least 90% sequence identity thereto
  • the TCR or antigen-binding fragment thereof comprises an alpha chain comprising the sequence of amino acids set forth in SEQ ID NO: 19, 29, 39, 49, 59,
  • the alpha chain and/or beta chain of the TCR is encoded by a sequence of nucleotides comprising a signal peptide (also called a leader sequence).
  • a signal peptide also called a leader sequence.
  • Non- limiting examples of such a signal peptide are signal peptides that have or comprise the sequence of amino acids set forth in any of SEQ ID NOS: 180-182, 184-194, 310, 311, 487, 540, 549, 564, 573, 582, 671, 680, 695, 704, 713, 730, 745, 754, 763, 770, 803, 810, 819, 834, 903, 912, 920, 1003, or 1011.
  • the TCR or antigen-binding fragment thereof is encoded by a sequence of nucleotides that encodes: a) an alpha chain comprising the sequence of amino acids set forth in SEQ ID NO: 318, 319, 322, 323, 326, 327, 330, 331, 334, 335, 338, 339, 130, 131, 134, 135, 195, 205, 222, 242, 253, 256, 313, 314, 475, 476, 490, 491, 502, 503, 508, 509, 520, 521, 534, 535, 552, 553, 567, 568, 585, 586, 597, 598, 609, 610, 621, 622, 635, 636, 647, 648, 659, 660, 674, 675, 689, 690, 707, 708, 724, 725, 739, 740, 757, 758, 773, 774, 785, 786, 797, 798,
  • the alpha chain and beta chain can be connected via a linker, such as any described elsewhere herein.
  • the TCR or antigen-binding fragment thereof recognizes or binds to an epitope or region of HPV 16 E6, such as a peptide epitope containing an amino acid sequence set forth in any of SEQ ID NOs: 232-234.
  • the TCR or antigen-binding fragment thereof does not recognize or bind the epitope E6(29-38) comprising the amino acid sequence TIHDIILECV (SEQ ID NO. 233).
  • the TCR or antigen-binding fragment thereof that recognizes or binds a peptide epitope derived from HPV 16 E6 is or comprises the sequence set forth in SEQ ID NO: 232 or SEQ ID NO: 234.
  • the TCR or antigen -binding fragment recognizes or binds to an epitope or region of HPV 16 E7 protein, such as a peptide epitope containing an amino acid sequence set forth in any of SEQ ID NOs: 235-239.
  • the TCR or antigen- binding fragment thereof does not recognize or bind the epitope E7(l 1-19) comprising the amino acid sequence YMLDLQPET (SEQ ID NO. 236).
  • the peptide derived from HPV16 E7 is or contains the sequence set forth in SEQ ID NO: 235. a. HPV 16 E6(29-38)
  • the TCR recognizes or binds a peptide epitope derived from HPV 16 E6 that is or contains E6(29-38) TIHDIILECV (SEQ ID NO: 233). In some embodiments, the TCR recognizes or binds HPV 16 E6 (29-38) in the context of an MHC, such as an MHC class I, e.g. HLA-A2.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence X1X2X3X4X5X6X7X8X9 10X11X12X13X14X15X10X17X18 (SEQ ID NO: 248), where Xi is A, I, or V; X 2 is M, L, or V; X 3 is R, L, or N; X 4 is E, V, T, P, or F; X 5 is G, I, L, A, or P; X 6 is R, T, G, or S; X 7 is G, R, or null; X 8 is T, G, or null; X9 is null or A; X 10 is null or G; Xn is null or G; X 12 is null or T; Xi 3 is null or S; Xi 4 is G, Y, or N; X15
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 X 7 X 8 X9Xio ii i2 i3 i4 i5 i6 i7 i8 (SEQ ID NO: 1205), where Xi is A, I, or V; X 2 is M, L, A, V, S, or E; X 3 is R, L, N, S, Q, K, G, or W; X 4 is E, V, P, T, F, A, G, N, D, or L; X 5 is G, I, D, L, A, P, H, N, R, T, or null; X 6 is G, N, R, T, M, S, P, or null; X 7 is G, V, D, L, Q, T, R, N, or
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence X1X2X3X4X5X6X7X8X9 10X11X12X13X14X15X16X17X18 (SEQ ID NO: 1220), where Xi is A, I, or V; X 2 is M, L, A, V, S, or E; X 3 is R, L, N, S, Q, K, G, or W; X 4 is E, V, P, T, F, A, G, N, D, or L; X 5 is G, I, D, L, A, P, N, R, T, or null; X 6 is G, N, R, T, M, S, P, or null; X 7 is G, V, D, L, Q, T, R, or null; X 8 is T, D, S, L, G, or null;
  • CDR-3 complementarity
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 X 7 X 8 X9Xio i i i2 i3 i4 i5 i6LT (SEQ ID NO: 1206), where Xi is A, I, or V; X 2 is L, M, V, or E; X 3 is L, R, N, G, or S; X 4 is V, T, F, N, E, P, G, or L; X 5 is I, A, P, N, G, or T; X 6 is R, G, S, or T; X 7 is G, R, L, V, or T; X 8 is T, G, L, or null; X 9 is A, G, Q, or null; X10 is G, or null; Xn is G,
  • CDR-3 complementarity
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AMRX 4 X 5 X 6 X7X8X9XioXiiXi2Xi3Xi4Xi5 (SEQ ID NO: 1207), where X 4 is E, T, A, D, or L; X 5 is G, A, N, or R; X 6 is R, G, R, T, M, or S ; X 7 is G, V, D, L, or null; X 8 is T, D, or null; X 9 is G, or null; X 10 is S, T, G, or null; Xn is G, Y, N, A, or W ; X 12 is F, G, N, D, S, or Y; Xi3 is K, D, Q, ; X 14 is T, L, M, or I; and X 15
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ⁇ 2 ⁇ 3 ⁇ 4 ⁇ 5 ⁇ 6 ⁇ 7 ⁇ 8 ⁇ 9 ⁇ ⁇ 2 ⁇ 3 ⁇ 4 ⁇ 5 ⁇ 7 ⁇ 8 (SEQ ID NO: 1208), where Xi is I, or V; X 2 is L, or V; X 3 is L, N, or R; X 4 is V, F, or G; X 5 is I, P, G, or T; X 6 is R, S, P, or G; X 7 is G, R, Q, T, or V; X 8 is T, G, S, or L; X9 is A, G, Q, or null; X10 is G, or null; Xn is G, or null; X12 IS T, or null; X 13 is G, or S; Xi 4 is Y, or N; X 15 is
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX 2 RX 4 AX 6 NNDMR (SEQ ID NO: 1221), where X 2 is V, or M; X 4 is P, or D; X 6 is N, or R.
  • CDR-3 complementarity determining region 3
  • the Va region contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence X iX 2 X 3 X 4 X 5 X 6 X7 (SEQ ID NO: 240), where Xi is T, D, or N; X 2 is I, or S; X 3 is S, D, or A; X 4 is G, Q, P, or null; X 5 is T, S, or I; X 6 is D, Y, or Q; and X 7 i s Y, G, N, or Q.
  • CDR-1 complementarity determining region 1
  • the Va region contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence ⁇ 2 ⁇ 3 ⁇ 4 ⁇ 5 ⁇ 6 ⁇ 7 (SEQ ID NO: 1209), where Xi is T, N, D, or S; X 2 is S, I, or R; X 3 is D, S, M, A, Y, N, or G; X 4 is Q, G, P, or null; X 5 is S, T, F, I, or N; X 6 is Y, D, Q, P, N, or E; and X 7 is G, Y, N, S, or A.
  • CDR-1 complementarity determining region 1
  • the Va region contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 X 7 X8 (SEQ ID NO: 244), where Xi is G, Q, I, or V; X 2 is L, S, Q, or Y; X 3 is T, G, or S; X 4 is Y, S, or null; X5 is null or D; X 6 is null, E, Q, or S; X 7 is S, Q, R, or G; and X 8 is N or E.
  • the Va region contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence
  • XiX 2 X 3 X 4 X 5 X 6 7 8 (SEQ ID NO: 1210), where Xi is Q, G, I, V, Y, M, R, or N; X 2 is G, L, S, Q, Y, T, N, or V; X 3 is S, T, L, or K; X 4 is Y, I, S, A, N, F, or null; X 5 is D, A, or null; X 6 is E, K, Q, S, T, G, D, or null; X 7 is Q, S, N, R, G, L, or D; and X 8 is N, K, E, V, or L.
  • the TCR or antigen -binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ASSX 4 X 5 X 6 X 7 X 8 X9Xio n i2 i3 (SEQ ID NO: 258), where X 4 is H, P, L, or Y; X 5 is L, G, W, F, or S; X 6 is A, G, or L; X 7 is G, E, A, T, or null; X 8 is F, G, T, or S; X 9 is T, N, H, or A; X10 is G, T, Q, D, or Y; X n is E, P, T, or G; X n is L, A, Q, or Y; and X 13 is F, H, Y, or T.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ⁇ 2 ⁇ 3 ⁇ 4 ⁇ 5 ⁇ 6 ⁇ 7 ⁇ 8 ⁇ 9 ⁇ 2 ⁇ 3 ⁇ 4 ⁇ 5 (SEQ ID NO: 1211), where Xi is A, S, or V; X 2 is S, A, or V; X 3 is S, V, R, or Q; X 4 is H, P, Q, L, Y, G, T, F, S, R, or E; X 5 is L, G, R, W, F, S, V, T, Y, Q, or null; X 6 is A, G, L, T, E, P, or null; X 7 is G, T, A, R, Q, N, S, or null; X 8 is G, S, or null; X 9 is G, or null; X 10 is F, G, A, S,
  • the TCR or antigen -binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X1 X15 (SEQ ID NO: 1222), where Xi is A, S, or V; X 2 is S, A, or V; X 3 is S, R, or Q; X 4 is H, P, Q, L, Y, G, T, F, S, R, or E; X 5 is L, G, R, W, F, S, V, T, Y, Q, or null; X 6 is A, G, L, E, P, or null; X 7 is G, T, A, R, Q, N, S, or null; X 8 is G, S, or null; X9 IS G, or null; Xio is F, G, A, S,
  • CDR-3 complementar
  • the TCR or antigen -binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ASSX 4 X 5 X 6 X7X8X9 ioXnXi2Xi3Xi4 (SEQ ID NO: 1212), where X 4 is H, P, Q, L, Y, F, R, or E; X 5 is L, G, R, W, F, S, V, T, Y, or Q; X 6 is A, G, L, E P; X 7 is G, T, A, R, Q, S, or null; X 8 is G, S, or null; X 9 is F, G, A, S, T, R, L, or null; X 10 is T, N, A, F, R, S, or G; Xn is G, T, L, D, Y, Q, S, E, or N; X i2 is E,
  • the TCR or antigen -binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 X 7 X 8 X9XioXnXi2Xi3QY (SEQ ID NO: 1213), where Xi is A, or S; X 2 is S, V, or A; X 3 is S, or V; X 4 is L, Y, P, or S; X 5 is W, F, V, L, or Y; X 6 is G, T, or A; X 7 is A, R, Q, S, or null; X 8 is G, or null; Xg is G, or null; Xio is S, T, R, or G; Xn is T, A, R, S, or N; X 12 is D, Y, T, or G; and X 13 is T, or E
  • CDR-3 complementar
  • the TCR or antigen -binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence XiX 2 SX 4 X 5 X 6 X 7 X 8 X9XioXiiXi2Xi3Q (SEQ ID NO: 1223), where Xi is A, or S; X 2 is S, or A; X 4 is L, Y, P, or S; X 5 is W, F, V, L, or Y; X 6 is G, or A; X 7 is A, R, Q, S, or null; X 8 is G, or null; X9 is G, or null; X 10 is S, T, R, or G; Xn is T, A, R, S, or N; X 12 is D, Y, T, or G; and X 13 is T, or E.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen -binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ASX3X4X5X6X7X8X9X10X11X12F (SEQ ID NO: 1214), where X 3 is S, Q, or R; X 4 is H, P, T, or E; X 5 is L, G, W, or F; X 6 is A, G, or null; X 7 is G, N, S, R, or null; X 8 is F, G, Q, L, A, or null; X9 IS T, N, or A; Xio is G, T, N, or E; Xn is E, N, or K; and Xn is L, A, or Q.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen -binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ASSX 4 X 5 X 6 X 7 X 8 NYXnYT (SEQ ID NO: 1215), where X 4 is L, or R; X 5 is S, or T; X 6 is G, T, or A; X 7 is T, or null; X 8 is G, or null; and Xn is G, or null.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen -binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ASSX 4 WGX 7 SNQPXi 2 H (SEQ ID NO: 1216), where X 4 is L, F, or P; X 7 is R, or Q; and Xi 2 is Q, or L.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen -binding fragment thereof contains a ⁇ region that contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ASSX 4 X 5 X 6 X 7 X 8 SGNTIY (SEQ ID NO: 1217), where X 4 is L, or R; X 5 is W, or Q; X 6 is G, or P; X 7 is R, or S; and X 8 is S, or null.
  • CDR-3 complementarity determining region 3
  • the ⁇ region contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence XiX 2 HX 4 Xs (SEQ ID NO: 252), where X 1 is S or M; X 2 is G, E, D, or N; X 4 is V, N, or E; and X5 is S, R, N, or Y.
  • CDR-1 complementarity determining region 1
  • the ⁇ region contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 (SEQ ID NO: 1218), where Xi is S, M, D, or L; X 2 is G, E, D, N, Q, S, or F; X 3 is H, V, Y, N, or Q; X 4 is A, S, F, or null; X 5 is W V, N, E, T, P, Y, K, D, or L; and X 6 is S, R, A, N, Y, M, or T.
  • CDR-1 complementarity determining region 1
  • the ⁇ region contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence XiX 2 X 3 X 4 XsX 6 (SEQ ID NO: 255), where Xi is F or S; X 2 is Q, Y, or V; X 3 is N, D, or G; X 4 is E or V; X 5 is A, K, or G; and X 6 is Q, M, or T.
  • CDR-2 complementarity determining region 2
  • the ⁇ region contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence ⁇ 2 ⁇ 3 ⁇ 4 ⁇ 5 ⁇ 6 ⁇ 7 (SEQ ID NO: 1219), where Xi is F, Y, S, A M; X 2 is N, Q, V, T, Y, or A; X 3 is N, D, E, S, G, I, F, Q, or L; X 4 is G, A, N, or null; X 5 is E, K, V, E, S, T, G, or N; X 6 is A, E, K, G, L, D, V, or N; and X 7 is Q, M, T, A, V, E, P, D, or I.
  • the Va region contains a complementarity determining region 3 (CDR-3) comprising an amino acid sequence set forth in any of SEQ ID NOs: 138, 144, 147,
  • the Va region contains a CDR3 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, or 676, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Va region further contains a complementarity determining region 1 (CDR-1) comprising an amino acid sequence set forth in any of SEQ ID NOs: 136, 142, 161, 165 171, 302, 306, 537, 570, or 677, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-1 complementarity determining region 1
  • the Va region contains a CDR- 1 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, or 676, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Va region further contains a complementarity determining region 2 (CDR-2) comprising an amino acid sequence set forth in any of SEQ ID NOs: 137, 143, 162, 166, 172, 303, 307, 538, 571, or 678, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-2 complementarity determining region 2
  • the Va region contains a CDR-2 contained within the amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, or 676,or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the ⁇ region contains a complementarity determining region 3 (CDR-3) comprising an amino acid sequence set forth in any of SEQ ID NOs: 141, 146, 150,
  • the ⁇ region contains a complementarity determining region 1 (CDR-1) comprising an amino acid sequence set forth in any of SEQ ID NOs: 139, 145, 148, 168, 484, 546, 561, 579, or 668, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-1 complementarity determining region 1
  • the ⁇ region contains a CDR-1 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 122, 124 126, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, or 685, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the ⁇ region further contains a complementarity determining region 2 (CDR-2) comprising an amino acid sequence set forth in any of SEQ ID NOs: 140, 149, 169, 485, 547, 562, 580, or 669, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-2 complementarity determining region 2
  • the ⁇ region contains a CDR-2 contained within the amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 122, 124 126, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, or 685, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a complementarity determining region 1 (CDR-1) comprising an amino acid sequence set forth in any of SEQ ID NOs: 136, 142, 161, 165, 171, 302, 306, 537, 570, or 677, a complementarity determining region 2 (CDR-2) comprising an amino acid sequence set forth in any of SEQ ID NOs: 137, 143, 162, 166, 172, 303, 307, 538, 571, or 678, and/or a
  • CDR-1 complementarity determining region 1
  • CDR-2 complementarity determining region 2
  • CDR-3 complementarity determining region 3 (CDR-3) comprising an amino acid sequence set forth in any of SEQ ID NOs: 138, 144, 147, 163, 167 173, 304, 308, 478, 493, 505, 511, 523, 539, 555, 572, 588, 600, 612, 624, 638, 650, 662, or 679. Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a ⁇ region that contains a complementarity determining region 1 (CDR-1) comprising an amino acid sequence set forth in any of SEQ ID NOs: 139, 145, 148, 168, 484, 546, 561, 579, or 668, a complementarity determining region 2 (CDR-2) comprising an amino acid sequence set forth in any of SEQ ID NOs: 140, 149, 169, 485, 547, 562, 580, or 669, and/or a complementarity determining region 3 (CDR-3) comprising an amino acid sequence set forth in any of SEQ ID NOs: 141, 146, 150, 164, 170 174, 305, 309, 486, 499, 517, 531, 548, 563, 581, 594, 606, 618, 630, 644, 656, 670, or 686.
  • CDR-1 complementarity determining region 1
  • CDR-2 complementarity determining region 2
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 138, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 139, 140, and 141, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 142, 143, and 144, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 145, 140, and 146, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 147, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 150, respectively.
  • Also among the provided TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 161, 162, and 163, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 164, respectively.
  • Also among the provided TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 165, 166, and 167, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 168, 169, and 170, respectively.
  • Also among the provided TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 171, 172, and 173, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 174, respectively.
  • Also among the provided TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 302, 303, and 304, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 139, 140, and 305, respectively.
  • Also among the provided TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 306, 307, and 308, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 309, respectively.
  • Also among the provided TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 478, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 484, 485, and 486, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 161, 162, and 493, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 499, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 165, 166, and 505, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 499, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 161, 162, and 511, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 517, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 523, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 531, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 537, 538, and 539, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 546, 547, and 548, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 555, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 561, 562, and 563, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 570, 571, and 572, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 579, 580, and 581, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 588, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 594, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 600, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 606, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 612, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 618, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 624, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 168, 169, and 630, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 142, 143, and 638, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 561, 562, and 644, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 171, 172, and 650, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 148, 149, and 656, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 136, 137, and 662, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 668, 669, and 670, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 677, 678, and 679, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 686, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, or 676.
  • CDR-1 complementarity determining region 1
  • CDR-2 CDR-2
  • CDR-3 respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599
  • the ⁇ region contains a complementarity determining region 1 (CDR- 1), a CDR-2, and a CDR-3, respectively comprising the CDR- 1, CDR-2, and CDR-3 amino acid sequences contained within a ⁇ region amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 122, 124 126, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, or 685.
  • TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment includes a Va region that contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 2; and aVp region that contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 2.
  • CDR-1 complementarity determining region 1
  • CDR-2 CDR-2
  • CDR-3 CDR-3 amino acid sequences set forth in Table 2
  • aVp region that contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 2.
  • the provided TCRs are those containing sequences at least at or about 90, 91, 92,
  • the TCR or antigen-binding fragment thereof contains Va and ⁇ regions containing the amino acid sequences of SEQ ID NOs: 111 and 112, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 113 and 114, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 115 and 116, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 121 and 122, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 123 and 124, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 125 and 126, respectively. In some examples, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 297 and 298, respectively. In some examples, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 299 and 300, respectively. In some embodiments, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 477 and 483, respectively. In some examples, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 492 and 498, respectively. In some cases, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 504 and 498, respectively.
  • the TCR or antigen-binding fragment thereof contains Va and ⁇ regions containing the amino acid sequences of SEQ ID NOs: 510 and 516, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 522 and 530, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 536 and 545, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 554 and 560, respectively.
  • the TCR or antigen-binding fragment thereof contains Va and ⁇ regions containing the amino acid sequences of SEQ ID NOs: 569 and 578, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 587 and 593, respectively. In some examples, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 599 and 605, respectively. In some embodiments, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 611 and 617, respectively. In some cases, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 623 and 629, respectively. In some instances, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 637 and 643, respectively. In some cases, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 649 and 655, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 661 and 667, respectively. In some cases, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 676 and 685, respectively. Also among the provided TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the alpha chain of the TCR or antigen-binding fragment thereof further contains a Ca region or portion thereof and/or the beta chain further contains a C ⁇ region or portion thereof.
  • the Ca region or portion thereof comprises the amino acid sequence set forth in any of SEQ ID NOs: 212, 213, 215, 218, or 524, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the C ⁇ region contains the amino acid sequence set forth in SEQ ID NO: 214, 216, or 631, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Ca and/or C ⁇ regions are modified, for example, by incorporation of one or more non-native cysteine residues, such as any described herein.
  • the Ca region or portion thereof contains a non-native cysteine at residue 48 and comprises the amino acid sequence set forth in any of SEQ ID NOs: 196, 198, 201, 203, or 525, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence and that contains the introduced non-native cysteine residue (e.g. Cys48).
  • the C ⁇ region contains a non-native cysteine at residue 57 and contains the amino acid sequence set forth in SEQ ID NO: 197, 199, or 632, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the TCR or antigen-binding fragment thereof comprises an alpha chain comprising the sequence of amino acids set forth in SEQ ID NO: 18, 28, 38, 68, 78, 88, 287, 291, 473, 488, 500, 506, 518, 532, 550, 565, 583, 595, 607, 619, 633, 645, 657, or 672, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence and/or a beta chain comprising the sequence of amino acids set forth in SEQ ID NO:
  • sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the TCR or antigen-binding fragment thereof comprises an alpha chain comprising the sequence of amino acids set forth in SEQ ID NO: 19, 29, 39, 69, 79,
  • sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Va and ⁇ regions contain the amino acid sequences corresponding to the SEQ ID NOs. set forth in Table 3 or Table 4.
  • the TCR contains constant alpha and constant beta region sequences, such as those corresponding to the SEQ ID NOs. set forth in Table 3 or Table 4.
  • the TCR contains a full sequence comprising the variable and constant chain, such as a sequence corresponding to the SEQ ID NOs. set forth in Tables 3 or 4("Full").
  • the full sequence containing the variable and constant regions also includes a signal sequence and thus comprises a sequence corresponding to the SEQ ID NOs. set forth in Table 3 or 4 ("Full + signal").
  • TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR recognizes or binds a peptide epitope derived from HPV 16 E7 that is or contains E7(l l-19) YMLDLQPET (SEQ ID NO: 236). In some embodiments, the TCR recognizes or binds HPV 16 E7(l 1-19) in the context of an MHC, such as an MHC class I, e.g., HLA-A2.
  • an MHC such as an MHC class I, e.g., HLA-A2.
  • the TCR or antigen-binding fragment thereof contains a Va region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence XiX 2 SX 4 X 5 X 6 X 7 X 8 X9XioXn (SEQ ID NO: 249), where Xi is A or V; X 2 is E or V; X 4 is I or R; X5 is R or D; X 6 is G or N; X 7 is F or Y; X 8 is N or Q; X9 is V or N; X10 is L or F; and Xn is H or V.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a Va region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 X 7 X 8 X9XioXi 1X12X13X14 (SEQ ID NO: 1183), where Xi is V, or A; X 2 is V, A, G, Q, M, or E; X 3 is S, G, A, N, Y, R, T, or P; X 4 is E, A, S, G, R.
  • CDR-3 complementarity determining region 3
  • X 5 is R, N, H, T, D, G, S, A, P, L, Q, or F
  • X 6 is G, H, N, A, S, L, T, or null
  • X 7 is T, S, G, or null
  • X 8 is G, or null
  • X 9 is G, Y, N, S, or null
  • Xi 0 is T, G, S, D, F, Y, A, N, or null
  • X n is Y, F, Y, Q, N, or R
  • X 12 is N, K, Q, or D
  • X 13 is Y, L, T, F, M, or V
  • X 14 is I, T, S, V, R, or Y.
  • the TCR or antigen-binding fragment thereof contains a Va region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence VVX 3 X 4 X 5 X 6 X 7 X 8 GXioXi 1X12X13 (SEQ ID NO: 1184), where X 3 is S, N, or T; X 4 is R, or F; Xs is D, or A; X 6 is N, or L; X 7 is T, or null; X 8 is Y, or G; Xio is Q, or F; Xn is N, or K; X12 is F, or T; and X13 is V, or I.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a Va region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX2X3X4X5X6X7X8X9X10X11X12X13X14 (SEQ ID NO: 1185), where X 2 is A, G, V, Q, M, or E; X 3 is S, G, N, A, Y, R, or P; X 4 is E, S, A, G, F, N, D, V, P, L, I, M, or R; X 5 is R, N, H, T, D, G, S, P, L, Q, or F; X 6 is G, H, A, S, T, or null; X 7 is T, S, G, or null; X 8 is G, or null; X 9 is G, N, S, or null; X 10 is T, G, S, D, F, Y, A, or
  • the TCR or antigen-binding fragment thereof contains a Va region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence XiX ⁇ X ⁇ sXeX T s g ioKX ⁇ I (SEQ ID NO: 1186), where Xi is A, or V; X 2 is A, V, or E; X 3 is S, N, T, R, or P; X 4 is E, A, G, F, V, P, I, D, or S; X 5 is R, H, T, A P, S, G, or F; X 6 is G, H, L, T, S, A, or null; X 7 is S, T, or null; X 8 is G, or null; X9 is G, T, or null; X10 is F, Y, or N; and X12 is Y, T, or L.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a Va region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX 2 X 3 X 4 X 5 X 6 X 7 X 8 X9 YI (SEQ ID NO: 1187), where X 2 is A, V, or E; X 3 is S, N, or R; X 4 is E, G, V, P, I, or D; X 5 is R, T, P, S, G, or F; X 6 is G, T, S, or null; X 7 is S, or null; X 8 is G, or null; and X9 is T, or null.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a Va region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX2X3X X5X6X7X8X9X10X11X12X13X14 (SEQ ID NO: 1188), where X 2 is G, V, Q, or M; X 3 is G, A, Y, S, N, or R; X 4 is S, G, L, I, M, or R; X 5 is N, D, G, S, L, Q, or R; X 6 is A, S, G, or null; X 7 is G, or null; X 8 is G, or null; X9 is G, N, S, or null; X10 is S, D, Y, A, N, or null; Xn is Y, Q, or R; Xi 2 is K, or Q; X 13 is L, or V; and Xi 4 is
  • the TCR or antigen-binding fragment thereof contains a Va region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ⁇ 2 ⁇ 3 ⁇ 4 ⁇ 5 ⁇ 6 ⁇ 7 ⁇ 8 ⁇ 9 ⁇ 2 ⁇ 3 ⁇ (SEQ ID NO: 1189), where X 2 is G, V, or Q; X 3 is G, Y, S, or N; X 4 is S, L, or M; X 5 is N, G, L, or R; X 6 is A, S, G, or null; X 7 is G, or null; X 8 is G, or null; X9 is G, S, or null; X10 is S, Y, A, N, or null; Xn is Y, Q, or R; X12 is K, or Q; and Xi 3 is L, or V.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a Va region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX 2 X 3 X 4 X 5 X 6 X 7 YKLS (SEQ ID NO: 1190), where X 2 is G, or V; X 3 is A, or Y; X 4 is G, S, or R; X5 is D, or S; X 6 is N, or null; and X 7 is D, or null.
  • CDR-3 complementarity determining region 3
  • the Va region contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence XiSX X 4 X 5 X 6 (SEQ ID NO: 241), where Xi is D or V; X 3 is S, or P; X 4 is S or F; X5 is T or S; and X 6 i s Y or N.
  • CDR-1 complementarity determining region 1
  • the Va region contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 (SEQ ID NO: 1191), where Xi is N, S, D, T, or V; X 2 is S, V, R, T, or I ; X 3 is M, F, G, S, N, A, L, V, or P; X 4 is F, S, N, A, or null; X 5 is D, S, Q, Y, N, V, T, or P; and X 6 is Y, S, R, N, G, or T.
  • CDR-1 complementarity determining region 1
  • the Va region contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence XiX 2 X X 4 X 5 X 6 X 7 (SEQ ID NO: 245), where Xi is I or M; X 2 is F or T; X 3 is S or F; X 4 is N or S; X 5 is M or E; X 6 is D or N; and X 7 is M or T.
  • CDR-2 complementarity determining region 2
  • the Va region contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence XiX 2 X 3 X 4 XsX 6 X 7 X8 (SEQ ID NO: 1192), where Xi is I, V, L, G, N, T, Y, or M; X 2 is S, V, Y, L, P, F, I, or T; X 3 is S, Y, K, L, T, or F; X 4 is I, G, N, A, S, or null; X 5 is S, D, or null; X 6 is K, G, N, S, D, T, or E; X 7 is D, E, G, A, K, L, or N; and X 8 is K, V, D, P, N, T, L, or M.
  • CDR-2 complementarity determining region 2
  • Xi is I, V, L, G, N, T, Y, or M
  • X 2 is S, V,
  • the TCR or antigen -binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX 2 TX 4 RX 6 X 7 YX 9 Xi 0 Xii (SEQ ID NO: 259), where X 2 is S or I; X 4 is T or D; X 6 is S or T; X 7 is S or N; X9 is E or G; X10 is Q or Y; and Xn is Y or T.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ⁇ 2 ⁇ 4 ⁇ 5 ⁇ 6 ⁇ 7 ⁇ 8 ⁇ 9 ⁇ 2 (SEQ ID NO: 1194), where X 2 is S, M, I, or K; X 4 is P, T, G, A, S, or D; X 5 is R, or S; X 6 is D, G, S, T, or V; X 7 is R, S, or null; X 8 is T, Y, G, N, or S; X 9 is Y, N, or K; Xi 0 is E, or G; Xn is Q, A, or Y; and X i2 is Y, F, or T.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX2X3X4X5X6X7X8X9X10X11X12X13X14 (SEQ ID NO: 1195), where X 2 is S, M, I, or K; X 3 is S, T, A, or N; X 4 is R, V, S, P, T, G, L, or A; X 5 is F, G, R, Y, S, V, or T; X 6 is L, G, D, A, S, T, V, or null; X 7 is G, D, R, T, or null; X 8 is S, or null; X 9 is S, H, G, R, V, T, L, or null; X 10 is T, S, Y, A, N, G, or P; Xn is D, Y, N, K,
  • CDR-3 complementarity
  • the TCR or antigen-binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX2X3X4X5X6X7X8X9X1 oX 11 Q Y (SEQ ID NO: 1196), where X 2 is S, M, I, or K; X 3 is S, T, A, or N; X 4 is R, P, S, G, L, A, or T; X 5 is F, R, Y, V, or T; X 6 is L, D, A, S, T, V, or null; X 7 is G, R, or null; X 8 is S, G, V, or null; X 9 is T, A, G, N, S, or P; X 10 is D, Y, or E; and Xn is T, or E.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX 2 X 3 X 4 X 5 X 6 X 7 X 8 X9l EQY (SEQ ID NO: 1197), where X 2 is S, M, I, or K; X 3 is S, T, A, or N; X 4 is P, S, G, T, or A; X 5 is R, or Y; X 6 is D, A, S, T, or V; X 7 is R, or null; X 8 is G, V, or null; and X9 is S, T, A, or N.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ASTX 4 X 5 X 6 X 7 X 8 X9XioXiiEXi 3 Xi 4 (SEQ ID NO: 1198), where X 4 is T, P, or G; X 5 is R, or S; X 6 is S, D, G, or V; X 7 is D, or null; X 8 is S, or null; X9 IS S, R, or null; Xio is S, T, Y, or G ; Xn is Y, N, or K; X 13 is Q, or A; and X 14 is Y, or F.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX 2 X 3 X 4 X 5 X 6 X 7 X 8 YGYT (SEQ ID NO: 1199), where X 2 is S, or I; X 3 is S, or T; X 4 is L, A, or D; X5 is L, T, or R; X 6 is L, T, or R; X 7 is G, D, or null; and X 8 is A, or N.
  • CDR-3 complementarity determining region 3
  • the TCR or antigen-binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence AX 2 X 3 X 4 X 5 X 6 X 7 X 8 X9Xio ii i2 i3 i4 (SEQ ID NO: 1200), where X 2 is S, V, or I; X 3 is S, N, or A; X 4 is R, V, S, L, P, G, I, or A; X 5 is F, G, Y, L, V, R, T, or S; X 6 is L, G, A, D, R, V, or null; X 7 is G, D, R, S, T, or null; X 8 is S, or null; X9 IS S, H, G, V, T, D, L, or null; Xio is T, S, A, G, P, N, or Y; X
  • the TCR or antigen-binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ASSX ⁇ XsXeX T XsXgXioXnXiiXisXi ⁇ SEQ ID NO: 1201), where X 4 is R, V, S, L, G, or A; X 5 is F, G, Y, L, V, T, or S; X 6 is A, L, R, D, G, or null; X 7 is G, D, T, or null; X 8 is S, or null; X 9 is S, H, G, T, D, L, or null; X 10 is T, S, A, G, P, N, or Y; Xn is D, Y, E, G, or N; X 12 is T, E, G, or T; X 13 is Q, Y, or L; and X 14 is Y, F,
  • the TCR or antigen-binding fragment thereof contains a ⁇ region containing a complementarity determining region 3 (CDR-3) comprising the amino acid sequence ASSX 4 X 5 X 6 X 7 X 8 X9Xi 0 TQY (SEQ ID NO: 1202), where X 4 is R, L, or G; X 5 is F, V, T, or Y; X 6 is L, A, or null; X 7 is G, or null; X 8 is S, G, or null; X9 is T, G, P, or S; and X10 is D, or E.
  • CDR-3 complementarity determining region 3
  • the ⁇ region contains a complementarity determining region
  • CDR-1 comprising the amino acid sequence SX 2 X 3 X 4 X 5 (SEQ ID NO: 1203), where X 2 is G, or N; X 3 is H, or D; X 4 is T, L, N, or V; and X 5 is A, S, Y, or T.
  • the ⁇ region contains a complementarity determining region
  • CDR-2 comprising the amino acid sequence XiX 2 X 3 X 4 X 5 X 6 (SEQ ID NO: 1204), where Xi is F, or Y; X 2 is Q, Y, or N; X 3 is G, N, R, or Y; X 4 is N, G, E, or T; X 5 is S, E, A, or G; and X 6 is A, E, I, or Q.
  • the ⁇ region contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence set forth in SEQ ID NO: 154, 701, 719, or 751.
  • the ⁇ region contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence set forth in SEQ ID NO: 155, 702, 720, 752, 918, or 1009.
  • the Va region contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence set forth in any of SEQ ID NOs: 153, 159, 301, 694, 712, 729, 744, 762, 776, 788, 802, 818, 832, 846, 858, 870, 882, 896, 911, 926, 940, 952, 964, 976, 988, or 1002, or a CDR3 contained within the amino acid sequence set forth in any of SEQ ID NOs: 117, 119, 295, 691, 709, 726, 741, 759, 775, 787, 799, 815, 830, 845, 857, 869, 881, 895, 908, 925, 937, 951, 963, 975, 987, or 999.
  • the Va region contains a CDR3 sequence at least at or about 90, 91, 92, 93, 94, 95,
  • the Va region further contains a complementarity determining region 1 (CDR-1) comprising an amino acid sequence set forth in any of SEQ ID NOs: 151, 157, 692, 710, 727, 742, 760, 800, 816, 909, 938, or 1000, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-1 complementarity determining region 1
  • the Va region further contains a complementarity determining region 2 (CDR-2) comprising an amino acid sequence set forth in any of SEQ ID NOs: 152, 158, 693, 711, 728, 743, 761, 801, 817, 831, 833, 910, 939, or 1001, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-2 complementarity determining region 2
  • the ⁇ region contains a complementarity determining region 3 (CDR-3) comprising an amino acid sequence set forth in any of SEQ ID NOs: 156, 160, 703, 721, 736, 753, 769, 782, 794, 809, 825, 840, 852, 864, 876, 888, 902, 919, 932, 946, 958, 970, 982, 994, or 1010, or a CDR3 contained within the amino acid sequence set forth in any of SEQ ID NOs: 118, 120, 296, 700, 718, 735, 750, 768, 781, 793, 808, 824, 839, 851, 863, 875, 887, 901, 917, 931, 945, 957, 969, 981, 993, or 1008.
  • CDR-3 complementarity determining region 3
  • the Vp region contains a CDR3 sequence at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the ⁇ region contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence set forth in SEQ ID NO: 154, 701, 719, or 751, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-1 complementarity determining region 1
  • the ⁇ region contains a complementarity determining region 2 (CDR-2) comprising the amino acid sequence set forth in SEQ ID NO: 155, 702, 720, 752, 918, or 1009, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-2 complementarity determining region 2
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 151, 152, and 153, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 156, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 157, 158, and 159, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 160, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 151, 152, and 301, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 156, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 692, 693, and 694, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 701, 702, and 703, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 710, 711, and 712, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 719, 720, and 721, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 727, 728, and 729, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 736, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 742, 743, and 744, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 751, 752, and 753, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 760, 761, and 762, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 719, 720, and 769, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 171, 172, and 776, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 782, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 742, 743, and 788, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 139, 140, and 794, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 800, 801, and 802 respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 751, 752, and 809, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 816, 817, and 818, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 825, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 816, 831, and 832, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 840, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 171, 172, and 846, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 852, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 816, 833, and 858, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 864, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 727, 728, and 870, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 876, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 570, 571, and 882, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 719, 720, and 888, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 816, 817, and 896, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 701, 702, and 902, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 909, 910, and 911, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 701, 918, and 919, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 727, 728, and 926, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 932, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 938, 939, and 940, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 946, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 727, 728, and 952, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 958, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 151, 152, and 964, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 719, 720, and 970, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 727, 728, and 976, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 154, 155, and 982, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 710, 711, and 988, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 719, 720, and 994, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment thereof contains a Va region that contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 1000, 1001, and 1002, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 139, 1009, and 1010, respectively.
  • Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in any of SEQ ID NOs: 117, 119, 295, 691, 709, 726, 741, 759, 775, 787, 799, 815, 830, 845, 857, 869, 881, 895, 908, 925, 937, 951, 963, 975, 987, or 999.
  • CDR-1 complementarity determining region 1
  • CDR-2 complementarity determining region 1
  • CDR-3 CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in any of SEQ ID NOs: 117, 119, 295, 691, 709, 726, 741, 759, 775, 787, 799, 815, 830, 845, 857, 869, 881
  • the Vp region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a ⁇ region amino acid sequence set forth in any of SEQ ID NOs: 118, 120, 296, 700, 718, 735, 750, 768, 781, 793, 808, 824, 839, 851, 863, 875, 887, 901, 917, 931, 945, 957, 969, 981, 993, or 1008.
  • TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment includes a Va region that contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 5and a ⁇ region that contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 5.
  • CDR-1 complementarity determining region 1
  • CDR-2 CDR-2
  • CDR-3 respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 5.
  • the TCR or antigen-binding fragment thereof contains Va and ⁇ regions containing the amino acid sequences of SEQ ID NOs: 117 and either 118 or 296, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 119 and 120, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 295 and either 118 or 296, respectively.
  • Also among the provided TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 691 and 700, respectively. In some instances, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 709 and 718, respectively. In some aspects, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 726 and 735, respectively. In some embodiments, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 741 and 750, respectively. In some cases, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 759 and 768, respectively. In some aspects, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 775 and 781, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 787 and 793, respectively. In some examples, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 799 and 808, respectively. In some cases, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 815 and 824, respectively. In some instances, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 830 and 839, respectively. In some embodiments, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 845 and 851, respectively. In some aspects, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 857 and 863, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 869 and 875, respectively. In some instances, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 881 and 887, respectively. In some embodiments, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 895 and 901, respectively. In some aspects, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 908 and 917, respectively. In some cases, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 925 and 931, respectively. In some instances, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 937 and 945, respectively.
  • the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 951 and 957, respectively. In some cases, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 963 and 969, respectively. In some instances, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 975 and 981, respectively. In some cases, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 987 and 993, respectively. In some embodiments, the Va and ⁇ regions contain the amino acid sequences of SEQ ID NOs: 999 and 1008, respectively.
  • the alpha chain of the TCR or antigen-binding fragment thereof further contains a Ca region or portion thereof and/or the beta chain further contains a C ⁇ region or portion thereof.
  • the Ca region or portion thereof comprises the amino acid sequence set forth in any of SEQ ID NO: 213, 217, 218, or 524, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the C ⁇ region contains the amino acid sequence set forth in SEQ ID NO: 214, 216, 631, or 889, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Ca and/or CP regions are modified, for example, by incorporation of one or more non-native cysteine residues, such as any described herein.
  • the Ca region or portion thereof contains a non-native cysteine at residue 48 and comprises the amino acid sequence set forth in any of SEQ ID NOs: 196, 200, 201, 203, or 525, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence and that contains the introduced non-native cysteine residue (e.g., Cys48).
  • the CP region contains a non-native cysteine at residue 57 and contains the amino acid sequence set forth in SEQ ID NO: 197, 199, or 890, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93,
  • the TCR or antigen-binding fragment thereof comprises an alpha chain comprising the sequence of amino acids set forth in SEQ ID NO: 48, 58, 283, 687,
  • the TCR or antigen-binding fragment thereof comprises an alpha chain comprising the sequence of amino acids set forth in SEQ ID NO: 49, 59, 284, 688,
  • 972, 984, or 996 or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence and/or a beta chain comprising the sequence of amino acids set forth in SEQ ID NO: 53, 63, 286, 697, 715, 732, 747, 765, 778, 790, 805, 821, 836, 848, 860, 872, 884,
  • the Va and ⁇ regions contain the amino acid sequences corresponding to the SEQ ID NOs. set forth in Table 6 or Table 7.
  • the TCR contains constant alpha and constant beta region sequences, such as those corresponding to the SEQ ID NOs. set forth in Table 6 or Table 7.
  • the TCR contains a full sequence comprising the variable and constant chain, such as a sequence corresponding to the SEQ ID NOs. set forth in Table 6 or Table 7 ("Full").
  • the full sequence containing the variable and constant regions also includes a signal sequence and thus comprises a sequence corresponding to the SEQ ID NOs. set forth in Table 6 or Table 7 ("Full + signal").
  • TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR recognizes or binds a peptide epitope derived from HPV 16 E7 that is or contains E7(86-93) TLGIVCPI (SEQ ID NO: 235). In some embodiments, the TCR recognizes or binds HPV 16 E7(86-93) in the context of an MHC, such as an MHC class I, e.g. HLA-A2.
  • an MHC such as an MHC class I, e.g. HLA-A2.
  • the Va region contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence set forth in SEQ ID NO: 175.
  • the Va region contains a CDR3 sequence at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a complementarity determining region 1 (CDR-1) comprising the amino acid sequence set forth in SEQ ID NO: 142, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Va region comprises a
  • CDR-2 complementarity determining region 2
  • SEQ ID NO: 143 or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the ⁇ region contains a complementarity determining region 3 (CDR-3) comprising the amino acid sequence set forth in SEQ ID NO: 178, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • CDR-3 complementarity determining region 3
  • the ⁇ region contains a complementarity determining region 1 (CDR-1) comprising an amino acid sequence set forth in SEQ ID NO: 176, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the ⁇ region contains a complementarity determining region 2 (CDR-2) comprising an amino acid sequence set forth in SEQ ID NO: 177, or a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Va region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 142, 143, and 175, respectively.
  • the ⁇ region contains a CDR-1, CDR-2, and CDR-3, comprising the amino acid sequences of SEQ ID NOs: 176, 177, and 178, respectively. Also among the provided TCRs are those having sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the Va region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in SEQ ID NO: 127.
  • the ⁇ region contains a CDR-1, a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a ⁇ region amino acid sequence set forth in SEQ ID NO: 128.
  • TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the TCR or antigen-binding fragment includes a Va region contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 8. and a ⁇ region that contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 8.
  • CDR-1 complementarity determining region 1
  • CDR-2 CDR-2
  • CDR-3 respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 8.
  • a ⁇ region that contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences set forth in Table 8.
  • the provided TCRs are those containing sequences at least
  • the TCR or antigen-binding fragment thereof contains Va and ⁇ regions comprise the amino acid sequences of SEQ ID NOs: 127 and 128, respectively. Also among the provided TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the alpha chain of the TCR or antigen-binding fragment thereof further contains a Ca region or portion thereof and/or the beta chain further contains a CP region or portion thereof.
  • the Ca region or portion thereof comprises the amino acid sequence set forth in any of SEQ ID NO: 212, 213 or 217, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the CP region contains the amino acid sequence set forth in SEQ ID NO: 214, or 216, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Ca and/or CP regions are modified, for example, by incorporation of one or more non-native cysteine residues, such as any described herein.
  • the Ca region or portion thereof contains a non-native cysteine at residue 48 and comprises the amino acid sequence set forth in SEQ ID NO: 200, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence and that contains the introduced non-native cysteine residue (e.g. Cys48).
  • the CP region contains a non-native cysteine at residue 57 and contains the amino acid sequence set forth in SEQ ID NO: 197 or 199, or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the TCR or antigen-binding fragment thereof comprises an alpha chain comprising the sequence of amino acids set forth in SEQ ID NO: 98 or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence and/or a beta chain comprising the sequence of amino acids set forth in SEQ ID NO: 102 or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the TCR or antigen-binding fragment thereof comprises an alpha chain comprising the sequence of amino acids set forth in SEQ ID NO: 99 or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence and/or a beta chain comprising the sequence of amino acids set forth in SEQ ID NO: 103 or a sequence of amino acids that has at least 90% sequence identity thereto, such as a sequence having at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with such a sequence.
  • the Va and ⁇ regions contain the amino acid sequences corresponding to the SEQ ID NOs. set forth in Table 9 or Table 10.
  • the TCR contains constant alpha and constant beta region sequences, such as those corresponding to the SEQ ID NOs. set forth in Table 9 or Table 10.
  • the TCR contains a full sequence comprising the variable and constant chain, such as a sequence corresponding to the SEQ ID NOs. set forth in Table 9 or Table 10 ("Full").
  • the full sequence containing the variable and constant regions also includes a signal sequence and thus comprises a sequence corresponding to the SEQ ID NOs. set forth in Table 9 or Table 10 ("Full + signal").
  • TCRs are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the binding molecule e.g., TCR or antigen-binding fragment thereof
  • the binding molecules include one or more amino acid variations, e.g., substitutions, deletions, insertions, and/or mutations, compared to the sequence of a binding molecule, e.g., TCR, described herein.
  • Exemplary variants include those designed to improve the binding affinity and/or other biological properties of the binding molecule.
  • Amino acid sequence variants of a binding molecule may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the binding molecule, or by peptide synthesis.
  • Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the binding molecule. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
  • directed evolution methods are used to generate TCRs with altered properties, such as with higher affinity for a specific peptide in the context of an MHC molecule.
  • directed evolution is achieved by display methods including, but not limited to, yeast display (Holler et al. (2003) Nat Immunol, 4, 55-62; Holler et al. (2000) Proc Natl Acad Sci U S A, 97, 5387-92), phage display (Li et al. (2005) Nat Biotechnol, 23, 349-54), or T cell display (Chervin et al. (2008) J Immunol Methods, 339, 175-84).
  • display approaches involve engineering, or modifying, a known, parent or reference TCR.
  • a reference TCR such as any provided herein, can be used as a template for producing mutagenized TCRs in which in one or more residues of the CDRs are mutated, and mutants with an desired altered property, such as higher affinity for peptide epitope in the context of an MHC molecule, are selected.
  • the binding molecules e.g., TCRs or antigen-binding fragments thereof, include one or more amino acid substitutions, e.g., as compared to a binding molecule, e.g., TCR, sequence described herein and/or compared to a sequence of a natural repertoire, e.g., human repertoire.
  • Sites of interest for substitutional mutagenesis include the CDRs, FRs and /or constant regions.
  • Amino acid substitutions may be introduced into a binding molecule of interest and the products screened for a desired activity, e.g., retained/improved antigen affinity or avidity, decreased immunogenicity, improved half-life, CD8-independent binding or activity, surface expression, promotion of TCR chain pairing and/or other improved properties or functions.
  • a desired activity e.g., retained/improved antigen affinity or avidity, decreased immunogenicity, improved half-life, CD8-independent binding or activity, surface expression, promotion of TCR chain pairing and/or other improved properties or functions.
  • one or more residues within a CDR of a parent binding molecule is/are substituted.
  • the substitution is made to revert a sequence or position in the sequence to a germline sequence, such as a binding molecule sequence found in the germline (e.g., human germline), for example, to reduce the likelihood of immunogenicity, e.g., upon administration to a human subject.
  • substitutions, insertions, or deletions may occur within one or more CDRs so long as such alterations do not substantially reduce the ability of the binding molecule, e.g., TCR or antigen-binding fragment thereof, to bind antigen.
  • each CDR either is unaltered, or contains no more than one, two or three amino acid substitutions.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
  • the TCR or antigen-binding fragment thereof may contain one or more modifications in the alpha chain and/or beta chain such that when the TCR or antigen- binding fragment thereof is expressed in a cell, the frequency of mis-pairing between the TCR alpha chain and beta chain and an endogenous TCR alpha chain and beta chain is reduced, the expression of the TCR alpha chain and beta chain is increased, and/or the stability of the TCR alpha chain and beta chain is increased.
  • the TCR contains one or more non-native cysteine residues to introduce a covalent disulfide bond linking a residue of the immunoglobulin region of the constant domain of the a chain to a residue of the immunoglobulin region of the constant domain of the ⁇ chain.
  • one or more cysteines can be incorporated into the constant region extracellular sequences of the first and second segments of the TCR polypeptide. Exemplary non-limiting modifications in a TCR to introduce a non-native cysteine residues are described herein (see also, International PCT No. WO2006/000830 and
  • both a native and a non-native disulfide bond may be desirable.
  • the TCR or antigen-binding fragment is modified such that the interchain disulfide bond in a native TCR is not present.
  • the transmembrane domain of the constant region of the TCR can be modified to contain a greater number of hydrophobic residues (see e.g. Haga-Friedman et al. (2012) Journal of Immunology, 188:5538-5546).
  • the tranmembrane region of TCR a chain contains one or more mutations corresponding to S 116L, Gl 19V or F120L, with reference to numbering of a Ca set forth in any of SEQ ID NOS: 212, 213, 215, 217, 220, or 524.
  • the cell expressing the TCR further includes a marker, such as a cell surface marker, which may be used to confirm transduction or engineering of the cell to express the TCR, such as a truncated version of a cell surface receptor, such as truncated EGFR (tEGFR).
  • a marker such as a cell surface marker, which may be used to confirm transduction or engineering of the cell to express the TCR, such as a truncated version of a cell surface receptor, such as truncated EGFR (tEGFR).
  • the marker includes all or part (e.g., truncated form) of CD34, a NGFR, or epidermal growth factor receptor (e.g., tEGFR).
  • the nucleic acid encoding the marker is operably linked to a polynucleotide encoding for a linker sequence, such as a cleavable linker sequence, e.g., T2A.
  • a linker sequence such as a cleavable linker sequence, e.g., T2A.
  • introduction of a construct encoding the TCR and EGFRt separated by a T2A, P2A or other ribosome switch can express two proteins from the same construct, such that the EGFRt can be used as a marker to detect cells expressing such construct. Exemplary of such markers that can be used are described below.
  • the TCR or antigen-binding fragment thereof is encoded by a nucleotide sequence that is or has been codon-optimized. Exemplary codon-optimized variants are described elsewhere herein.
  • the binding molecule is an antibody or antigen-binding fragment thereof that contains any one or more of the CDRs as described above with respect to TCRs.
  • the antibody or antigen-binding fragment contains variable heavy and light chain containing a CDRl, CDR2 and/or CDR3 contained in the alpha chain and a CDRl, CDR2 and/or CDR3 contained in the beta chain as set forth in Table 2, Table 5, or Table 8. Also among the provided antibodies or antigen-binding fragments are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the antibody or antigen-binding fragment contains a variable region that contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587, 599, 611, 623, 637, 649, 661, or 676.
  • CDR-1 complementarity determining region 1
  • CDR-2 complementarity determining region 1
  • CDR-3 CDR-3 amino acid sequences contained within a Va region amino acid sequence set forth in any of SEQ ID NOs: 111, 113, 115, 121, 123 125, 297, 299, 477, 492, 504, 510, 522, 536, 554, 569, 587
  • the antibody or antigen-binding fragment contains a variable region that contains a complementarity determining region 1 (CDR-1), a CDR-2, and a CDR-3, respectively comprising the CDR-1, CDR-2, and CDR-3 amino acid sequences contained within a ⁇ region amino acid sequence set forth in any of SEQ ID NOs: 112, 114, 116, 122, 124 126, 298, 300, 483, 498, 498, 516, 530, 545, 560, 578, 593, 605, 617, 629, 643, 655, 667, or 685.
  • Also among the provided antibodies or antigen-bind fragments are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences.
  • the provided antibody or antibody fragment is a human antibody.
  • the provided antibody or antibody fragment contains a V H region that contains a portion having at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to an amino acid sequence encoded by a germline nucleotide human heavy chain V segment, a portion with at least 95%, 96%, 97%, 98%, 99%, or 100 % identity to an amino acid sequence encoded by a germline nucleotide human heavy chain D segment, and/or a portion having at least 95%, 96%, 97%, 98%, 99%, or 100 % identity to an amino acid sequence encoded by a germline nucleotide human heavy chain J segment; and/or contains a V L region that contains a portion with at least 95%, 96%, 97%, 98%, 99%, or 100 % identity to an amino acid sequence encoded by a germline nucleotide human kappa or lambda chain V segment
  • the portion of the V H region corresponds to the CDR-H1, CDR-H2 and/or CDR- H3. In some embodiments, the portion of the V H region corresponds to the framework region 1 (FRl), FR2, FR2 and/or FR4. In some embodiments, the portion of the V L region corresponds to the CDR-L1, CDR-L2 and/or CDR-L3. In some embodiments, the portion of the V L region corresponds to the FRl, FR2, FR2 and/or FR4.
  • the antibody or antigen-binding fragment contains a framework region that contains human germline gene segment sequences.
  • the antibody or antigen-binding fragment contains a V H region in which the framework region, e.g. FRl, FR2, FR3 and FR4, has at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a framework region encoded by a human germline antibody segment, such as a V and/or J segment.
  • the human antibody contains a V L region in which the framework region e.g.
  • FRl, FR2, FR3 and FR4 has at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a framework region encoded by a human germline antibody segment, such as a V and/or segment.
  • the framework sequence of the V H and/or V L sequence differs by no more than 10 amino acids, such as no more than 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid, compared to the framework region encoded by a human germline antibody segment.
  • the antibodies and antigen binding fragments thereof e.g. TCR-like antibodies, specifically recognize a peptide epitope in the context of an MHC molecule, such as an MHC class I.
  • the MHC class I molecule is an HLA-A2 molecule, e.g. HLA-A2*01.
  • the antibody or antigen-binding fragment thereof recognizes or binds to an epitope or region of HPV 16 E6, such as a peptide epitope containing an amino acid sequence set forth in any of SEQ ID NOs: 232-234.
  • the TCR or antigen- binding fragment thereof that recognizes or binds a peptide epitope derived from HPV 16 E6 is or comprises the sequence set forth in SEQ ID NO: 233.
  • the TCR or antigen -binding fragment recognizes or binds to an epitope or region of HPV 16 E7 protein, such as a peptide epitope containing an amino acid sequence set forth in any of SEQ ID NOs: 235-239.
  • the TCR or antigen- binding fragment thereof does not recognize or bind the epitope E7 (11-19) comprising the amino acid sequence YMLDLQPET (SEQ ID NO. 236).
  • the peptide derived from HPV16 E7 is or contains the sequence set forth in SEQ ID NO: 235.
  • anti-HPV antibodies including functional antibody fragments.
  • the antibodies V H and/or V L domains, or antigen- binding site thereof, and are capable of specifically binding to a peptide epitope of HPV 16.
  • the antibodies include a variable heavy chain and a variable light chain, such as scFvs.
  • the antibodies include antibodies that specifically bind to HPV, e.g., HPV 16 E6 or HPV 16 E7.
  • the provided anti-HPV antibodies are human antibodies.
  • the antibodies include isolated antibodies. Also provided are molecules containing such antibodies, e.g., single-chain proteins, fusion proteins, and/or recombinant receptors such as chimeric receptors, including antigen receptors.
  • antibody herein is used in the broadest sense and includes polyclonal and monoclonal antibodies, including intact antibodies and functional (antigen-binding) antibody fragments, including fragment antigen binding (Fab) fragments, F(ab') 2 fragments, Fab' fragments, Fv fragments, recombinant IgG (rlgG) fragments, variable heavy chain (V H ) regions capable of specifically binding the antigen, single chain antibody fragments, including single chain variable fragments (scFv), and single domain antibodies (e.g., sdAb, sdFv, nanobody) fragments.
  • Fab fragment antigen binding
  • rlgG Fab' fragments
  • V H variable heavy chain
  • the term encompasses genetically engineered and/or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies, multispecific, e.g., bispecific, antibodies, diabodies, triabodies, and tetrabodies, tandem di-scFv, tandem tri-scFv.
  • antibody should be understood to encompass functional antibody fragments thereof.
  • the term also encompasses intact or full-length antibodies, including antibodies of any class or sub-class, including IgG and sub-classes thereof, IgM, IgE, IgA, and IgD.
  • the heavy and light chains of an antibody can be full-length or can be an antigen-binding portion (a Fab, F(ab')2, Fv or a single chain Fv fragment (scFv)).
  • the antibody heavy chain constant region is chosen from, e.g., IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE, particularly chosen from, e.g., IgGl, IgG2, IgG3, and IgG4, more particularly, IgGl (e.g., human IgGl).
  • the antibody light chain constant region is chosen from, e.g., kappa or lambda, particularly kappa.
  • antibody fragments refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
  • antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab') 2 ; diabodies; linear antibodies;
  • variable heavy chain (V H ) regions single-chain antibody molecules such as scFvs and single- domain V H single antibodies; and multispecific antibodies formed from antibody fragments.
  • the antibodies are single-chain antibody fragments comprising a variable heavy chain region and/or a variable light chain region, such as scFvs.
  • variable region when used in reference to an antibody, such as an antibody fragment, refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
  • the variable domains of the heavy chain and light chain (V H and V L , respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three CDRs.
  • FRs conserved framework regions
  • a single V H or V L domain may be sufficient to confer antigen-binding specificity.
  • antibodies that bind a particular antigen may be isolated using a V H or V L domain from an antibody that binds the antigen to screen a library of complementary V L or V H domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
  • Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
  • a single-domain antibody is a human single-domain antibody.
  • Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells.
  • the antibodies are recombinantly-produced fragments, such as fragments comprising arrangements that do not occur naturally, such as those with two or more antibody regions or chains joined by synthetic linkers, e.g., peptide linkers, and/or that are may not be produced by enzyme digestion of a naturally-occurring intact antibody.
  • the antibody fragments are scFvs.
  • human antibodies are human antibodies.
  • a "human antibody” is an antibody with an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences, including human antibody libraries.
  • the term excludes humanized forms of non-human antibodies comprising non-human antigen- binding regions, such as those in which all or substantially all CDRs are non-human.
  • the term includes antigen-binding fragments of human antibodies.
  • a “humanized” antibody is an antibody in which all or substantially all CDR amino acid residues are derived from non-human CDRs and all or substantially all FR amino acid residues are derived from human FRs.
  • a humanized antibody optionally may include at least a portion of an antibody constant region derived from a human antibody.
  • a "humanized form" of a non-human antibody refers to a variant of the non-human antibody that has undergone humanization, typically to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody.
  • Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic animals, the endogenous immunoglobulin loci have generally been inactivated. Human antibodies also may be derived from human antibody libraries, including phage display and cell-free libraries, containing antibody-encoding sequences derived from a human repertoire.
  • monoclonal antibodies including monoclonal antibody fragments.
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from or within a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical, except for possible variants containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts.
  • polyclonal antibody preparations which typically include different antibodies directed against different epitopes
  • each monoclonal antibody of a monoclonal antibody preparation is directed against a single epitope on an antigen.
  • a monoclonal antibody may be made by a variety of techniques, including but not limited to generation from a hybridoma, recombinant DNA methods, phage-display and other antibody display methods.
  • a "corresponding form" of an antibody means that when comparing a property or activity of two antibodies, the property is compared using the same form of the antibody. For example, if it is stated that an antibody has greater activity compared to the activity of the corresponding form of a first antibody, that means that a particular form, such as a scFv of that antibody, has greater activity compared to the scFv form of the first antibody.
  • Antibody effector functions refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.
  • the antibody e.g., antibody fragment
  • the constant regions include a light chain constant region and/or a heavy chain constant region 1 (CHI).
  • the antibody includes a CH2 and/or CH3 domain, such as an Fc region.
  • the Fc region is an Fc region of a human IgG, such as an IgGl or IgG4.
  • Fc region herein is used to define a C-terminal region of an
  • immunoglobulin heavy chain that contains at least a portion of the constant region.
  • the term includes native sequence Fc regions and variant Fc regions.
  • a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain.
  • the C-terminal lysine (Lys447) of the Fc region may or may not be present.
  • numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
  • full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
  • an "isolated" antibody is one which has been separated from a component of its natural environment.
  • an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC).
  • electrophoretic e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatographic e.g., ion exchange or reverse phase HPLC
  • the antibodies or antigen-binding fragments thereof include one or more amino acid variations, e.g., substitutions, deletions, insertions, and/or mutations, compared to the sequence of an antibody described herein.
  • Exemplary variants include those designed to improve the binding affinity and/or other biological properties of the antibody.
  • Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
  • the antibodies include one or more amino acid substitutions, e.g., as compared to an antibody sequence described herein and/or compared to a sequence of a natural repertoire, e.g., human repertoire.
  • Sites of interest for substitutional mutagenesis include the CDRs and FRs.
  • Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, improved half-life, and/or improved effector function, such as the ability to promote antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).
  • ADCC antibody-dependent cellular cytotoxicity
  • CDC complement-dependent cytotoxicity
  • one or more residues within a CDR of a parent antibody is/are substituted.
  • the substitution is made to revert a sequence or position in the sequence to a germline sequence, such as an antibody sequence found in the germline (e.g., human germline), for example, to reduce the likelihood of immunogenicity, e.g., upon administration to a human subject.
  • alterations are made in CDR "hotspots," residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207: 179-196 (2008)), and/or residues that contact antigen, with the resulting variant V H or V L being tested for binding affinity.
  • Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom et al. in Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001)).
  • affinity maturation diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis).
  • a secondary library may then be created and screened to identify any antibody variants with the desired affinity.
  • Another method to introduce diversity involves CDR-directed approaches, in which several CDR residues (e.g., 4-6 residues at a time) are randomized.
  • CDR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling.
  • CDR-H3 and CDR-L3 in particular are often targeted.
  • substitutions, insertions, or deletions may occur within one or more CDRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen.
  • conservative alterations e.g., conservative substitutions as provided herein
  • Such alterations may, for example, be outside of antigen contacting residues in the CDRs.
  • each CDR either is unaltered, or contains no more than one, two or three amino acid substitutions.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
  • terminal insertions include an antibody with an N-terminal methionyl residue.
  • Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme or a polypeptide which increases the serum half-life of the antibody.
  • the antibody or antigen-binding fragment thereof is altered to increase or decrease the extent to which the antibody is glycosylated, for example, by removing or inserting one or more glycosylation sites by altering the amino acid sequence and/or by modifying the oligosaccharide(s) attached to the glycosylation sites, e.g., using certain cell lines.
  • modified antibodies are those having one or more amino acid
  • modifications in the Fc region such as those having a human Fc region sequence or other portion of a constant region (e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g., a substitution) at one or more amino acid positions.
  • a human Fc region sequence or other portion of a constant region e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region
  • an amino acid modification e.g., a substitution
  • Such modifications can be made, e.g., to improve half-life, alter binding to one or more types of Fc receptors, and/or alter effector functions.
  • cysteine engineered antibodies such as "thioMAbs" and other cysteine engineered variants, in which one or more residues of an antibody are substituted with cysteine residues, in order to generate reactive thiol groups at accessible sites, e.g., for use in conjugation of agents and linker- agents, to produce immunoconjugates.
  • Cysteine engineered antibodies are described, e.g., in U.S. Patent Nos. 7,855,275 and 7,521,541.
  • the antibodies are modified to contain additional amino acids
  • nonproteinaceous moieties including water soluble polymers.
  • exemplary polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-l,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either
  • polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
  • the polymer may be of any molecular weight, and may be branched or unbranched.
  • the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
  • the antibody or antigen-binding portion thereof is expressed on cells as part of a recombinant receptor, such as an antigen receptor.
  • a recombinant receptor such as an antigen receptor.
  • the antigen receptors are functional non-TCR antigen receptors, such as chimeric antigen receptors (CARs).
  • CARs chimeric antigen receptors
  • a CAR containing an antibody or antigen-binding fragment that exhibits TCR-like specificity directed against a peptide in the context of an MHC molecule also may be referred to as a TCR-like CAR.
  • antigen receptors such as those that include one of the provided antibodies, e.g., TCR-like antibodies.
  • the antigen receptors and other chimeric receptors specifically bind to a region or epitope of HPV 16 E6 or E7, such as antigen receptors containing the provided anti-HPV 16 E6 or E7 antibodies or antibody fragments, e.g. TCR-like antibodies.
  • the antigen receptors are functional non-TCR antigen receptors, such as chimeric antigen receptors (CARs).
  • CARs chimeric antigen receptors
  • cells expressing the CARs and uses thereof in adoptive cell therapy such as treatment of diseases and disorders associated with HPV 16 E6 or E7 expression.
  • TCR-like CARs that contain a non-TCR molecule that exhibits T cell receptor specificity, such as for a T cell epitope or peptide epitope when displayed or presented in the context of an MHC molecule.
  • a TCR-like CAR can contain an antibody or antigen-binding portion thereof, e.g., TCR-like antibody, such as described herein.
  • the antibody or antibody-binding portion thereof is reactive against specific peptide epitope in the context of an MHC molecule, wherein the antibody or antibody fragment can differentiate the specific peptide in the context of the MHC molecule from the MHC molecule alone, the specific peptide alone, and, in some cases, an irrelevant peptide in the context of an MHC molecule.
  • an antibody or antigen-binding portion thereof can exhibit a higher binding affinity than a T cell receptor.
  • Exemplary antigen receptors including CARs, and methods for engineering and introducing such receptors into cells, include those described, for example, in international patent application publication numbers WO2000/14257, WO2013/126726, WO2012/129514, WO2014/031687, WO2013/166321, WO2013/071154, WO2013/123061 U.S. patent application publication numbers US2002/131960, US2013/287748, US2013/0149337, U.S.
  • the antigen receptors include a CAR as described in U.S. Patent No.: 7,446,190, and those described in International Patent Application Publication No.: WO2014/055668 Al.
  • Exemplary of the CARs include CARs as disclosed in any of the aforementioned publications, such as
  • the CARs generally include an extracellular antigen (or ligand) binding domain, including as an antibody or antigen-binding fragment thereof specific for a peptide in the context of an MHC molecule, linked to one or more intracellular signaling components, in some aspects via linkers and/or transmembrane domain(s).
  • an extracellular antigen (or ligand) binding domain including as an antibody or antigen-binding fragment thereof specific for a peptide in the context of an MHC molecule, linked to one or more intracellular signaling components, in some aspects via linkers and/or transmembrane domain(s).
  • such molecules can typically mimic or approximate a signal through a natural antigen receptor, such as a TCR, and, optionally, a signal through such a receptor in combination with a co stimulatory receptor.
  • a natural antigen receptor such as a TCR
  • the CAR typically includes in its extracellular portion one or more antigen binding molecules, such as one or more antigen-binding fragment, domain, or portion, or one or more antibody variable domains, and/or antibody molecules.
  • the CAR includes an antigen-binding portion or portions of an antibody molecule, such as a single-chain antibody fragment (scFv) derived from the variable heavy (VH) and variable light (VL) chains of a monoclonal antibody (mAb).
  • scFv single-chain antibody fragment
  • VH variable heavy
  • VL variable light chains of a monoclonal antibody
  • the CAR contains a TCR-like antibody, such as an antibody or an antigen-binding fragment (e.g., scFv) that specifically recognizes a peptide epitope presented on the cell surface in the context of an MHC molecule.
  • a TCR-like antibody such as an antibody or an antigen-binding fragment (e.g., scFv) that specifically recognizes a peptide epitope presented on the cell surface in the context of an MHC molecule.
  • the antigen-specific binding, or recognition component is linked to one or more transmembrane and intracellular signaling domains.
  • the CAR includes a transmembrane domain fused to the extracellular domain of the CAR.
  • the transmembrane domain that naturally is associated with one of the domains in the CAR is used.
  • the transmembrane domain is selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.
  • the transmembrane domain in some embodiments is derived either from a natural or from a synthetic source. Where the source is natural, the domain in some aspects is derived from any membrane-bound or transmembrane protein.
  • Transmembrane regions include those derived from (i.e. comprise at least the transmembrane region(s) of) the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154.
  • the transmembrane domain in some embodiments is synthetic.
  • the synthetic transmembrane domain comprises predominantly hydrophobic residues such as leucine and valine. In some aspects, a triplet of phenylalanine, tryptophan and valine will be found at each end of a synthetic transmembrane domain.
  • a short oligo- or polypeptide linker for example, a linker of between 2 and 10 amino acids in length, such as one containing glycines and serines, e.g., glycine-serine doublet, is present and forms a linkage between the transmembrane domain and the cytoplasmic signaling domain of the CAR.
  • the CAR e.g., TCR-like CAR, such as the antibody portion thereof, further includes a spacer, which may be or include at least a portion of an
  • the constant region or portion is of a human IgG, such as IgG4 or IgGl.
  • the portion of the constant region serves as a spacer region between the antigen-recognition component, e.g., scFv, and transmembrane domain.
  • the spacer can be of a length that provides for increased responsiveness of the cell following antigen binding, as compared to in the absence of the spacer. In some examples, the spacer is at or about 12 amino acids in length or is no more than 12 amino acids in length.
  • Exemplary spacers include those having at least about 10 to 229 amino acids, about 10 to 200 amino acids, about 10 to 175 amino acids, about 10 to 150 amino acids, about 10 to 125 amino acids, about 10 to 100 amino acids, about 10 to 75 amino acids, about 10 to 50 amino acids, about 10 to 40 amino acids, about 10 to 30 amino acids, about 10 to 20 amino acids, or about 10 to 15 amino acids, and including any integer between the endpoints of any of the listed ranges.
  • a spacer region has about 12 amino acids or less, about 119 amino acids or less, or about 229 amino acids or less.
  • Exemplary spacers include IgG4 hinge alone, IgG4 hinge linked to CH2 and CH3 domains, or IgG4 hinge linked to the CH3 domain.
  • Exemplary spacers include, but are not limited to, those described in Hudecek et al. (2013) Clin. Cancer Res., 19:3153 or international patent application publication number WO2014/031687.
  • the constant region or portion is of a human IgG, such as IgG4 or IgGl.
  • the spacer has the sequence ESKYGPPCPPCP (set forth in SEQ ID NO: 268), and is encoded by the sequence set forth in SEQ ID NO: 269.
  • the spacer has the sequence set forth in SEQ ID NO: 270.
  • the spacer has the sequence set forth in SEQ ID NO: 271.
  • the constant region or portion is of IgD.
  • the spacer has the sequence set forth in SEQ ID NO: 272.
  • the spacer has a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS: 268, 270, 271, or 272.
  • the antigen recognition domain generally is linked to one or more intracellular signaling components, such as signaling components that mimic activation through an antigen receptor complex, such as a TCR complex, in the case of a CAR, and/or signal via another cell surface receptor.
  • the antibody or antigen-binding fragment thereof is linked to one or more transmembrane and intracellular signaling domains.
  • the transmembrane domain is fused to the extracellular domain.
  • a transmembrane domain that naturally is associated with one of the domains in the receptor, e.g., CAR is used.
  • the transmembrane domain is selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.
  • the transmembrane domain in some embodiments is derived either from a natural or from a synthetic source. Where the source is natural, the domain in some aspects is derived from any membrane-bound or transmembrane protein.
  • Transmembrane regions include those derived from (i.e. comprise at least the transmembrane region(s) of) the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD 16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154.
  • the transmembrane domain in some embodiments is synthetic.
  • the synthetic transmembrane domain comprises predominantly hydrophobic residues such as leucine and valine. In some aspects, a triplet of phenylalanine, tryptophan and valine will be found at each end of a synthetic transmembrane domain. In some embodiments, the linkage is by linkers, spacers, and/or transmembrane domain(s).
  • intracellular signaling domains are those that mimic or approximate a signal through a natural antigen receptor, a signal through such a receptor in combination with a costimulatory receptor, and/or a signal through a costimulatory receptor alone.
  • a short oligo- or polypeptide linker for example, a linker of between 2 and 10 amino acids in length, such as one containing glycines and serines, e.g., glycine- serine doublet, is present and forms a linkage between the transmembrane domain and the cytoplasmic signaling domain of the CAR.
  • the CAR generally includes at least one intracellular signaling component or components.
  • the CAR includes an intracellular component of the TCR complex, such as a TCR CD3 + chain that mediates T-cell activation and cytotoxicity, e.g., CD3 zeta chain.
  • the antigen binding molecule is linked to one or more cell signaling modules.
  • cell signaling modules include CD3 transmembrane domain, CD3 intracellular signaling domains, and/or other CD transmembrane domains.
  • the CAR further includes a portion of one or more additional molecules such as Fc receptor ⁇ , CD8, CD4, CD25, or CD16.
  • the CAR includes a chimeric molecule between CD3-zeta (CD3 ⁇ ) or Fc receptor ⁇ and CD8, CD4, CD25 or CD16.
  • the cytoplasmic domain or intracellular signaling domain of the CAR activates at least one of the normal effector functions or responses of the immune cell, e.g., T cell engineered to express the CAR.
  • the CAR induces a function of a T cell such as cytolytic activity or T-helper activity, such as secretion of cytokines or other factors.
  • a truncated portion of an intracellular signaling domain of an antigen receptor component or costimulatory molecule is used in place of an intact immuno stimulatory chain, for example, if it transduces the effector function signal.
  • the intracellular signaling domain or domains include the cytoplasmic sequences of the T cell receptor (TCR), and in some aspects also those of co-receptors that in the natural context act in concert with such receptor to initiate signal transduction following antigen receptor engagement, and/or any derivative or variant of such molecules, and/or any synthetic sequence that has the same functional capability.
  • TCR T cell receptor
  • a component for generating secondary or co-stimulatory signal is also included in the CAR.
  • the CAR does not include a component for generating a costimulatory signal.
  • an additional CAR is expressed in the same cell and provides the component for generating the secondary or costimulatory signal.
  • the cell comprises a first CAR which contains signaling domains to induce the primary signal and a second CAR which binds to a second antigen and contains the component for generating a costimulatory signal.
  • a first CAR can be an activating CAR and the second CAR can be a costimulatory CAR.
  • both CARs must be ligated in order to induce a particular effector function in the cell, which can provide specificity and selectivity for the cell type being targeted.
  • T cell activation is in some aspects described as being mediated by two classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the TCR (primary cytoplasmic signaling sequences), and those that act in an antigen- independent manner to provide a secondary or co- stimulatory signal (secondary cytoplasmic signaling sequences).
  • primary cytoplasmic signaling sequences those that initiate antigen-dependent primary activation through the TCR
  • secondary cytoplasmic signaling sequences those that act in an antigen- independent manner to provide a secondary or co- stimulatory signal.
  • the CAR includes one or both of such signaling components.
  • the CAR includes a primary cytoplasmic signaling sequence that regulates primary activation of the TCR complex.
  • Primary cytoplasmic signaling sequences that act in a stimulatory manner may contain signaling motifs which are known as immunoreceptor tyrosine-based activation motifs or ITAMs.
  • ITAM containing primary cytoplasmic signaling sequences include those derived from TCR or CD3 zeta, FcR gamma, CD3 gamma, CD3 delta or CD3 epsilon.
  • cytoplasmic signaling molecule(s) in the CAR contain(s) a cytoplasmic signaling domain, portion thereof, or sequence derived from CD3 zeta.
  • the CAR includes a signaling domain and/or transmembrane portion of a costimulatory receptor, such as CD28, 4-1BB, OX40, DAP10, and ICOS.
  • a costimulatory receptor such as CD28, 4-1BB, OX40, DAP10, and ICOS.
  • the same CAR includes both the activating and costimulatory components; in other aspects, the activating domain is provided by one CAR whereas the costimulatory component is provided by another CAR recognizing another antigen.
  • the activating domain is included within one CAR, whereas the costimulatory component is provided by another chimeric receptor recognizing another antigen.
  • the CARs include activating or stimulatory CARs, and costimulatory receptors, both expressed on the same cell (see WO2014/055668).
  • the HPV 16 E6 or E7 antibody-containing receptor is the stimulatory or activating CAR; in other aspects, it is the costimulatory receptor.
  • the cells further include inhibitory CARs (iCARs, see Fedorov et al., Sci. Transl.
  • an inhibitory receptor recognizing a peptide epitope other than HPV 16 E6 or HPV16 E7, whereby an activating signal delivered through the HPV 16-targeting CAR is diminished or inhibited by binding of the inhibitory CAR to its ligand, e.g., to reduce off-target effects.
  • the cell expressing the provided TCR or other binding molecule further expresses an additional receptor, such as a receptor capable of delivering a costimulatory or survival-promoting signal, such as a costimulatory receptor (see
  • the cell may further include one or more other exogenous or recombinant or engineered components, such as one or more exogenous factors and/or costimulatory ligands, which are expressed on or in or secreted by the cells and can promote function, e.g., in the microenviroment.
  • ligands and components include, e.g., TNFR and/or Ig family receptors or ligands, e.g., 41BBL, CD40, CD40L, CD80, CD86, cytokines, chemokines, and/or antibodies or other molecules, such as scFvs. See, e.g., patent application publication Nos WO2008121420 Al, WO2014134165 Al, US20140219975 Al.
  • the cells comprise one or more inhibitory receptor ((iCARs, see Fedorov et al., Sci. Transl.
  • the intracellular signaling domain comprises a CD28 transmembrane and signaling domain linked to a CD3 (e.g., CD3-zeta) intracellular domain.
  • the intracellular signaling domain comprises a chimeric CD28 and CD 137 (4- IBB, TNFRSF9) co- stimulatory domains, linked to a CD3 zeta intracellular domain.
  • the CAR encompasses one or more, e.g., two or more, costimulatory domains and an activation domain, e.g., primary activation domain, in the cytoplasmic portion.
  • exemplary CARs include intracellular components of CD3-zeta, CD28, and 4- IBB.
  • the cell expressing the CAR or other antigen receptor further includes a marker, such as a cell surface marker, which may be used to confirm transduction or engineering of the cell to express the receptor, such as a truncated version of a cell surface receptor, such as truncated EGFR (tEGFR).
  • the marker includes all or part (e.g., truncated form) of CD34, a NGFR, or epidermal growth factor receptor (e.g., tEGFR).
  • the nucleic acid encoding the marker is operably linked to a polynucleotide encoding for a linker sequence, such as a cleavable linker sequence, e.g., T2A. See
  • introduction of a construct encoding the CAR and EGFRt separated by a T2A ribosome switch can express two proteins from the same construct, such that the EGFRt can be used as a marker to detect cells expressing such construct.
  • a marker, and optionally a linker sequence can be any as disclosed in published patent application No. WO2014031687.
  • the marker can be a truncated EGFR (tEGFR) that is, optionally, linked to a linker sequence, such as a T2A cleavable linker sequence.
  • tEGFR truncated EGFR
  • An exemplary polypeptide for a truncated EGFR e.g.
  • tEGFR comprises the sequence of amino acids set forth in SEQ ID NO: 273 or 343 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 273 or 343.
  • An exemplary T2A linker sequence comprises the sequence of amino acids set forth in SEQ ID NO: 211 or 274 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 211 or 274.
  • the marker is a molecule, e.g., cell surface protein, not naturally found on T cells or not naturally found on the surface of T cells, or a portion thereof.
  • the molecule is a non-self molecule, e.g., non-self protein, i.e., one that is not recognized as "self by the immune system of the host into which the cells will be adoptively transferred.
  • the marker serves no therapeutic function and/or produces no effect other than to be used as a marker for genetic engineering, e.g., for selecting cells successfully engineered.
  • the marker may be a therapeutic molecule or molecule otherwise exerting some desired effect, such as a ligand for a cell to be encountered in vivo, such as a costimulatory or immune checkpoint molecule to enhance and/or dampen responses of the cells upon adoptive transfer and encounter with ligand.
  • CARs are referred to as first, second, and/or third generation CARs.
  • a first generation CAR is one that solely provides a CD3 -chain induced signal upon antigen binding;
  • a second-generation CARs is one that provides such a signal and costimulatory signal, such as one including an intracellular signaling domain from a costimulatory receptor such as CD28 or CD137;
  • a third generation CAR in some aspects is one that includes multiple costimulatory domains of different costimulatory receptors.
  • the chimeric antigen receptor includes an extracellular portion containing a TCR-like antibody or fragment described herein and an intracellular signaling domain.
  • the antibody or fragment includes a scFv and the intracellular domain contains an IT AM.
  • the intracellular signaling domain includes a signaling domain of a zeta chain of a CD3-zeta ( ⁇ 3 ⁇ ) chain.
  • the chimeric antigen receptor includes a transmembrane domain linking the extracellular domain and the intracellular signaling domain.
  • the transmembrane domain contains a transmembrane portion of CD28. The extracellular domain and transmembrane can be linked directly or indirectly.
  • the extracellular domain and transmembrane are linked by a spacer, such as any described herein.
  • the chimeric antigen receptor contains an intracellular domain of a T cell costimulatory molecule, such as between the transmembrane domain and intracellular signaling domain.
  • the T cell costimulatory molecule is CD28 or 4 IBB.
  • the CAR contains a TCR-like antibody, e.g., an antibody fragment, as provided herein, a transmembrane domain that is or contains a transmembrane portion of CD28 or a functional variant thereof, and an intracellular signaling domain containing a signaling portion of CD28 or functional variant thereof and a signaling portion of CD3 zeta or functional variant thereof.
  • a TCR-like antibody e.g., an antibody fragment, as provided herein
  • a transmembrane domain that is or contains a transmembrane portion of CD28 or a functional variant thereof
  • an intracellular signaling domain containing a signaling portion of CD28 or functional variant thereof and a signaling portion of CD3 zeta or functional variant thereof.
  • the CAR contains a TCR-like antibody, e.g., antibody fragment, as provided herein, a transmembrane domain that is or contains a transmembrane portion of CD28 or a functional variant thereof, and an intracellular signaling domain containing a signaling portion of a 4- IBB or functional variant thereof and a signaling portion of CD3 zeta or functional variant thereof.
  • the CAR further includes a spacer containing a portion of an Ig molecule, such as a human Ig molecule, such as an Ig hinge, e.g. an IgG4 hinge, such as a hinge-only spacer.
  • the transmembrane domain of the receptor is a transmembrane domain of human CD28 (e.g., Accession No. P01747.1) or variant thereof, such as a transmembrane domain that comprises the sequence of amino acids set forth in SEQ ID NO: 275 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 275.
  • human CD28 e.g., Accession No. P01747.1
  • variant thereof such as a transmembrane domain that comprises the sequence of amino acids set forth in SEQ ID NO: 275 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 275
  • the transmembrane-domain containing portion of the CAR comprises the sequence of amino acids set forth in SEQ ID NO: 276 or a sequence of amino acids having at least at or about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 276.
  • the intracellular signaling component(s) of the CAR e.g., the TCR-like CAR
  • the intracellular signaling domain can comprise the sequence of amino acids set forth in SEQ ID NO: 277 or 278 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 277 or 278.
  • the intracellular domain comprises an intracellular costimulatory signaling domain of 4-1BB (e.g. (Accession No. Q07011.1) or functional variant or portion thereof, such as the sequence of amino acids set forth in SEQ ID NO: 279 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 279.
  • 4-1BB e.g. (Accession No. Q07011.1
  • functional variant or portion thereof such as the sequence of amino acids set forth in SEQ ID NO: 279 or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 279.
  • the intracellular signaling domain of the CAR e.g. the TCR- like CAR
  • the intracellular signaling domain comprises the sequence of amino acids of SEQ ID NO: 280, 281, or 282, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 280, 281, or 282.
  • the spacer contains only a hinge region of an IgG, such as only a hinge of IgG4 or IgGl, such as the hinge only spacer set forth in SEQ ID NO: 268.
  • the spacer is or contains an Ig hinge, e.g., an IgG4-derived hinge, optionally linked to a CH2 and/or CH3 domains.
  • the spacer is an Ig hinge, e.g., an IgG4 hinge, linked to CH2 and CH3 domains, such as set forth in SEQ ID NO: 271.
  • the spacer is an Ig hinge, e.g., an IgG4 hinge, linked to a CH3 domain only, such as set forth in SEQ ID NO: 270.
  • the spacer is or comprises a glycine- serine rich sequence or other flexible linker such as known flexible linkers.
  • the TCR-like CAR includes a TCR-like antibody or fragment, such as any provided herein, including scFvs, a spacer such as any of the Ig-hinge containing spacers, a CD28 transmembrane domain, a CD28 intracellular signaling domain, and a CD3 zeta signaling domain.
  • a TCR-like antibody or fragment such as any provided herein, including scFvs, a spacer such as any of the Ig-hinge containing spacers, a CD28 transmembrane domain, a CD28 intracellular signaling domain, and a CD3 zeta signaling domain.
  • the TCR-like CAR includes the a TCR-like antibody or fragment, such as any provided herein, including scFvs, a spacer such as any of the Ig-hinge containing spacers, a CD28 transmembrane domain, a CD28 intracellular signaling domain, and a CD3 zeta signaling domain.
  • such TCR-like CAR constructs further includes a T2A ribosomal skip element and/or a tEGFR sequence, e.g., downstream of the CAR.
  • such CAR constructs further includes a T2A ribosomal skip element and/or a tEGFR sequence, e.g., downstream of the CAR, such as set forth in SEQ ID NO: 211 or 274 and a tEGFR sequence set forth in SEQ ID NO: 273 or 343, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 211, 273, 343, or 274.
  • a T2A ribosomal skip element e.g., downstream of the CAR, such as set forth in SEQ ID NO: 211 or 274 and a tEGFR sequence set forth in SEQ ID NO: 273 or 343, or a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 9
  • the CAR includes an HPV 16 E6 or E7 antibody or fragment, such as any of the HPV16 E6 or E7 antibodies, including sdAbs (e.g. containing only the V H region) and scFvs, described herein, a spacer such as any of the Ig-hinge containing spacers, a CD28 transmembrane domain, a CD28 intracellular signaling domain, and a CD3 zeta signaling domain.
  • sdAbs e.g. containing only the V H region
  • scFvs described herein
  • spacer such as any of the Ig-hinge containing spacers
  • CD28 transmembrane domain e.g. containing only the V H region
  • CD28 intracellular signaling domain e.g. zeta signaling domain
  • CD3 zeta signaling domain e.g. zeta signaling domain
  • the CAR includes the HPV 16 antibody or fragment, such as any of the HPV 16 E6 or E7 antibodies, including sdAbs and scFvs described herein, a spacer such as any of the Ig -hinge containing spacers, a CD28 transmembrane domain, a CD28 intracellular signaling domain, and a CD3 zeta signaling domain.
  • such CAR constructs further includes a T2A ribosomal skip element and/or a tEGFR sequence, e.g., downstream of the CAR.
  • the provided binding molecules e.g. TCRs or TCR-like CAR have one or more specified functional features, such as binding properties, including binding to particular epitopes, lack of off-target binding or activity and/or particular binding affinities.
  • any one or more of the features of a provided TCR can be assessed by expressing the TCR, e.g., by introducing one or more nucleic acid encoding the TCR, into a T cell, such a primary T cell or a T cell line.
  • the T cell line is a Jurkat cell or a Jurkat-derived cell line.
  • a Jurkat-derived cell line is the J.RT3-T3.5 (ATCC® TIB-153TM) cell line, produced by treatment of the Jurkat leukemia cell line with irradiation mutagenesis and negative selection with OKT3 monoclonal antibody (see Weiss & Stobo, J. Ex. Med. 160(5): 1284-1299 (1984)).
  • the provided binding molecules are capable of binding to a peptide epitope of HPV 16, e.g. an epitope of HPV 16 E6 or E7 such as described above, with at least a certain affinity, as measured by any of a number of known methods.
  • a peptide epitope of HPV 16 e.g. an epitope of HPV 16 E6 or E7 such as described above.
  • the peptide epitope is a peptide in the context of an MHC molecule or ligand.
  • the affinity is represented by an equilibrium dissociation constant (K D ) or an association constant (k a ). In some embodiments, the affinity is represented by EC50.
  • the binding molecule binds, such as specifically binds, to a peptide epitope, e.g., in complex with an MHC molecule, with an affinity or KA (i.e., an equilibrium association constant of a particular binding interaction with units of 1/M; equal to the ratio of the on-rate [k on or k a ] to the off -rate [k 0 ff or k d ] for this association reaction, assuming bimolecular interaction) equal to or greater than 10 5 M "1 .
  • the TCR or fragment thereof exhibits a binding affinity for the peptide epitope with a K D (i.e., an KA).
  • the equilibrium dissociation constant of a particular binding interaction with units of M equal to the ratio of the off-rate [k 0 ff or k d ] to the on-rate [k on or k a ] for this association reaction, assuming bimolecular interaction) of equal to or less than 10 ⁇ 5 M.
  • the equilibrium dissociation constant e s from or from about 10 - " 5 M to or to about 10 - " 12
  • K D rang M such as from or from about 10 "6 M to or to about 10 "10 M, from or from about 10 "7 M to or to about 10 "11 M, from or from about 10 - " 6 M to or to about 10 - “ 8 M, or from or from about 10 - " 7 M to or to about 10 "
  • dissociation rate constant (dissociation rate constant; k 0ff or k d ; units of 1/s) can be determined using any of the assay methods known in the art, for example, surface plasmon resonance (SPR).
  • SPR surface plasmon resonance
  • binding affinity may be classified as high affinity or as low affinity.
  • the binding molecule e.g. TCR
  • the binding molecule that exhibits low to moderate affinity binding exhibits a KA of up to 10 7 M “1 , up to 10 6 M “1 , up to 10 5 M “1 .
  • a binding molecule that exhibits high affinity binding to a particular epitope interacts with such epitope with a K A of at least 10 7 M "1 , at least 10 8 M “1 , at least 10 9 M “1 , at least 10 10 M “1 , at least 10 11 M “1 , at least 10 12 M “1 , or at least 10 13 M “1 .
  • the binding affinity (EC 50 ) and/or the dissociation constant of the binding molecule to a peptide epitope of HPV 16 E6 or E7 is from or from about 0.1 nM to 1 ⁇ , 1 nM to 1 ⁇ , 1 nM to 500 nM, 1 nM to 100 nM, 1 nM to 50 nM, 1 nM to 10 nM, 10 nM to 500 nM, 10 nM to 100 nM, 10 nM to 50 nM, 50 nM to 500 nM, 50 nM to 100 nM or 100 nM to 500 nM.
  • the binding affinity (EC 50 ) and/or the dissociation constant of the binding molecule to a peptide epitope of HPV 16 E6 or E7 is at or about or less than at or about 1 ⁇ , 500 nm, 100 nM, 50 nM, 40 nM, 30 nM, 25 nM, 20 nM, 19 nM, 18 nM, 17 nM, 16 nM, 15 nM, 14 nM, 13 nM, 12 nM, 11 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM.
  • a variety of assays are known for assessing binding affinity and/or determining whether a binding molecule specifically binds to a particular ligand (e.g. peptide in the context of an MHC molecule). It is within the level of a skilled artisan to determine the binding affinity of a binding molecule, e.g., TCR, for a T cell epitope of a target polypeptide, such as by using any of a number of binding assays that are well known in the art.
  • a BIAcore machine can be used to determine the binding constant of a complex between two proteins. The dissociation constant for the complex can be determined by monitoring changes in the refractive index with respect to time as buffer is passed over the chip.
  • suitable assays for measuring the binding of one protein to another include, for example, immunoassays such as enzyme linked immunosorbent assays (ELISA) and radioimmunoassays (RIA), or determination of binding by monitoring the change in the spectroscopic or optical properties of the proteins through fluorescence, UV absorption, circular dichroism, or nuclear magnetic resonance (NMR).
  • exemplary assays include, but are not limited to, Western blot, ELISA, analytical ultracentrifugation, spectroscopy and surface plasmon resonance (Biacore®) analysis (see, e.g., Scatchard et ah, Ann. N.Y. Acad. Sci. 51 :660, 1949; Wilson, Science 295:2103, 2002; Wolff et ah, Cancer Res. 53:2560, 1993; and U.S. Patent Nos.
  • apparent affinity for a TCR is measured by assessing binding to various concentrations of tetramers, for example, by flow cytometry using labeled tetramers.
  • apparent K D of a TCR is measured using 2-fold dilutions of labeled tetramers at a range of concentrations, followed by determination of binding curves by non-linear regression, apparent K D being determined as the concentration of ligand that yielded half-maximal binding.
  • the binding molecules display a binding preference for antigen recognition of HPV 16 E6- or E7-expressing cells as compared to HPV 16 E6- or E7- negative cells, such as particular cells known and/or described herein to express HPV 16 E6 or E7 and known not to express HPV 16 E6 or E7.
  • the binding preference is observed where a significantly greater degree of binding is measured to the HPV 16 E6- or E7-expressing, as compared to the non-HPV 16 E6- or E7-expressing cells.
  • the fold change in degree of binding detected for example, as measured by mean fluorescence intensity in a flow cytometry-based assay and/or dissociation constant or EC 50 , to the HPV 16 E6- or E7-expressing cells as compared to the non-HPV 16 E6- or E7-expressing cells, is at least at or about 1.5, 2, 3, 4, 5, 6, or more.
  • the binding molecule e.g. TCR
  • the binding molecule e.g. TCR
  • the provided binding molecules e.g.
  • the binding molecule e.g., TCR
  • the binding molecule does not recognize, such as does not specifically bind, a sequence-related peptide epitope of the HPV 16 E6 or E7 epitope set forth in any of SEQ ID NOS: 232-239, i.e., does not recognize an epitope sharing some amino acids in common with an HPV 16 E6 or E7 epitope set forth in any of SEQ ID NOS: 232- 239, such as does not recognize an epitope that differs in 1, 2, 3, 4, 5 or 6 amino acid residues from such epitope when the epitopes are aligned.
  • the binding molecule e.g., TCR
  • the binding molecule does not recognize a sequence-unrelated epitope of the HPV 16 E6 or E7 epitope set forth in any of SEQ ID NOS: 232-239, i.e., does not recognize an epitope that is substantially different in sequence compared to an HPC 16 E6 or E7 epitope set forth in any of SEQ ID NOS: 232-239, such as differing in more than 6, 7, 8, 9, 10 or more amino acid residues from such epitope when the epitopes are aligned.
  • the binding molecule e.g., TCR
  • the binding molecule does not recognize the HPV 16 E6 or E7 epitope set forth in any of SEQ ID NOS: 232-239 in the context of a different MHC allele, such as in the context of an MHC allele other than HLA- A2.
  • binding molecule e.g. TCR
  • a peptide epitope e.g. in complex with an MHC
  • CDRs complementarity determining regions
  • specifically binds does not mean that the particular peptide epitope, e.g. in complex with an MHC, is the only thing to which the MHC-peptide molecule may bind, since non-specific binding interactions with other molecules may also occur.
  • binding of binding molecule to a peptide in the context of an MHC molecule is with a higher affinity than binding to such other molecules, e.g.
  • Another peptide in the context of an MHC molecule or an irrelevant (control) peptide in the context of an MHC molecule such as at least about 2-fold, at least about 10-fold, at least about 20-fold, at least about 50-fold, or at least about 100-fold higher than binding affinity to such other molecules.
  • the binding molecule e.g., TCR
  • the binding molecule can be assessed for safety or off-target binding activity using any of a number of screening assays known in the art.
  • generation of an immune response to a particular binding molecule, e.g., TCR can be measured in the presence of cells that are known not to express the target peptide epitope, such as cells derived from normal tissue(s), allogenic cell lines that express one or more different MHC types or other tissue or cell sources.
  • the cells or tissues include normal cells or tissues.
  • cells or tissues can include brain, muscle, liver, colon, kidney, lung, ovary, placenta, heart, pancreas, prostate, epithelium or skin, testis, adrenal, intestine, bone marrow or spleen.
  • the binding to cells can be tested in 2 dimensional cultures.
  • the binding to cells can be tested in 3 dimensional cultures.
  • the tissues or cells can be ones that are known to express the target epitope.
  • the immune response can be assessed directly or indirectly, such as by assessing activation of immune cells such as T cells (e.g. cytotoxic activity), production of cytokine (e.g. interferon gamma), or activation of a signaling cascade.
  • potential off-targets can be identified by performing a homology scan of the human genome using the particular target epitope, e.g., to identify potential sequence-related epitopes.
  • a protein sequence database can be analyzed to identify peptides with similarity to the target peptide epitope.
  • a binding motif can first be identified.
  • the binding motif can be identified by peptide scanning, such as an alanine mutagenesis scan, of the target epitope (e.g., HPV 16 E6 or E7 epitope set forth in any of SEQ ID NOS: 232-239) to identify the binding motif recognized by the binding molecule, see e.g. WO2014/096803.
  • the binding motif can be identified by mutagenesis of the target peptide so that a series of mutants are generated in which each amino acid or a subset thereof is changed to another amino acid residue, tested for its activity relative to the original target epitope, and those residues that are involved in or required for binding are identified.
  • a series of mutants may be made in which the amino acid residue at each position of the target epitope is mutated to all alternative amino acids.
  • protein databases may be searched for proteins that contain the binding motif.
  • suitable protein databases include but are not limited to UniProtKB/Swiss-Prot (http://www.uniprot.org/), Protein Information Resource (PI R)
  • Searching for a peptide motif may be carried out using any one of a number of tools, which may be found on bioinformatics resource sites such as ExPASY (http://www.expasy.org/).
  • the search tool ScanProsite identifies user-defined motifs in all protein sequences in the UniProtKB/Swiss-Prot Protein Knowledgebase (De Castro et al. Nucleic Acids Res. 2006 Jul 1; 34 (Web Server issue):W362-5).
  • the search may be carried out for peptides that are of human origin or of organisms which are commonly present in humans, such as viral or bacterial pathogens, or commensal bacteria.
  • the binding molecule e.g., TCR
  • TCR can be redesigned so that there is no longer any cross reactivity to the off target peptide(s), while maintaining binding, preferably with high affinity, to the target peptide epitope.
  • T cell receptors can be redesigned by mutagenesis using the methods described in WO 03/020763.
  • the binding molecules e.g., engineered cells comprising the binding molecules, e.g., TCRs
  • cytotoxic T lymphocytes may be activated when cells containing the binding molecules, e.g., TCRs, are contacted with target cells, such as those that express HPV 16, such as HPV 16 E6 or HPV 16 E7.
  • target cells such as those that express HPV 16, such as HPV 16 E6 or HPV 16 E7.
  • target cells such as those that express HPV 16, such as HPV 16 E6 or HPV 16 E7.
  • target cells such as those that express HPV 16, such as HPV 16 E6 or HPV 16 E7.
  • target cells such as HPV 16-expressing, e.g., HPV 16 E6- or E7- expressing cells.
  • the ability of the binding molecules, such as cells expressing the binding molecules, e.g., TCRs or CARs, to elicit an immune response can be determined by measuring cytokine release.
  • cytokine release in response to coculture with or exposure to cells expressing the binding molecules, e.g., TCRs or CARs, a variety of cytokines are released when the cells are stimulated by an appropriate target cell known to express HPV 16, such as HPV 16 E6 or HPV 16 E7.
  • HPV 16 E6 or HPV 16 E7 Non-limiting examples of such cytokines include IFN- ⁇ , TNF-a, and GM-CSF.
  • Exemplary cells known to express HPV 16 include, but are not limited to, CaSki cells (ATCC No.
  • CRL- 1550 which contain about 600 copies of integrated HPV 16 or other tumor cell expressing the relevant MHC molecule and the corresponding peptide epitope, e.g., HPV 16 E6 or E7 epitope, such as any of those set forth in SEQ ID NOs: 232-239.
  • CTL activation can be determined.
  • CTL activity can be assessed by assaying the culture for the presence of CTLs that lyse radio-labeled target cells, such as specific peptide-pulsed targets. These techniques include the labeling of target cells with radionuclides such as Na 2 , 51 Cr0 4 or 3 H-thymidine, and measuring the release or retention of the radionuclides from the target cells as an index of cell death.
  • radionuclides such as Na 2 , 51 Cr0 4 or 3 H-thymidine
  • CTL are known to release a variety of cytokines when they are stimulated by an appropriate target cell, such as a tumor cell expressing the relevant MHC molecule and the corresponding peptide epitope, and the presence of such epitope- specific CTLs can be determined by measuring cytokine release.
  • cytokines include IFN- ⁇ , TNF-a, and GM-CSF.
  • Assays for these cytokines are well known in the art, and their selection is left to the skilled artisan. Methodology for measuring both target cell death and cytokine release as a measure of CTL reactivity are given in Coligan, J. E. et al. (Current Protocols in Immunology, 1999, John Wiley & Sons, Inc., New York).
  • cytokine production can be measured as an indicator of an immune response.
  • measured cytokines can include, without limitation, interlekukin-2 (IL-2), interferon-gamma (IFNy), interleukin-4 (IL-4), TNF-alpha, interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12) or TGF-beta.
  • Assays to measure cytokines are well known in the art, and include, without limitation, ELISA, intracellular cytokine staining, cytometric bead array, RT-PCR, ELISPOT, flow cytometry and bio-assays in which cells responsive to the relevant cytokine are tested for responsiveness (e.g. proliferation) in the presence of a test sample.
  • cells exposed to the binding molecules are assessed for an immunological readout, such as using a T cell assay.
  • the binding molecule-containing cells can activate a CD8+ T cell response.
  • CD8+ T cell responses can be assessed by monitoring CTL reactivity using assays that include, but are not limited to, target cell lysis via 51 Cr release or detection of interferon gamma release, such as by enzyme-linked immunosorbent spot assay (ELISA), intracellular cytokine staining or ELISPOT.
  • the binding molecules e.g., cells containing the binding molecules, such as TCRs or CARs, can activate a CD4+ T cell response.
  • CD4+ T cell responses can be assessed by assays that measure proliferation, such as by incorporation of [3H] -thymidine into cellular DNA and/or by the production of cytokines, such as by ELISA, intracellular cytokine staining or ELISPOT.
  • the cytokine can include, for example, interleukin-2 (IL-2), interferon-gamma (IFN-gamma), interleukin-4 (IL-4), TNF-alpha, interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12) or TGF beta.
  • recognition or binding of the peptide epitope, such as a MHC class II epitope, by the binding molecule can elicit or activate a CD4+ T cell response and/or a CD8+ T cell response.
  • the binding specificity and/or function (e.g., ability to elicit an immune response to HPV 16) of the binding molecule, e.g., TCR or antigen-binding fragment thereof, is at least partially CD8-independent.
  • TCR recognition of a peptide in the context of an MHC molecule and subsequent T cell activation is facilitated in the presence of a CD8 co-receptor.
  • CD8 coreceptor engagement can facilitate low- to moderate- TCR affinity interactions and/or T cell activation (See, for example, Kerry et al. J. Immunology (2003) 171(9): 4493-4503 and Robbins et al. J Immunology (2008) 180(9): 6116-6131).
  • the provided binding molecules are molecules, e.g. TCRs, that exhibit CD8-independent binding for an HPV E6 or E7 peptide epitope.
  • such binding molecules e.g. TCR
  • the provided CD8-independent binding molecules, such as TCRs can be expressed or engineered in cells, e.g. T cells, that do not express CD8, such as can be expressed or engineered in CD4+ cells.
  • the provided engineered non-CD8-expressing cells e.g.
  • CD4+ cells are cells expressing a recombinant binding molecule, e.g., TCR or antigen-binding fragment, that exhibit at least or at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the binding specificity, affinity and/or avidity for a peptide in the context of an MHC molecule as the same binding molecule (e.g., TCR or antigen-binding fragment thereof) that is expressed on a CD8+ T cell.
  • a recombinant binding molecule e.g., TCR or antigen-binding fragment
  • nucleic acids encoding any of the provided binding molecules, e.g., TCRs or antigen-binding fragments thereof or antibodies or antigen-binding fragments thereof or CARs containing such antibodies, such as those described herein.
  • the nucleic acids may include those encompassing natural and/or non-naturally occurring nucleotides and bases, e.g., including those with backbone modifications.
  • the terms "nucleic acid molecule,” “nucleic acid,” and “polynucleotide” may be used interchangeably, and refer to a polymer of nucleotides.
  • nucleic acid sequence refers to the linear sequence of nucleotides that comprise the nucleic acid molecule or polynucleotide.
  • the binding molecule e.g. TCR, or antigen binding portion thereof may be a recombinantly produced natural protein or mutated form thereof in which one or more property, such as binding characteristic, has been altered.
  • the nucleic acid is synthetic.
  • the nucleic acid is or contains cDNA.
  • the nucleic acid molecule can be modified for use in the constructs described herein, such as for codon optimization.
  • the sequences can be designed to contain terminal restriction site sequences for purposes of cloning into vectors.
  • nucleic acid molecule encoding the binding molecule can be obtained from a variety of sources, such as by polymerase chain reaction (PCR) amplification of encoding nucleic acids within or isolated from a given cell or cells.
  • the TCR is obtained from a biological source, such as from cells such as from a T cell (e.g. cytotoxic T cell), T cell hybridomas or other publicly available source.
  • a TCR may be derived from one of various animal species, such as human, mouse, rat, or other mammal, such as generally from a human.
  • the T cells can be obtained from in vivo isolated cells, such as from normal (or healthy) subjects or diseased subjects, including T cells present in peripheral blood mononuclear cells (PBMCs) or tumor-infiltrating lymphocytes (TILs).
  • the T cells can be a cultured T cell hybridoma or clone.
  • the a and ⁇ chains can be PCR amplified from total cDNA isolated from a T cell clone expressing the TCR of interest and cloned into an expression vector.
  • the a and ⁇ chains can be synthetically generated.
  • the a and ⁇ chains are cloned into the same vector.
  • the TCR or antigen-binding portion thereof can be synthetically generated from knowledge of the sequence of the TCR.
  • the nucleic acid molecule contains a nucleic acid sequence encoding an alpha chain and/or a nucleotide sequence encoding a beta chain.
  • the nucleic acid sequence encoding the alpha chain comprises one of the following: residues 61-816 of SEQ ID NO: 20, residues 58-804 of SEQ ID NO: 30, residues 61-825 of SEQ ID NO: 40, residues 64-813 of SEQ ID NO: 50, residues 64-816 of SEQ ID NO: 60, residues 58-807 of SEQ ID NO: 70, residues 61-825 of SEQ ID NO: 80, residues 67-831 of SEQ ID NO: 90, residues 58-801 of SEQ ID NO: 100, residues 64-810 of SEQ ID NO: 183, residues 58-801 of SEQ ID NO: 202, residues 67-813 of SEQ ID NO: 219, a degenerate sequence thereof or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto.
  • the nucleotide sequence encoding the beta chain comprises one of the following: residues 58-936 of SEQ ID NO: 17, residues 58-930 of SEQ ID NO: 16, residues 58-939 of SEQ ID NO: 24, residues 64- 930 of SEQ ID NO: 34 or 44, residues 58-933 of SEQ ID NO: 55, residues 58-927 of SEQ ID NO: 64, residues 64-936 of SEQ ID NO: 74, residues 58-933 of SEQ ID NO: 84, residues 63- 930 of SEQ ID NO: 94, residues 46-936 of SEQ ID NO: 104, residues 58-933 of SEQ ID NO: 108, a degenerate sequence thereof or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto.
  • the nucleotide sequence encoding the alpha chain and/or the nucleotide sequence encoding the beta chain is codon-optimized.
  • codon optimization involves balancing the percentages of codons selected with the published abundance of human transfer RNAs so that none is overloaded or limiting. This may be necessary in some cases because most amino acids are encoded by more than one codon, and codon usage varies from organism to organism. Differences in codon usage between transfected genes and host cells can have effects on protein expression and immunogenicity of a nucleic acid construct. In general, for codon optimization, codons are chosen to select for those codons that are in balance with human usage frequency.
  • the redundancy of the codons for amino acids is such that different codons code for one amino acid.
  • it may be desired that the resulting mutation is a silent mutation such that the codon change does not affect the amino acid sequence.
  • the last nucleotide of the codon can remain unchanged without affecting the amino acid sequence.
  • the nucleic acid sequence encoding the alpha chain contains one of the following: residues 67-825 of SEQ ID NO: 10, residues 58-813 of SEQ ID NO: 11, residues 64- 822 of SEQ ID NO: 12 residues 61-825 of SEQ ID NO: 21, residues 58-813 of SEQ ID NO: 31, residues 61-834 of SEQ ID NO: 41, residues 63-822 of SEQ ID NO: 51, residues 64-825 of SEQ ID NO: 61, residues 58-816 of SEQ ID NO: 71, residues 61-834 of SEQ ID NO: 81, residues 67-840 of SEQ ID NO: 91, residues 58-810 of SEQ ID NO: 101, a degenerate sequence thereof or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto.
  • the nucleotide sequence encoding the beta chain contains one of the following: residues 58-930 of SEQ ID NO: 7, residues 58-936 of SEQ ID NO: 8, residues 58-933 of SEQ ID NO: 9residues 58-939 of SEQ ID NO: 25, residues 64-930 of SEQ ID NO: 35, 45, or 95, residues 58-933 of SEQ ID NO: 54 or 85, residues 58-927 of SEQ ID NO: 65, residues 64-936 of SEQ ID NO: 75, residues 46-936 of SEQ ID NO: 105, a degenerate sequence thereof or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto.
  • the nucleic acid molecule encoding an alpha chain and/or beta chain of a TCR comprises a nucleic acid sequence corresponding to a SEQ ID NO. set forth in Table 11. Also among the provided nucleic acid molecules encoding a TCR are those containing sequences at least at or about 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to such sequences. Exemplary TCRs encoded by such sequences, or their modified versions, also are set forth in the Table 11.
  • vectors or constructs containing such nucleic acid molecules contain one or more promoters operatively linked to the nucleotide encoding the alpha chain and/or beta chain. In some embodiments, the promoter is operatively linked to one or more than one nucleic acid molecule.
  • the vector or construct can contain a single promoter that drives the expression of one or more nucleic acid molecules.
  • promoters can be multicistronic (bicistronic or tricistronic, see e.g., U.S. Patent No. 6,060,273).
  • transcription units can be engineered as a bicistronic unit containing an IRES (internal ribosome entry site), which allows coexpression of gene products (e.g. encoding an alpha chain and/or beta chain of a TCR) by a message from a single promoter.
  • IRES internal ribosome entry site
  • a single promoter may direct expression of an RNA that contains, in a single open reading frame (ORF), two or three genes (e.g. encoding an alpha chain and/or beta chain of a TCR) separated from one another by sequences encoding a self-cleavage peptide (e.g., T2A) or a protease recognition site (e.g., furin).
  • ORF open reading frame
  • the ORF thus encodes a single polyprotein, which, either during (in the case of 2A e.g., T2A) or after translation, is cleaved into the individual proteins.
  • the peptide such as T2A
  • T2A can cause the ribosome to skip (ribosome skipping) synthesis of a peptide bond at the C-terminus of a 2A element, leading to separation between the end of the 2A sequence and the next peptide downstream (see, for example, de Felipe. Genetic Vaccines and Ther. 2: 13 (2004) and deFelipe et al. Traffic 5:616- 626 (2004)).
  • Examples of 2A cleavage peptides including those that can induce ribosome skipping, are Thosea asigna virus (T2A, e.g., SEQ ID NO: 211 or 274), porcine teschovirus-1 (P2A, e.g., SEQ ID NO: 204 or 345), equine rhinitis A virus (E2A, e.g., SEQ ID NO: 346) and 2A sequences from the foot-and-mouth disease virus (F2A, e.g., SEQ ID NO: 344) as described in U.S. Patent Publication No. 2007/0116690.
  • T2A e.g., SEQ ID NO: 211 or 274
  • P2A porcine teschovirus-1
  • E2A equine rhinitis A virus
  • F2A foot-and-mouth disease virus
  • nucleotide sequence encoding the alpha chain and the nucleotide sequence encoding the beta chain are separated by a nucleotide sequence encoding an internal ribosome entry site (IRES) or a peptide sequence that causes ribosome skipping.
  • the nucleotide sequence encoding the alpha chain and the nucleotide sequence encoding the beta chain are separated by a peptide sequence that causes ribosome skipping.
  • the peptide that causes ribosome skipping is a P2A or T2A peptide and/or contains the sequence of amino acids set forth in SEQ ID NO: 204, 211, 274 or 345.
  • the nucleotide sequence encoding the peptide that causes ribosome skipping contains the sequence set forth in SEQ ID NO: 4, 5, 6, 207, 208, 209, or 210, 347, 1096, 1179, 1180, or 1181.
  • the nucleic acid sequence encoding the alpha chain and the nucleotide sequence encoding the beta chain are present in any order, separated by the nucleotide sequence encoding an internal ribosome entry site (IRES) or a peptide sequence that causes ribosome skipping.
  • the nucleic acid molecule comprises a nucleic acid sequence encoding a beta chain, a nucleic acid sequence encoding an IRES or peptide sequence that causes ribosome skipping, e.g., a P2A or T2A sequence as described herein, and a nucleic acid sequence that encodes an alpha chain, in that order.
  • the nucleic acid molecule contains a nucleic acid sequence that encodes an alpha chain, a nucleic acid sequence that encodes an IRES or peptide sequence that causes ribosome skipping, and a nucleic acid sequence that encodes a beta chain, in that order.
  • the nucleic acid molecule encodes a polypeptide comprising a beta chain, an IRES or peptide that causes ribosome skipping, and an alpha chain, in that order.
  • the nucleic acid molecule encodes a polypeptide comprising an alpha chain, an IRES or peptide that causes ribosome skipping, and a beta chain, in that order.
  • the nucleic acid molecule encodes a polypeptide containing an amino acid sequence set forth in Table 12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto.
  • the nucleic acid molecule encodes a polypeptide set forth in any of SEQ ID NOS: 1, 2, 3, 27, 37, 47, 57, 67, 77, 87, 97, 107, 223, 224, 225, 226, 227, 228, 229, 230, 231, 340-342, 350-388, or 391-429, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto.
  • the nucleic acid molecule comprises the nucleic acid sequence set forth in any of SEQ ID NOs: 13, 14, 15, 26, 36, 46, 56, 66, 76, 86, 96, 106, 432-472, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto.
  • polypeptides containing a sequence encoded by any of the provided nucleic acids comprises an amino acid sequence corresponding to a SEQ ID NO. shown in Table 12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto.
  • the polypeptide comprises the sequence set forth in any of SEQ ID NOS 1, 2, 3, 27, 37, 47, 57, 67, 77, 87, 97, 107, 223, 224, 225, 226, 227, 228, 229, 230, 231, 340-342, 350- 388, or 391-429, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto. Exemplary of such TCRs, or their modified versions, also are set forth in the Table 12.
  • the nucleic acid molecule may further encode a marker (e.g. EGFRt or other marker as described) that is separated from the CAR or separated from the TCR chains by a linker, such as a cleavable linker sequence or a peptide sequence that causes ribosome skipping, e.g., T2A or P2A.
  • a marker e.g. EGFRt or other marker as described
  • a linker such as a cleavable linker sequence or a peptide sequence that causes ribosome skipping, e.g., T2A or P2A.
  • the construct can be arranged in any order so that the encoding marker sequence is either 3' to the alpha and/or beta sequence, 5' to the alpha and/or beta sequence and/or between the alpha and beta sequence, where, in some cases, each separate component is separated by a cleavable linker sequence or a peptide that causes ribosome skipping (e.g. T2A or P2A) or an IRES.
  • the nucleic acid molecule contains a nucleic acid sequence that encodes a marker (e.g., EGFRt), cleavable linker or ribosome skip sequence (e.g.
  • the nucleic acid molecule contains a nucleic acid sequence that encodes a marker (e.g., EGFRt), cleavable linker or ribosome skip sequence (e.g., T2A or P2A), alpha chain, cleavable linker or ribosome skip sequence (e.g., T2A or P2A), and beta chain, in that order.
  • a marker e.g., EGFRt
  • cleavable linker or ribosome skip sequence e.g., T2A or P2A
  • alpha chain cleavable linker or ribosome skip sequence
  • the nucleic acid molecule contains a nucleic acid sequence that encodes a beta chain, cleavable linker or ribosome skip sequence (e.g., T2A or P2A), an alpha chain, a cleavable linker or ribosome skip sequence (e.g., T2A or P2A) and a marker (e.g. EGFRt), in that order.
  • the nucleic acid molecule contains a nucleic acid sequence that encodes a alpha chain, cleavable linker or ribosome skip sequence (e.g.
  • the nucleic acid molecule contains a nucleic acid sequence that encodes a alpha chain, cleavable linker or ribosome skip sequence (e.g., T2A or P2A), a marker (e.g., EGFRt), a cleavable linker or ribosome skip sequence (e.g., T2A or P2A) and a beta chain, in that order.
  • the nucleic acid molecule contains a nucleic acid sequence that encodes a alpha chain, cleavable linker or ribosome skip sequence (e.g., T2A or P2A), a marker (e.g., EGFRt), a cleavable linker or ribosome skip sequence (e.g., T2A or P2A) and a beta chain, in that order.
  • the nucleic acid molecule contains a nucleic acid sequence that encodes a beta chain, cleavable linker or ribosome skip sequence (e.g., T2A or P2A), a marker (e.g. EGFRt), a cleavable linker or ribosome skip sequence (e.g., T2A or P2A) and a alpha chain, in that order.
  • a nucleic acid sequence that encodes a beta chain, cleavable linker or ribosome skip sequence e.g., T2A or P2A
  • a marker e.g. EGFRt
  • a cleavable linker or ribosome skip sequence e.g., T2A or P2A
  • alpha chain in that order.
  • introduction of a construct encoding the CAR and EGFRt separated by a T2A ribosome switch can express two proteins from the same construct, such that the EGFRt can be used as a marker to detect cells expressing such construct.
  • the nucleic acid may encode an amino acid sequence comprising the variable alpha (Va) region or variable light (VL) region of the TCR or antibody, respectively.
  • the nucleic acid encodes an amino acid sequence comprising the variable beta ( ⁇ ) region or variable heavy (VH) region of the TCR or antibody, respectively.
  • one or more vectors comprising such nucleic acid are provided.
  • nucleic acid or nucleic acids encoding one or both chains of a binding molecule are cloned into a suitable expression vector or vectors.
  • the expression vector can be any suitable recombinant expression vector, and can be used to transform or transfect any suitable host.
  • Suitable vectors include those designed for propagation and expansion or for expression or both, such as plasmids and viruses.
  • the vector is an expression vector.
  • the vector can a vector of the pUC series (Fermentas Life Sciences), the pBluescript series (Stratagene, LaJolla, Calif.), the pET series (Novagen,
  • bacteriophage vectors such as GIO, GTl l, ZapII (Stratagene), EMBL4, and ⁇ 149, also can be used.
  • plant expression vectors can be used and include pBIOl, pBI101.2, pBI101.3, pBI121 and pBIN19 (Clontech).
  • animal expression vectors include pEUK-Cl, pMAM and pMAMneo (Clontech).
  • the vector is a viral vector.
  • the viral vector is a retroviral vector, such as a lentiviral vector.
  • the lentiviral vector is derived from HIV-1.
  • the recombinant expression vectors can be prepared using standard recombinant DNA techniques.
  • vectors can contain regulatory sequences, such as transcription and translation initiation and termination codons, which are specific to the type of host (e.g., bacterium, fungus, plant, or animal) into which the vector is to be introduced, as appropriate and taking into consideration whether the vector is DNA- or RNA- based.
  • the vector can contain a nonnative promoter operably linked to the nucleotide sequence encoding the binding molecule, such as TCR, antibody or antigen- binding fragment thereof.
  • the promoter can be a non- viral promoter or a viral promoter, such as a cytomegalovirus (CMV) promoter, an SV40 promoter, an RSV promoter, and a promoter found in the long-terminal repeat of the murine stem cell virus.
  • CMV cytomegalovirus
  • SV40 SV40 promoter
  • RSV RSV promoter
  • promoter found in the long-terminal repeat of the murine stem cell virus a promoter found in the long-terminal repeat of the murine stem cell virus.
  • Other promoters known to a skilled artisan also are contemplated.
  • nucleic acid encoding the binding molecule e.g., as described above, may be isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
  • nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the alpha and beta chains of the TCR or the heavy and light chains of the antibody).
  • a method of making the binding molecule comprises culturing a host cell comprising a nucleic acid encoding the binding molecule, as provided above, under conditions suitable for expression of the binding molecule, and optionally recovering the binding molecule from the host cell (or host cell culture medium).
  • a host cell comprises (e.g., has been transformed with): a vector comprising a nucleic acid that encodes an amino acid sequence comprising the ⁇ region of the TCR or antigen-binding fragment thereof and a nucleic acid that encodes an amino acid sequence comprising the Va region of the TCR or antigen-binding fragment thereof.
  • a host cell comprises (e.g. has been transformed with): a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody or antigen- binding fragment thereof and the VL of the antibody or antigen-binding fragment thereof.
  • a host cell comprises (e.g., has been transformed with): a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the Va region of the TCR or antigen-binding fragment thereof and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the ⁇ region of the TCR or antigen-binding fragment thereof.
  • a host cell comprises (e.g. has been transformed with): a first vector comprising a nucleic acid that encodes an amino acid sequence or comprising the VL of the antibody or antigen-binding fragment thereof and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody or antigen-binding fragment thereof.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for binding molecule-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been modified to mimic or approximate those in human cells. See Gerngross, Nat. Biotech. 22: 1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).
  • Exemplary eukaryotic cells that may be used to express polypeptides include, but are not limited to, COS cells, including COS 7 cells; 293 cells, including 293-6E cells; CHO cells, including CHO-S, DG44. Lecl3 CHO cells, and FUT8 CHO cells; PER.C6 ® cells; and NSO cells.
  • a particular eukaryotic host cell is selected based on its ability to make desired post-translational modifications to the binding molecule.
  • CHO cells produce polypeptides that have a higher level of sialylation than the same polypeptide produced in 293 cells.
  • the binding molecule is produced in a cell-free system.
  • Exemplary cell-free systems are described, e.g., in Sitaraman et al., Methods Mol. Biol. 498: 229-44 (2009); Spirin, Trends Biotechnol. 22: 538-45 (2004); Endo et al, Biotechnol. Adv. 21: 695-713 (2003).
  • kits for identifying and generating T cell receptors directed towards a target antigen involve subjecting biological samples containing T cells, such as primary T cells, including those derived from normal donors or patients having a disease or condition of interest, to multiple rounds of antigen exposure and assessment.
  • the rounds involve the use of artificial or engineered antigen presenting cells, such as autologous dendritic cells or other APCs pulsed with a desired peptide antigen, to promote presentation on an MHC, such as a class I or II MHC.
  • T cells are sorted following one or more of the rounds, e.g., based on ability to bind to the desired antigen (such as peptide-MHC tetramers).
  • sorting is carried out by flow cytometry.
  • cells from cells deemed to bind to the desired antigen (positive fraction) and cells deemed not to bind to the antigen are assessed, e.g., by single-cell sequencing methods.
  • the methods sequence and identify, at a single-cell level, TCR pairs present in each sample.
  • the methods can quantify the number of copies of a given TCR pair present in a sample, and as such can assess the abundance of a given TCR in a given sample, and/or enrichment thereof over another sample, such as enrichment or abundance in the positive (antigen-binding) fraction, e.g., over one or more rounds, for example, as compared to the negative fraction.
  • such assays are performed to generate antigen- specific T cell receptors (TCRs) that specifically bind to human papillomavirus 16 or 18 peptide antigens such as peptides derived from E6 or E7, such as E6(29-38) or E7(l l-19) peptide, e.g., presented on MHC-I molecules and survived and/or were enriched over time, following multiple rounds of antigen-stimulation.
  • TCRs antigen- specific T cell receptors
  • peptides derived from E6 or E7 such as E6(29-38) or E7(l l-19) peptide
  • clonal T cell lines are generated and the sequences of individual paired TCR alpha and beta chains and abundance thereof in various populations were determined on a single-cell basis, using high-throughput paired TCR sequencing.
  • peptide-pulsed HLA:A02:01APCs were generated with HPV 16 E6(29-38) peptide (TIHDIILECV; SEQ ID NO:233) or E7(l l-19) peptide (YMLDLQPET; SEQ ID NO:236).
  • TIHDIILECV HPV 16 E6(29-38) peptide
  • YMLDLQPET E7(l l-19) peptide
  • Autologous CD8+ T cells from normal human donors are incubated over multiple rounds with the peptide-pulsed cells, and selections were carried out based on binding to peptide-loaded autologous MHC tetramers.
  • cells were subjected to multiple, such as a total of two or three or more, rounds of stimulation, in the presence of peptide-pulsed cells (such as with a particular peptide concentration of lOOOng/mL maintained over the three rounds). Following one or more of, such as following the first and/or following the second and third rounds of stimulation, cells were sorted by flow cytometry into populations positive and negative, respectively, for binding to peptide-MHC tetramers containing the appropriate tetramer.
  • Cells of the tetramer-positive and negative populations following each or one or more of of the one or more, such as the second and third, rounds in some aspects are subjected to single-cell TCR sequencing, to assess the presence and frequency of individual TCRs in the different populations, and the persistence of TCR clones over multiple rounds of antigen stimulation.
  • cell populations from the positive and negative fractions are subject to high-throughput single-cell sequencing for TCR alpha and beta chain pairs.
  • High throughput single cell TCR sequencing in some aspects is performed as generally described in published PCT patent applications, publication numbers WO2012/048340, WO2012/048341 and WO2016/044227.
  • the sequencing methods thus in some aspects employ single-cell droplets and sample and molecular barcodes, to identify individual pairs of TCR alpha and beta chain sequences at a single-cell level, for each of a large number (e.g., millions) of single cells present in a single starting composition, and to assess abundance of each TCR pair in various populations assessed.
  • the ability to identify and quantify TCR pairs at a single-cell level in some embodiments permits the assessment of the frequency of each of various TCR pairs in each of the individual positive and negative fractions, and to assess enrichment and persistence of TCRs over multiple rounds of antigen stimulation.
  • the methods generate, identify, isolate and/or select TCR pairs that are enriched in antigen-binding, e.g., peptide-binding, fractions following at least one and in some aspects a plurality of, multiple rounds of stimulation.
  • the TCRs are present in and/or present at a desired abundance in and/or preferentially enriched following, rounds 1, 2 and/or and 3 and in some aspects at least multiple rounds, of antigen exposure.
  • the TCRs are enriched in the population over time following multiple rounds of exposure to antigen.
  • TCRs generated or identified using such methods such as TCRs having such properties, such as the ability to survive and/or expand over multiple rounds of antigen exposure, such as in a peptide-pulsed APC assay.
  • cells such as cells that have been engineered to contain the binding molecule described herein.
  • populations of such cells compositions containing such cells and/or enriched for such cells, such as in which cells expressing the binding molecule make up at least 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more percent of the total cells in the composition or cells of a certain type such as T cells or CD8+ or CD4+ cells.
  • the cells are primary T cells.
  • pharmaceutical compositions and formulations for administration such as for adoptive cell therapy.
  • therapeutic methods for administering the cells and compositions to subjects e.g., patients.
  • the cells generally are eukaryotic cells, such as mammalian cells, and typically are human cells.
  • the cells are derived from the blood, bone marrow, lymph, or lymphoid organs, are cells of the immune system, such as cells of the innate or adaptive immunity, e.g. , myeloid or lymphoid cells, including lymphocytes, typically T cells and/or NK cells.
  • Other exemplary cells include stem cells, such as multipotent and pluripotent stem cells, including induced pluripotent stem cells (iPSCs).
  • the cells typically are primary cells, such as those isolated directly from a subject and/or isolated from a subject and frozen.
  • the cells include one or more subsets of T cells or other cell types, such as whole T cell populations, CD4+ cells, CD8+ cells, and subpopulations thereof, such as those defined by function, activation state, maturity, potential for differentiation, expansion, recirculation, localization, and/or persistence capacities, antigen-specificity, type of antigen receptor, presence in a particular organ or compartment, marker or cytokine secretion profile, and/or degree of differentiation.
  • the cells may be allogeneic and/or autologous.
  • the methods include off-the-shelf methods.
  • the cells are pluripotent and/or multipotent, such as stem cells, such as induced pluripotent stem cells (iPSCs).
  • the methods include isolating cells from the subject, preparing, processing, culturing, and/or engineering them, as described herein, and re-introducing them into the same patient, before or after cryopreservation.
  • T N naive T
  • T EF FX memory T cells and sub-types thereof such as stem cell memory T (TSCMX central memory T (TCMX effector memory T (T EM ), or terminally differentiated effector memory T cells, tumor-infiltrating lymphocytes (TIL), immature T cells, mature T cells, helper T cells, cytotoxic T cells, mucosa-associated invariant T (MAIT) cells, naturally occurring and adaptive regulatory T (Treg) cells, helper T cells, such as TH1 cells, TH2 cells, TH3 cells, TH17 cells, TH9 cells, TH22 cells, follicular helper T cells, alpha/beta T cells, and delta/gamma T cells.
  • T N effector T cells
  • T EF FX memory T cells and sub-types thereof such as stem cell memory T (TSCMX central memory T (TCMX effector memory T (T EM ), or terminally differentiated effector memory T cells, tumor-infil
  • the cells are natural killer (NK) cells.
  • the cells are monocytes or granulocytes, e.g., myeloid cells, macrophages, neutrophils, dendritic cells, mast cells, eosinophils, and/or basophils.
  • the cells include one or more nucleic acids introduced via genetic engineering, and thereby express recombinant or genetically engineered products of such nucleic acids.
  • the nucleic acids are heterologous, i.e., normally not present in a cell or sample obtained from the cell, such as one obtained from another organism or cell, which for example, is not ordinarily found in the cell being engineered and/or an organism from which such cell is derived.
  • the nucleic acids are not naturally occurring, such as a nucleic acid not found in nature, including one comprising chimeric combinations of nucleic acids encoding various domains from multiple different cell types.
  • genes and/or gene products (and/or expression thereof) in the provided cells, and/or compositions containing such cells are reduced, deleted, eliminated, knocked-out or disrupted.
  • Such genes and/or gene products in some aspects include one or more of the gene encoding (or product thereof) TCR alpha constant region (TRAC) and/or TCR beta constant region (TRBC; encoded in humans by TRBC1 or TRBC2), e.g., to reduce or prevent expression of the endogenous TCR in the cell, e.g. T cell, and/or a chain thereof.
  • the genes and/or gene products such as TRAC and/or TRBC, is reduced, deleted, eliminated, knocked-out or disrupted in any of the engineered cells provided herein and/or in any of the methods for producing engineered cells provided herein.
  • engineered cells and/or engineered cells produced by the methods are cells that have been engineered to express the binding molecule described herein, populations of such cells, compositions containing such cells and/or enriched for such cells.
  • genes and/or gene products such as the TRAC and/or TRBC, is reduced, deleted, eliminated, knocked- out or disrupted in primary T cells, to reduce, delete, eliminate, knock-out or disrupt the expression of the endogenous TCR in primary T cells, e.g., that are engineered to express any of the binding molecules, e.g., TCRs, described herein.
  • the genes and/or gene products targeted for reduction, deletion, elimination, knock-out or disruption are endogenous genes encoding the TCR or a chain, a domain and/or a region thereof.
  • a target site for disruption is in a T cell receptor alpha constant (TRAC) gene.
  • TRAC T cell receptor alpha constant
  • a target site for disruption is in a T cell receptor beta constant 1 (TRBCl) or T cell receptor beta constant 2 (TRBC2) gene.
  • the one or more target site(s) is in a TRAC gene and one or both of a TRBCl and a TRBC2 gene.
  • the endogenous TCR Ca is encoded by the TRAC gene (IMGT nomenclature).
  • TRAC TRAC gene
  • An exemplary nucleotide sequence of the human T cell receptor alpha constant chain (TRAC) gene locus is set forth in SEQ ID NO: 348 (NCBI Reference Sequence: NG_001332.3, TRAC).
  • the endogenous TCR C is encoded by TRBCl or TRBC2 genes (IMGT nomenclature).
  • TRBCl human T cell receptor beta constant chain 1
  • TRBC2 human T cell receptor beta constant chain 2
  • gene(s) targeted for disruption or knock-out is at or near one or more of the TRAC, TRBCl and/or TRBC2 loci.
  • the TRAC gene is knocked out.
  • the TRBCl gene is knocked out.
  • the TRBC2 gene is knocked out.
  • the TRAC gene and the TRBCl gene are knocked out.
  • the TRAC gene and the TRBC2 gene are knocked out.
  • the TRAC gene and both the TRBCl and TRBC2 genes are knocked out, e.g., targeting a sequence that is conserved between TRBCl and TRBC2.
  • reducing or preventing endogenous TCR expression can lead to a reduced risk or chance of mispairing between chains of the engineered TCR and the endogenous TCR, thereby creating a new TCR that could potentially result in a higher risk of undesired or unintended antigen recognition and/or side effects, and/or could reduce expression levels of the desired exogenous TCR.
  • reducing or preventing endogenous TCR expression can increase expression of the engineered TCR in the cells as compared to cells in which expression of the TCR is not reduced or prevented, such as increased by 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold or more.
  • suboptimal expression of an engineered or recombinant TCR can occur due to competition with an endogenous TCR and/or with TCRs having mispaired chains, for the invariant CD3 signaling molecules that are involved in permitting expression of the complex on the cell surface.
  • the reduction, deletion, elimination, knockout or disruption involve the use of one or more agent(s) capable of introducing a genetic disruption, a cleavage, a double strand break (DSB) and/or a nick at a target site in the genomic DNA, resulting in a the reduction, deletion, elimination, knockout or disruption after repair by various cellular DNA repair mechanisms.
  • agent(s) capable of introducing a genetic disruption, a cleavage, a double strand break (DSB) and/or a nick at a target site in the genomic DNA, resulting in a the reduction, deletion, elimination, knockout or disruption after repair by various cellular DNA repair mechanisms.
  • the one or more agent(s) capable of introducing a cleavage comprises a DNA binding protein or DNA-binding nucleic acid that specifically binds to or hybridizes to a target site in the genome, e.g., in TRAC and/or TRBC genes.
  • the targeted cleavage, e.g., DNA break, of the endogenous genes encoding TCR is achieved using a protein or a nucleic acid is coupled to or complexed with a gene editing nuclease, such as in a chimeric or fusion protein.
  • the one or more agent(s) capable of introducing a cleavage comprises a fusion protein comprising a DNA-targeting protein and a nuclease or an RNA-guided nuclease.
  • reduction, deletion, elimination, knockout or disruption is carried out by gene editing methods, such as using a zinc finger nuclease (ZFN), TALEN or a CRISPR/Cas system with an engineered single guide RNA that cleaves a TCR gene.
  • ZFN zinc finger nuclease
  • TALEN TALEN
  • CRISPR/Cas system with an engineered single guide RNA that cleaves a TCR gene.
  • reducing expression of an endogenous TCR is carried out using an inhibitory nucleic acid molecule against a target nucleic acids encoding specific TCRs (e.g., TCR-a and TCR- ⁇ ).
  • the inhibitory nucleic acid is or contains or encodes a small interfering RNA (siRNA), a microRN A- adapted shRNA, a short hairpin RNA (shRNA), a hairpin siRNA, a microRNA (miRNA-precursor) or a microRNA (miRNA).
  • siRNA small interfering RNA
  • shRNA short hairpin RNA
  • shRNA hairpin siRNA
  • miRNA-precursor a microRNA
  • miRNA microRNA
  • Exemplary methods for reducing or preventing endogenous TCR expression are known in the art, see e.g. U.S. Patent No. 9,273,283; U.S. publication no. US2014/0301990; and PCT publication No. WO2015/161276.
  • the agent capable of introducing a targeted cleavage comprises various components, such as a fusion protein comprising a DNA-targeting protein and a nuclease or an RNA-guided nuclease.
  • the targeted cleavage is carried out using a DNA-targeting molecule that includes a DNA-binding protein such as one or more zinc finger protein (ZFP) or transcription activator-like effectors (TALEs), fused to a nuclease, such as an endonuclease.
  • ZFP zinc finger protein
  • TALEs transcription activator-like effectors
  • the targeted cleavage is carried out using RNA-guided nucleases such as a clustered regularly interspaced short palindromic nucleic acid (CRISPPv)-associated nuclease (Cas) system (including Cas and/or Cfpl).
  • CRISPPv clustered regularly interspaced short palindromic nucleic acid
  • Cas Cas-associated nuclease
  • the targeted cleavage is carried using agents capable of introducing a cleavage, such as sequence-specific or targeted nucleases, including DNA-binding targeted nucleases and gene editing nucleases such as zinc finger nucleases (ZFN) and transcription activator-like effector nucleases (TALENs), and RNA-guided nucleases such as a CRISPR-associated nuclease (Cas) system, specifically engineered and/or designed to be targeted to the at least one target site(s), sequence of a gene or a portion thereof.
  • agents capable of introducing a cleavage such as sequence-specific or targeted nucleases, including DNA-binding targeted nucleases and gene editing nucleases such as zinc finger nucleases (ZFN) and transcription activator-like effector nucleases (TALENs), and RNA-guided nucleases such as a CRISPR-associated nuclease (Cas) system, specifically engineered and/or designed to be targeted to
  • the one or more agent(s) specifically targets the at least one target site(s), e.g., at or near TRAC and/or TRBC genes.
  • the agent comprises a ZFN, TALEN or a CRISPR/Cas9 combination that specifically binds to, recognizes, or hybridizes to the target site(s).
  • the CRISPR/Cas9 system includes an engineered crRNA/tracr RNA ("single guide RNA”) to guide specific cleavage.
  • the agent comprises nucleases based on the Argonaute system (e.g., from T.
  • thermophilus known as tAgo', (Swarts et at (2014) Nature 507(7491): 258-261).
  • Zinc finger proteins ZFPs
  • transcription activator-like effectors TALEs
  • CRISPR system binding domains can be "engineered” to bind to a predetermined nucleotide sequence, for example via engineering (altering one or more amino acids) of the recognition helix region of a naturally occurring ZFP or TALE protein.
  • Engineered DNA binding proteins ZFPs or TALEs are proteins that are non-naturally occurring. Rational criteria for design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP and/or TALE designs and binding data. See, e.g., U.S. Pat. Nos.
  • the TRAC and/or TRBC genes can be targeted for cleavage by engineered ZFNs.
  • Exemplary ZFN that target endogenous T cell receptor (TCR) genes include those described in, e.g., US 2015/0164954, US 2011/0158957, US 8956828 and Torikawa et al. (2012) Blood 119:5697-5705, the disclosures of which are incorporated by reference in their entireties.
  • the TRAC and/or TRBC genes can be targeted for cleavage by engineered TALENs.
  • Exemplary TALEN that target endogenous T cell receptor (TCR) genes include those described in, e.g., WO 2017/070429, WO 2015/136001, US20170016025 and US20150203817, the disclosures of which are incorporated by reference in their entireties.
  • the TRAC and/or TRBC genes can be targeted for cleavage using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR- associated (Cas) proteins.
  • CRISPR system refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas”) genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g.
  • tracrRNA or an active partial tracrRNA a tracr-mate sequence (encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer” in the context of an endogenous CRISPR system), and/or other sequences and transcripts from a CRISPR locus.
  • the CRISPR/Cas nuclease or CRISPR/Cas nuclease system includes a non-coding guide RNA (gRNA), which sequence-specifically binds to DNA, and a Cas protein (e.g., Cas9), with nuclease functionality.
  • gRNA non-coding guide RNA
  • Cas protein e.g., Cas9
  • the CRISPR/Cas nuclease system comprises at least one of: a guide RNA (gRNA) having a targeting domain that is complementary with a target site of a TRAC gene; a gRNA having a targeting domain that is complementary with a target site of one or both of a TRBC1 and a TRBC2 gene; or at least one nucleic acid encoding the gRNA.
  • gRNA guide RNA
  • a guide sequence e.g., guide RNA
  • RNA is any polynucleotide sequences comprising at least a sequence portion, e.g., targeting domain, that has sufficient
  • target site sequence such as a target site in the TRAC, TRBC1 and/or TRBC2 genes in humans, to hybridize with the target sequence at the target site and direct sequence-specific binding of the CRISPR complex to the target sequence.
  • target site (also known as “target position,” “target DNA sequence” or “target location”) generally refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between the target sequence and a domain, e.g., targeting domain, of the guide RNA promotes the formation of a CRISPR complex.
  • a guide sequence is selected to reduce the degree of secondary structure within the guide sequence. Secondary structure may be determined by any suitable polynucleotide folding algorithm.
  • a CRISPR enzyme e.g. Cas9 nuclease
  • a guide sequence is delivered to the cell.
  • a CRISPR system is derived from a type I, type II, or type III CRISPR system.
  • one or more elements of a CRISPR system are derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes, Staphylococcus aureus or Neisseria meningitides.
  • a guide RNA (gRNA) specific to the target site e.g. TRAC, TRBC1 and/or TRBC2 in humans
  • RNA-guided nucleases e.g., Cas
  • Methods for designing gRNAs and exemplary targeting domains can include those described in, e.g., in International PCT Publication No. WO2015/161276.
  • Targeting domains of can be incorporated into the gRNA that is used to target Cas9 nucleases to the target site or target position.
  • the gRNA sequence is or comprises a sequence with minimal off-target binding to a non-target site or position.
  • the gRNA for targeting TRAC, TRBC1 and/or TRBC2 can be any that are described herein, or are described elsewhere.
  • the sequence targeted by the CRISPR/Cas9 gRNA in the TRAC gene locus is ATTCACCGATTTTGATTCTC (SEQ ID NO: 1182).
  • the sequence targeted by the CRISPR/Cas9 gRNA in the TRBC1 and/or TRBC2 gene loci is GATCGTCAGCGCCGAGGCC (SEQ ID NO: 1054).
  • the gRNA targeting domain sequence for targeting a target site in the TRAC gene locus is GAGAAUCAAAAUCGGUGAAU (SEQ ID NO: 1048).
  • the gRNA targeting domain sequence for targeting a target site in the TRBC1 and/or TRBC2 gene loci is GGCCUCGGCGCUGACGAUCU (SEQ ID NO: 1053).
  • Other exemplary gRNA sequences, or targeting domains contained in the gRNA and/or other methods of gene editing and/or knock-out targeting endogenous TCR genes, e.g., TRAC and/or TRBC genes include any described in, e.g., in International PCT Publication Nos. WO2015/161276, WO2014/191128, WO2015/136001, WO2016/069283, WO2016/016341; U.S. Publication Nos.
  • t reduction, deletion, elimination, knockout or disruption of the endogenous genes encoding TCR is carried out by delivering or introducing one or more agent(s) capable of introducing a cleavage, e.g., Cas9 and/or gRNA components, to a cell, using any of a number of known delivery method or vehicle for introduction or transfer to cells, for example, using lentiviral delivery vectors, or any of the known methods or vehicles for delivering Cas9 molecules and gRNAs. Exemplary methods are described in, e.g., Wang et al. (2012) J. Immunother. 35(9): 689-701; Cooper et al. (2003) Blood.
  • nucleic acid sequences encoding one or more components of one or more agent(s) capable of introducing a cleavage is introduced into the cells, e.g., by any methods for introducing nucleic acids into a cell described herein or known.
  • a vector encoding components of one or more agent(s) capable of introducing a cleavage such as a CRISPR guide RNA and/or a Cas9 enzyme can be delivered into the cell.
  • the one or more agent(s) capable of introducing a cleavage is introduced into the cell as a ribonucleoprotein (RNP) complex.
  • RNP complexes include a sequence of ribonucleotides, such as an RNA or a gRNA molecule, and a protein, such as a Cas9 protein or variant thereof.
  • the Cas9 protein is delivered as RNP complex that comprises a Cas9 protein and a gRNA molecule targeting the target sequence, e.g., using electroporation or other physical delivery method.
  • the RNP is delivered into the cell via electroporation or other physical means, e.g., particle gun, calcium phosphate transfection, cell compression or squeezing.
  • the RNP can cross the plasma membrane of a cell without the need for additional delivery agents (e.g., small molecule agents, lipids, etc.).
  • preparation of the engineered cells includes one or more culture and/or preparation steps.
  • the cells for introduction of the binding molecule, e.g., TCR or CAR may be isolated from a sample, such as a biological sample, e.g., one obtained from or derived from a subject.
  • the subject from which the cell is isolated is one having the disease or condition or in need of a cell therapy or to which cell therapy will be administered.
  • the subject in some embodiments is a human in need of a particular therapeutic intervention, such as the adoptive cell therapy for which cells are being isolated, processed, and/or engineered.
  • the cells in some embodiments are primary cells, e.g., primary human cells.
  • the samples include tissue, fluid, and other samples taken directly from the subject, as well as samples resulting from one or more processing steps, such as separation, centrifugation, genetic engineering (e.g. transduction with viral vector), washing, and/or incubation.
  • the biological sample can be a sample obtained directly from a biological source or a sample that is processed.
  • Biological samples include, but are not limited to, body fluids, such as blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine and sweat, tissue and organ samples, including processed samples derived therefrom.
  • the sample from which the cells are derived or isolated is blood or a blood-derived sample, or is or is derived from an apheresis or leukapheresis product.
  • exemplary samples include whole blood, peripheral blood mononuclear cells (PBMCs), leukocytes, bone marrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node, gut associated lymphoid tissue, mucosa associated lymphoid tissue, spleen, other lymphoid tissues, liver, lung, stomach, intestine, colon, kidney, pancreas, breast, bone, prostate, cervix, testes, ovaries, tonsil, or other organ, and/or cells derived therefrom.
  • PBMCs peripheral blood mononuclear cells
  • Samples include, in the context of cell therapy, e.g., adoptive cell therapy, samples from autologous and allogeneic sources.
  • the cells are derived from cell lines, e.g., T cell lines.
  • the cells in some embodiments are obtained from a xenogeneic source, for example, from mouse, rat, non-human primate, or pig.
  • isolation of the cells includes one or more preparation and/or non-affinity based cell separation steps.
  • cells are washed, centrifuged, and/or incubated in the presence of one or more reagents, for example, to remove unwanted
  • cells are separated based on one or more property, such as density, adherent properties, size, sensitivity and/or resistance to particular components.
  • cells from the circulating blood of a subject are obtained, e.g., by apheresis or leukapheresis.
  • the samples contain lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and/or platelets, and in some aspects contains cells other than red blood cells and platelets.
  • the blood cells collected from the subject are washed, e.g., to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps.
  • the cells are washed with phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • the wash solution lacks calcium and/or magnesium and/or many or all divalent cations.
  • a washing step is
  • a washing step is accomplished by tangential flow filtration (TFF) according to the manufacturer's instructions.
  • the cells are resuspended in a variety of biocompatible buffers after washing, such as, for example, Ca ++ /Mg ++ free PBS.
  • components of a blood cell sample are removed and the cells directly resuspended in culture media.
  • the methods include density-based cell separation methods, such as the preparation of white blood cells from peripheral blood by lysing the red blood cells and centrifugation through a Percoll or Ficoll gradient.
  • the isolation methods include the separation of different cell types based on the expression or presence in the cell of one or more specific molecules, such as surface markers, e.g., surface proteins, intracellular markers, or nucleic acid. In some embodiments, any known method for separation based on such markers may be used. In some embodiments, the separation is affinity- or immunoaffinity-based separation.
  • the isolation in some aspects includes separation of cells and cell populations based on the cells' expression or expression level of one or more markers, typically cell surface markers, for example, by incubation with an antibody or binding partner that specifically binds to such markers, followed generally by washing steps and separation of cells having bound the antibody or binding partner, from those cells having not bound to the antibody or binding partner.
  • Such separation steps can be based on positive selection, in which the cells having bound the reagents are retained for further use, and/or negative selection, in which the cells having not bound to the antibody or binding partner are retained. In some examples, both fractions are retained for further use. In some aspects, negative selection can be particularly useful where no antibody is available that specifically identifies a cell type in a heterogeneous population, such that separation is best carried out based on markers expressed by cells other than the desired population.
  • the separation need not result in 100% enrichment or removal of a particular cell population or cells expressing a particular marker.
  • positive selection of or enrichment for cells of a particular type refers to increasing the number or percentage of such cells, but need not result in a complete absence of cells not expressing the marker.
  • negative selection, removal, or depletion of cells of a particular type refers to decreasing the number or percentage of such cells, but need not result in a complete removal of all such cells.
  • multiple rounds of separation steps are carried out, where the positively or negatively selected fraction from one step is subjected to another separation step, such as a subsequent positive or negative selection.
  • a single separation step can deplete cells expressing multiple markers simultaneously, such as by incubating cells with a plurality of antibodies or binding partners, each specific for a marker targeted for negative selection.
  • multiple cell types can simultaneously be positively selected by incubating cells with a plurality of antibodies or binding partners expressed on the various cell types.
  • T cells such as cells positive or expressing high levels of one or more surface markers, e.g., CD28 + , CD62L + , CCR7 + , CD27 + , CD127 + , CD4 + , CD8 + , CD45RA + , and/or CD45RO + T cells, are isolated by positive or negative selection techniques.
  • CD3 + , CD28 + T cells can be positively selected using anti-CD3/anti- CD28 conjugated magnetic beads (e.g., DYNABEADS® M-450 CD3/CD28 T Cell Expander).
  • isolation is carried out by enrichment for a particular cell population by positive selection, or depletion of a particular cell population, by negative selection.
  • positive or negative selection is accomplished by incubating cells with one or more antibodies or other binding agent that specifically bind to one or more surface markers expressed or expressed (marker "1" ) at a relatively higher level (marker hlgh ) on the positively or negatively selected cells, respectively.
  • T cells are separated from a PBMC sample by negative selection of markers expressed on non-T cells, such as B cells, monocytes, or other white blood cells, such as CD 14.
  • a CD4 + or CD8 + selection step is used to separate CD4 + helper and CD8 + cytotoxic T cells.
  • Such CD4 + and CD8 + populations can be further sorted into sub-populations by positive or negative selection for markers expressed or expressed to a relatively higher degree on one or more naive, memory, and/or effector T cell subpopulations.
  • CD8 + cells are further enriched for or depleted of naive, central memory, effector memory, and/or central memory stem cells, such as by positive or negative selection based on surface antigens associated with the respective subpopulation.
  • enrichment for central memory T (T CM ) cells is carried out to increase efficacy, such as to improve long-term survival, expansion, and/or engraftment following administration, which in some aspects is particularly robust in such sub-populations. See Terakura et al. (2012) Blood.1:72-82; Wang et al. (2012) J Immunother. 35(9):689-701.
  • combining TcM-enriched CD8 + T cells and CD4 + T cells further enhances efficacy.
  • memory T cells are present in both CD62L “1” and CD62L " subsets of CD8 + peripheral blood lymphocytes.
  • PBMC can be enriched for or depleted of CD62L CD8 "1” and/or CD62L + CD8 + fractions, such as using anti-CD8 and anti-CD62L antibodies.
  • the enrichment for central memory T (T CM ) cells is based on positive or high surface expression of CD45RO, CD62L, CCR7, CD28, CD3, and/or CD 127; in some aspects, it is based on negative selection for cells expressing or highly expressing
  • isolation of a CD8 + population enriched for T CM cells is carried out by depletion of cells expressing CD4, CD 14, CD45RA, and positive selection or enrichment for cells expressing CD62L.
  • enrichment for central memory T (T CM ) cells is carried out starting with a negative fraction of cells selected based on CD4 expression, which is subjected to a negative selection based on expression of CD 14 and
  • CD45RA and a positive selection based on CD62L. Such selections in some aspects are carried out simultaneously and in other aspects are carried out sequentially, in either order.
  • the same CD4 expression-based selection step used in preparing the CD8 + cell population or subpopulation also is used to generate the CD4 + cell population or sub- population, such that both the positive and negative fractions from the CD4-based separation are retained and used in subsequent steps of the methods, optionally following one or more further positive or negative selection steps.
  • a sample of PBMCs or other white blood cell sample is subjected to selection of CD4 + cells, where both the negative and positive fractions are retained.
  • the negative fraction then is subjected to negative selection based on expression of CD 14 and CD45RA, and positive selection based on a marker characteristic of central memory T cells, such as CD62L or CCR7, where the positive and negative selections are carried out in either order.
  • CD4 + T helper cells are sorted into naive, central memory, and effector cells by identifying cell populations that have cell surface antigens.
  • CD4 + lymphocytes can be obtained by standard methods.
  • naive CD4 + T lymphocytes are CD45RO " , CD45RA + , CD62L + , CD4 + T cells.
  • central memory CD4 + cells are CD62L + and CD45RO + .
  • effector CD4 + cells are CD62L " and CD45RO " .
  • a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CDl lb, CD16, HLA-DR, and CD8.
  • the antibody or binding partner is bound to a solid support or matrix, such as a magnetic bead or paramagnetic bead, to allow for separation of cells for positive and/or negative selection.
  • the cells and cell populations are separated or isolated using immunomagnetic (or affinitymagnetic) separation techniques (reviewed in Methods in Molecular Medicine, vol. 58: Metastasis Research
  • the sample or composition of cells to be separated is incubated with small, magnetizable or magnetically responsive material, such as magnetically responsive particles or microparticles, such as paramagnetic beads (e.g., such as Dynalbeads or MACS beads).
  • small, magnetizable or magnetically responsive material such as magnetically responsive particles or microparticles, such as paramagnetic beads (e.g., such as Dynalbeads or MACS beads).
  • the magnetically responsive material e.g., particle
  • a binding partner e.g., an antibody
  • a molecule e.g., surface marker
  • the magnetic particle or bead comprises a magnetically responsive material bound to a specific binding member, such as an antibody or other binding partner.
  • a specific binding member such as an antibody or other binding partner.
  • Suitable magnetic particles include those described in Molday, U.S. Pat. No. 4,452,773, and in European Patent Specification EP 452342 B, which are hereby incorporated by reference.
  • Colloidal sized particles such as those described in Owen U.S. Pat. No. 4,795,698, and Liberti et al., U.S. Pat. No. 5,200,084 are other examples.
  • the incubation generally is carried out under conditions whereby the antibodies or binding partners, or molecules, such as secondary antibodies or other reagents, which specifically bind to such antibodies or binding partners, which are attached to the magnetic particle or bead, specifically bind to cell surface molecules if present on cells within the sample.
  • the antibodies or binding partners, or molecules such as secondary antibodies or other reagents, which specifically bind to such antibodies or binding partners, which are attached to the magnetic particle or bead, specifically bind to cell surface molecules if present on cells within the sample.
  • the sample is placed in a magnetic field, and those cells having magnetically responsive or magnetizable particles attached thereto will be attracted to the magnet and separated from the unlabeled cells.
  • positive selection cells that are attracted to the magnet are retained; for negative selection, cells that are not attracted (unlabeled cells) are retained.
  • negative selection cells that are not attracted (unlabeled cells) are retained.
  • a combination of positive and negative selection is performed during the same selection step, where the positive and negative fractions are retained and further processed or subject to further separation steps.
  • the magnetically responsive particles are coated in primary antibodies or other binding partners, secondary antibodies, lectins, enzymes, or streptavidin.
  • the magnetic particles are attached to cells via a coating of primary antibodies specific for one or more markers.
  • the cells, rather than the beads are labeled with a primary antibody or binding partner, and then cell-type specific secondary antibody- or other binding partner (e.g., streptavidin)-coated magnetic particles, are added.
  • streptavidin-coated magnetic particles are used in conjunction with biotinylated primary or secondary antibodies.
  • the magnetically responsive particles are left attached to the cells that are to be subsequently incubated, cultured and/or engineered; in some aspects, the particles are left attached to the cells for administration to a patient.
  • the magnetizable or magnetically responsive particles are removed from the cells. Methods for removing magnetizable particles from cells are known and include, e.g., the use of competing non-labeled antibodies, magnetizable particles or antibodies conjugated to cleavable linkers, etc. In some embodiments, the magnetizable particles are biodegradable.
  • the affinity-based selection is via magnetic-activated cell sorting (MACS) (Miltenyi Biotec, Auburn, CA). Magnetic Activated Cell Sorting (MACS) systems are capable of high-purity selection of cells having magnetized particles attached thereto.
  • MACS operates in a mode wherein the non-target and target species are sequentially eluted after the application of the external magnetic field. That is, the cells attached to magnetized particles are held in place while the unattached species are eluted. Then, after this first elution step is completed, the species that were trapped in the magnetic field and were prevented from being eluted are freed in some manner such that they can be eluted and recovered.
  • the non-target cells are labelled and depleted from the heterogeneous population of cells.
  • the isolation or separation is carried out using a system, device, or apparatus that carries out one or more of the isolation, cell preparation, separation, processing, incubation, culture, and/or formulation steps of the methods.
  • the system is used to carry out each of these steps in a closed or sterile environment, for example, to minimize error, user handling and/or contamination.
  • the system is a system as described in International Patent Application, Publication Number WO2009/072003, or US 2011/0003380 Al.
  • the system or apparatus carries out one or more, e.g., all, of the isolation, processing, engineering, and formulation steps in an integrated or self-contained system, and/or in an automated or programmable fashion.
  • the system or apparatus includes a computer and/or computer program in communication with the system or apparatus, which allows a user to program, control, assess the outcome of, and/or adjust various aspects of the processing, isolation, engineering, and formulation steps.
  • the separation and/or other steps is carried out using CliniMACS system (Miltenyi Biotec), for example, for automated separation of cells on a clinical-scale level in a closed and sterile system.
  • Components can include an integrated microcomputer, magnetic separation unit, peristaltic pump, and various pinch valves.
  • the integrated computer in some aspects controls all components of the instrument and directs the system to perform repeated procedures in a standardized sequence.
  • the magnetic separation unit in some aspects includes a movable permanent magnet and a holder for the selection column.
  • the peristaltic pump controls the flow rate throughout the tubing set and, together with the pinch valves, ensures the controlled flow of buffer through the system and continual suspension of cells.
  • the CliniMACS system in some aspects uses antibody-coupled magnetizable particles that are supplied in a sterile, non-pyrogenic solution.
  • the cells after labelling of cells with magnetic particles the cells are washed to remove excess particles.
  • a cell preparation bag is then connected to the tubing set, which in turn is connected to a bag containing buffer and a cell collection bag.
  • the tubing set consists of pre-assembled sterile tubing, including a pre-column and a separation column, and are for single use only. After initiation of the separation program, the system automatically applies the cell sample onto the separation column. Labelled cells are retained within the column, while unlabeled cells are removed by a series of washing steps.
  • the cell populations for use with the methods described herein are unlabeled and are not retained in the column. In some embodiments, the cell populations for use with the methods described herein are labeled and are retained in the column. In some embodiments, the cell populations for use with the methods described herein are eluted from the column after removal of the magnetic field, and are collected within the cell collection bag.
  • separation and/or other steps are carried out using the CliniMACS Prodigy system (Miltenyi Biotec).
  • the CliniMACS Prodigy system in some aspects is equipped with a cell processing unity that permits automated washing and
  • the CliniMACS Prodigy system can also include an onboard camera and image recognition software that determines the optimal cell fractionation endpoint by discerning the macroscopic layers of the source cell product. For example, peripheral blood may be automatically separated into erythrocytes, white blood cells and plasma layers.
  • the CliniMACS Prodigy system can also include an integrated cell cultivation chamber which accomplishes cell culture protocols such as, e.g., cell differentiation and expansion, antigen loading, and long-term cell culture. Input ports can allow for the sterile removal and replenishment of media and cells can be monitored using an integrated microscope. See, e.g., Klebanoff et al. (2012) J Immunother. 35(9): 651-660, Terakuraet al. (2012) Blood.1:72-82, and Wang et al. (2012) Immunother. 35(9):689-701.
  • a cell population described herein is collected and enriched (or depleted) via flow cytometry, in which cells stained for multiple cell surface markers are carried in a fluidic stream.
  • a cell population described herein is collected and enriched (or depleted) via preparative scale (FACS)-sorting.
  • a cell population described herein is collected and enriched (or depleted) by use of
  • MEMS microelectromechanical systems
  • the antibodies or binding partners are labeled with one or more detectable marker, to facilitate separation for positive and/or negative selection.
  • separation may be based on binding to fluorescently labeled antibodies.
  • separation of cells based on binding of antibodies or other binding partners specific for one or more cell surface markers are carried in a fluidic stream, such as by fluorescence- activated cell sorting (FACS), including preparative scale (FACS) and/or
  • MEMS microelectromechanical systems
  • the preparation methods include steps for freezing, e.g., cryopreserving, the cells, either before or after isolation, incubation, and/or engineering.
  • the freeze and subsequent thaw step removes granulocytes and, to some extent, monocytes in the cell population.
  • the cells are suspended in a freezing solution, e.g., following a washing step to remove plasma and platelets. Any of a variety of known freezing solutions and parameters in some aspects may be used.
  • a freezing solution e.g., following a washing step to remove plasma and platelets.
  • Any of a variety of known freezing solutions and parameters in some aspects may be used.
  • PBS containing 20% DMSO and 8% human serum albumin (HSA), or other suitable cell freezing media. This is then diluted 1 : 1 with media so that the final concentration of DMSO and HSA are 10% and 4%, respectively.
  • the cells are then frozen to -80° C. at a rate of 1° per minute and stored in the vapor phase of a liquid nitrogen
  • the provided methods include cultivation, incubation, culture, and/or genetic engineering steps.
  • the cell populations are incubated in a culture-initiating composition.
  • the incubation and/or engineering may be carried out in a culture vessel, such as a unit, chamber, well, column, tube, tubing set, valve, vial, culture dish, bag, or other container for culture or cultivating cells.
  • the cells are incubated and/or cultured prior to or in connection with genetic engineering.
  • the incubation steps can include culture, cultivation, stimulation, activation, and/or propagation.
  • the compositions or cells are incubated in the presence of stimulating conditions or a stimulatory agent. Such conditions include those designed to induce proliferation, expansion, activation, and/or survival of cells in the population, to mimic antigen exposure, and/or to prime the cells for genetic engineering, such as for the introduction of an antigen receptor.
  • the conditions can include one or more of particular media, temperature, oxygen content, carbon dioxide content, time, agents, e.g., nutrients, amino acids, antibiotics, ions, and/or stimulatory factors, such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other agents designed to activate the cells.
  • agents e.g., nutrients, amino acids, antibiotics, ions, and/or stimulatory factors, such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other agents designed to activate the cells.
  • the stimulating conditions or agents include one or more agent, e.g., ligand, which is capable of activating an intracellular signaling domain of a TCR complex.
  • the agent turns on or initiates TCR/CD3 intracellular signaling cascade in a T cell.
  • agents can include antibodies, such as those specific for a TCR component and/or costimulatory receptor, e.g., anti-CD3.
  • the stimulating conditions include one or more agent, e.g. ligand, which is capable of stimulating a
  • the expansion method may further comprise the step of adding anti-CD3 and/or anti CD28 antibody to the culture medium (e.g., at a concentration of at least about 0.5 ng/ml).
  • the stimulating agents include IL-2, IL-15 and/or IL-7. In some aspects, the IL-2 concentration is at least about 10 units/mL.
  • incubation is carried out in accordance with techniques such as those described in US Patent No. 6,040,1 77 to Riddell et al., Klebanoff et al.(2012) J
  • the T cells are expanded by adding to the culture-initiating composition feeder cells, such as non-dividing peripheral blood mononuclear cells (PBMC), (e.g., such that the resulting population of cells contains at least about 5, 10, 20, or 40 or more PBMC feeder cells for each T lymphocyte in the initial population to be expanded); and incubating the culture (e.g. for a time sufficient to expand the numbers of T cells).
  • the non-dividing feeder cells can comprise gamma-irradiated PBMC feeder cells.
  • the PBMC are irradiated with gamma rays in the range of about 3000 to 3600 rads to prevent cell division.
  • the feeder cells are added to culture medium prior to the addition of the populations of T cells.
  • the stimulating conditions include temperature suitable for the growth of human T lymphocytes, for example, at least about 25 degrees Celsius, generally at least about 30 degrees, and generally at or about 37 degrees Celsius.
  • the incubation may further comprise adding non-dividing EBV-transformed lymphoblastoid cells (LCL) as feeder cells.
  • LCL can be irradiated with gamma rays in the range of about 6000 to 10,000 rads.
  • the LCL feeder cells in some aspects is provided in any suitable amount, such as a ratio of LCL feeder cells to initial T lymphocytes of at least about 10: 1.
  • antigen-specific T cells such as antigen-specific CD4+ and/or CD8+ T cells
  • antigen-specific T cell lines or clones can be generated to cytomegalovirus antigens by isolating T cells from infected subjects and stimulating the cells in vitro with the same antigen.
  • nucleic acids, compositions, and kits for expressing the binding molecules, and for producing the genetically engineered cells expressing such binding molecules.
  • the genetic engineering generally involves introduction of a nucleic acid encoding the binding molecule, e.g. TCR or CAR, e.g. TCR-like CAR, into the cell, such as by retroviral transduction, transfection, or transformation.
  • gene transfer is accomplished by first stimulating the cell, such as by combining it with a stimulus that induces a response such as proliferation, survival, and/or activation, e.g., as measured by expression of a cytokine or activation marker, followed by transduction of the activated cells, and expansion in culture to numbers sufficient for clinical applications.
  • a stimulus such as proliferation, survival, and/or activation, e.g., as measured by expression of a cytokine or activation marker
  • the engineered cells include gene segments that cause the cells to be susceptible to negative selection in vivo, such as upon administration in adoptive immunotherapy.
  • the cells are engineered so that they can be eliminated as a result of a change in the in vivo condition of the patient to which they are administered.
  • the negative selectable phenotype may result from the insertion of a gene that confers sensitivity to an administered agent, for example, a compound.
  • Negative selectable genes include the Herpes simplex virus type I thymidine kinase (HSV-I TK) gene (Wigler et al., Cell 2 :223, 1977) which confers ganciclovir sensitivity; the cellular hypoxanthine phosphribosyltransferase (HPRT) gene, the cellular adenine
  • HSV-I TK Herpes simplex virus type I thymidine kinase
  • HPRT hypoxanthine phosphribosyltransferase
  • APRT phosphoribosyltransferase
  • the cells further are engineered to promote expression of cytokines or other factors.
  • cytokines e.g., IL-12, IL-12, IL-12, IL-12, and others.
  • Various methods for the introduction of genetically engineered components are well known and may be used with the provided methods and compositions. Exemplary methods include those for transfer of nucleic acids encoding the binding molecules, including via viral, e.g., retroviral or lentiviral, transduction, transposons, and electroporation.
  • recombinant nucleic acids are transferred into cells using recombinant infectious virus particles, such as, e.g., vectors derived from simian virus 40 (SV40), adenoviruses, adeno-associated virus (AAV).
  • recombinant nucleic acids are transferred into T cells using recombinant lentiviral vectors or retroviral vectors, such as gamma-retroviral vectors (see, e.g., Koste et al. (2014) Gene Therapy 2014 Apr 3. doi: 10.1038/gt.2014.25; Carlens et al.
  • the retroviral vector has a long terminal repeat sequence (LTR), e.g., a retroviral vector derived from the Moloney murine leukemia virus (MoMLV), myeloproliferative sarcoma virus (MPSV), murine embryonic stem cell virus (MESV), murine stem cell virus (MSCV), spleen focus forming virus (SFFV), or adeno-associated virus (AAV).
  • LTR long terminal repeat sequence
  • MoMLV Moloney murine leukemia virus
  • MPSV myeloproliferative sarcoma virus
  • MMV murine embryonic stem cell virus
  • MSCV murine stem cell virus
  • SFFV spleen focus forming virus
  • AAV adeno-associated virus
  • retroviral vectors are derived from murine retroviruses.
  • the retroviruses include those derived from any avian or mammalian cell source.
  • the retroviruses typically are amphotropic, meaning that they are capable of
  • the gene to be expressed replaces the retroviral gag, pol and/or env sequences.
  • retroviral systems e.g., U.S. Pat. Nos. 5,219,740; 6,207,453; 5,219,740; Miller and Rosman (1989) BioTechniques 7:980-990; Miller, A. D. (1990) Human Gene Therapy 1:5-14; Scarpa et al. (1991) Virology 180:849-852; Burns et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037; and Boris-Lawrie and Temin (1993) Cur. Opin. Genet. Develop. 3: 102-109.
  • recombinant nucleic acids are transferred into T cells via electroporation ⁇ see, e.g., Chicaybam et al, (2013) PLoS ONE 8(3): e60298 and Van Tedeloo et al. (2000) Gene Therapy 7(16): 1431-1437).
  • recombinant nucleic acids are transferred into T cells via transposition (see, e.g., Manuri et al. (2010) Hum Gene Ther 21(4): 427-437; Sharma et al. (2013) Molec Ther Nucl Acids 2, e74; and Huang et al. (2009) Methods Mol Biol 506: 115-126).
  • genes for introduction are those to improve the efficacy of therapy, such as by promoting viability and/or function of transferred cells; genes to provide a genetic marker for selection and/or evaluation of the cells, such as to assess in vivo survival or localization; genes to improve safety, for example, by making the cell susceptible to negative selection in vivo as described by Lupton S. D. et al., Mol. and Cell Biol., 11:6 (1991); and Riddell et al., Human Gene Therapy 3:319-338 (1992); see also the publications of
  • engineered cells such as those containing a binding molecule (such as TCR or antigen-binding fragment thereof or antibody or antigen- binding fragment thereof), nucleic acid, or vector as described herein.
  • the cell is produced by transducing the cell in vitro or ex vivo with a vector described herein.
  • the cell is a T cell, such as a CD8+ or CD4+ T cell.
  • the binding molecule is heterologous to the cell.
  • the engineered cell contains a heterologous TCR or antigen-binding fragment thereof that recognizes or binds a peptide epitope derived from HPV16 E6.
  • the TCR or antigen-binding fragment thereof does not recognize or bind the epitope E6(29-38) comprising the amino acid sequence TIHDIILECV (SEQ ID NO. 233).
  • the TCR or antigen-binding fragment thereof that recognizes or binds a peptide epitope derived from HPV16 E6 is or comprises the sequence set forth in SEQ ID NO: 232 or SEQ ID NO: 234.
  • the engineered cell contains a heterologous TCR or antigen- binding fragment thereof that recognizes or binds a peptide epitope derived from HPV16 E7.
  • the TCR or antigen-binding fragment thereof does not recognize or bind the epitope E7 (11-19) comprising the amino acid sequence YMLDLQPET (SEQ ID NO. 236).
  • the TCR or antigen-binding fragment thereof that recognizes or binds a peptide epitope derived from HPV16 E7 is or contains the sequence set forth in any of SEQ ID NOs: 235-239.
  • the peptide derived from HPV16 E7 is or contains the sequence set forth in SEQ ID NO: 235.
  • compositions including the binding molecules e.g. TCRs, and engineered cells, including pharmaceutical compositions and formulations, and methods of using and uses of the molecules and compositions, such as in the treatment of diseases, conditions, and disorders in which HPV16 E6 or E7 is expressed, and/or detection, diagnostic, and prognostic methods.
  • compositions including the binding molecules, e.g., TCR or antigen binding fragment thereof or antibody or antigen-binding fragment thereof, and/or the engineered cells expressing the binding molecules.
  • the pharmaceutical compositions and formulations generally include one or more optional pharmaceutically acceptable carrier or excipient.
  • the composition includes at least one additional therapeutic agent.
  • pharmaceutical formulation refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
  • a "pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
  • a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
  • the choice of carrier is determined in part by the particular cell or binding molecule, and/or by the method of administration. Accordingly, there are a variety of suitable formulations.
  • the pharmaceutical composition can contain preservatives. Suitable preservatives may include, for example, methylparaben, propylparaben, sodium benzoate, and benzalkonium chloride. In some aspects, a mixture of two or more preservatives is used. The preservative or mixtures thereof are typically present in an amount of about 0.0001% to about 2% by weight of the total composition. Carriers are described, e.g., by Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
  • Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arg
  • Buffering agents in some aspects are included in the compositions.
  • Suitable buffering agents include, for example, citric acid, sodium citrate, phosphoric acid, potassium phosphate, and various other acids and salts.
  • a mixture of two or more buffering agents is used.
  • the buffering agent or mixtures thereof are typically present in an amount of about 0.001% to about 4% by weight of the total composition.
  • Methods for preparing administrable pharmaceutical compositions are known. Exemplary methods are described in more detail in, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st ed. (May 1, 2005).
  • Formulations of the binding molecules can include lyophilized formulations and aqueous solutions.
  • the formulation or composition may also contain more than one active ingredient useful for the particular indication, disease, or condition being treated with the binding molecules or cells, preferably those with activities complementary to the binding molecule or cell, where the respective activities do not adversely affect one another.
  • active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
  • the pharmaceutical composition further includes other pharmaceutically active agents or drugs, such as chemotherapeutic agents, e.g., asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc.
  • chemotherapeutic agents e.g., asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc.
  • the cells or binding molecules are administered in the form of a salt, e.g., a pharmaceutically acceptable salt.
  • Suitable pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, and sulphuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, and arylsulphonic acids, for example, p-toluenesulphonic acid.
  • mineral acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, and sulphuric acids
  • organic acids such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, and arylsulphonic acids, for example, p-toluenesulphonic acid.
  • Active ingredients may be entrapped in microcapsules, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • the pharmaceutical composition is formulated as an inclusion complex, such as cyclodextrin inclusion complex, or as a liposome.
  • Liposomes can serve to target the host cells (e.g., T-cells or NK cells) to a particular tissue.
  • Many methods are available for preparing liposomes, such as those described in, for example, Szoka et al., Ann. Rev. Biophys. Bioeng., 9: 467 (1980), and U.S. Patents 4,235,871, 4,501,728, 4,837,028, and 5,019,369.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PCT/US2017/055005 2016-10-03 2017-10-03 Hpv-specific binding molecules Ceased WO2018067618A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US16/338,452 US11072660B2 (en) 2016-10-03 2017-10-03 HPV-specific binding molecules
EP17787729.7A EP3519433A1 (en) 2016-10-03 2017-10-03 Hpv-specific binding molecules
CN201780065335.3A CN110139873A (zh) 2016-10-03 2017-10-03 Hpv特异性结合分子
JP2019517952A JP2019536437A (ja) 2016-10-03 2017-10-03 Ｈｐｖ特異的結合分子
CA3037086A CA3037086A1 (en) 2016-10-03 2017-10-03 Hpv-specific binding molecules
KR1020197012569A KR20190062505A (ko) 2016-10-03 2017-10-03 Hpv-특이적 결합 분자
AU2017338827A AU2017338827B2 (en) 2016-10-03 2017-10-03 HPV-specific binding molecules
MX2019003768A MX2019003768A (es) 2016-10-03 2017-10-03 Moleculas de enlace especificas de hpv.
US17/384,589 US20210363258A1 (en) 2016-10-03 2021-07-23 Hpv-specific binding molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662403661P 2016-10-03 2016-10-03
US62/403,661 2016-10-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/338,452 A-371-Of-International US11072660B2 (en) 2016-10-03 2017-10-03 HPV-specific binding molecules
US17/384,589 Continuation US20210363258A1 (en) 2016-10-03 2021-07-23 Hpv-specific binding molecules

Publications (1)

Publication Number Publication Date
WO2018067618A1 true WO2018067618A1 (en) 2018-04-12

Family

ID=60153464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/055005 Ceased WO2018067618A1 (en) 2016-10-03 2017-10-03 Hpv-specific binding molecules

Country Status (10)

Country Link
US (2) US11072660B2 (enExample)
EP (1) EP3519433A1 (enExample)
JP (1) JP2019536437A (enExample)
KR (1) KR20190062505A (enExample)
CN (1) CN110139873A (enExample)
AU (1) AU2017338827B2 (enExample)
CA (1) CA3037086A1 (enExample)
MA (1) MA46354A (enExample)
MX (1) MX2019003768A (enExample)
WO (1) WO2018067618A1 (enExample)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019005897A1 (en) * 2017-06-28 2019-01-03 Regeneron Pharmaceuticals, Inc. HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
WO2019070541A1 (en) * 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
WO2019204683A1 (en) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
US20200010804A1 (en) * 2017-02-06 2020-01-09 National Cancer Center Japan Novel t-cell receptor
WO2020112815A1 (en) * 2018-11-27 2020-06-04 Duke University Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
WO2020227483A1 (en) * 2019-05-08 2020-11-12 Bluebird Bio, Inc. Engineered t cells
US20210155941A1 (en) * 2018-06-22 2021-05-27 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
WO2022099032A1 (en) * 2020-11-06 2022-05-12 Bioventures, Llc T cells and bifunctional protein against human papillomavirus
US20220168346A1 (en) * 2019-03-04 2022-06-02 University Health Network T cell receptors and methods of use thereof
EP3833364A4 (en) * 2018-08-11 2022-07-13 Tcrcure Biopharma Corp. MODIFIED DUAL-FUNCTION T LYMPHOCYTES WITH HPV E6 SPECIFICITY AND PD-1 BLOCKADE
US11427624B2 (en) * 2017-06-20 2022-08-30 Immunocore Limited T cell receptors
US11471489B2 (en) 2018-04-05 2022-10-18 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
WO2023002204A1 (en) * 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
WO2023077100A1 (en) * 2021-10-29 2023-05-04 Yafei Hou T cell receptor recognizing r175h mutation in p53 and its application
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
US20230365649A1 (en) * 2020-10-02 2023-11-16 The Usa, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
AU2022268348B2 (en) * 2021-11-10 2024-01-18 Tscan Therapeutics, Inc. Binding proteins recognizing hpv16 e7 antigen and uses thereof
WO2024148183A3 (en) * 2023-01-04 2024-08-15 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer
WO2024148178A3 (en) * 2023-01-04 2024-08-15 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer
US12139526B2 (en) 2015-12-03 2024-11-12 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
EP4384543A4 (en) * 2021-09-07 2025-06-11 Corregene Biotechnology Co., Ltd. ANTIGEN-BINDING PROTEINS AND USES THEREOF
US12344654B2 (en) 2019-03-27 2025-07-01 Medigene Immunotherapies Gmbh Mage A4 T cell receptors
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
GB201915359D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的t细胞受体及其编码序列
WO2021155518A1 (en) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Anti-hpv t cell receptors and engineered cells
CN113321726B (zh) * 2020-02-28 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
WO2021254458A1 (zh) * 2020-06-17 2021-12-23 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的高亲和力t细胞受体
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
KR20230104220A (ko) * 2020-11-05 2023-07-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Egfr 항원을 표적화하는 조작된 t 세포 수용체 및 사용 방법
CN114539385A (zh) * 2020-11-26 2022-05-27 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的tcr
CN112480239B (zh) * 2020-12-02 2022-06-07 中国科学院微生物研究所 人乳头瘤病毒特异性t细胞受体及其抗肿瘤用途
CA3167637A1 (en) * 2020-12-21 2022-06-30 Eric Escobar-Cabrera Stabilized tcr constructs and methods of use
CN114853878A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种针对hpv的高亲和力tcr
US20240108654A1 (en) 2021-03-03 2024-04-04 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
WO2022216574A1 (en) * 2021-04-05 2022-10-13 Janssen Biotech, Inc. Calr and jak2 t-cell receptors
BR112023021034A2 (pt) * 2021-04-14 2023-12-12 Tscan Therapeutics Inc Proteínas de ligação que reconhecem antígeno ha-2 e usos dos mesmos
US20240218053A1 (en) * 2021-04-22 2024-07-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Engineering biologics to hpv oncoproteins
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
CN113754756B (zh) * 2021-09-28 2022-11-01 深圳普瑞金生物药业股份有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
CN113831404B (zh) * 2021-10-14 2023-05-12 深圳大学总医院 应用于疾病治疗的t细胞受体
CA3234897A1 (en) * 2021-10-14 2023-04-20 Kunle Odunsi Compositions and methods for use of recombinant t cell receptors against claudin 6
CN116262779A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法
JP2025523003A (ja) * 2022-07-11 2025-07-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｖｃｙ抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
KR20250114396A (ko) * 2022-11-29 2025-07-29 블루스피어 바이오, 인크. 부 조직적합성 항원 ha-2를 표적으로 하는 t 세포 수용체
AU2024227623A1 (en) * 2023-10-27 2025-05-15 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
WO2025193663A2 (en) * 2024-03-11 2025-09-18 Affini-T Therapeutics, Inc. Compositions and methods for treating neoplasia

Citations (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5087616A (en) 1986-08-07 1992-02-11 Battelle Memorial Institute Cytotoxic drug conjugates and their delivery to tumor cells
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0452342B1 (en) 1988-12-28 1994-11-30 MILTENYI, Stefan Methods and materials for high gradient magnetic separation of biological materials
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
WO1997030087A1 (en) 1996-02-16 1997-08-21 Glaxo Group Limited Preparation of glycosylated antibodies
WO1998053058A1 (en) 1997-05-23 1998-11-26 Gendaq Limited Nucleic acid binding proteins
WO1998053059A1 (en) 1997-05-23 1998-11-26 Medical Research Council Nucleic acid binding proteins
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999018129A1 (en) 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6040177A (en) 1994-08-31 2000-03-21 Fred Hutchinson Cancer Research Center High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")
US6060273A (en) 1992-08-27 2000-05-09 Beiersdorf Ag Multicistronic expression units and their use
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6207453B1 (en) 1996-03-06 2001-03-27 Medigene Ag Recombinant AAV vector-based transduction system and use of same
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
WO2002016536A1 (fr) 2000-08-23 2002-02-28 Kao Corporation Detergent bactericide antisalissures, destine aux surfaces dures
US6355424B1 (en) 1997-12-12 2002-03-12 Digene Corporation Assessment of human papillomavirus-related disease
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
US20020164328A1 (en) 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
WO2003020763A2 (en) 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040109865A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US20040110282A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US20050123546A1 (en) 2003-11-05 2005-06-09 Glycart Biotechnology Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2006000830A2 (en) 2004-06-29 2006-01-05 Avidex Ltd Cells expressing a modified t cell receptor
WO2006037960A2 (en) 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20070116690A1 (en) 2001-12-10 2007-05-24 Lili Yang Method for the generation of antigen-specific lymphocytes
WO2008121420A1 (en) 2007-03-30 2008-10-09 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
WO2010033140A2 (en) 2008-05-06 2010-03-25 Innovative Micro Technology Removable/disposable apparatus for mems particle sorting device
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US20110158957A1 (en) 2009-11-10 2011-06-30 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US20110301073A1 (en) 2010-05-17 2011-12-08 Sangamo Biosciences, Inc. Novel DNA-binding proteins and uses thereof
WO2012048340A2 (en) 2010-10-08 2012-04-12 President And Fellows Of Harvard College High-throughput immune sequencing
WO2012048341A1 (en) 2010-10-08 2012-04-12 President And Fellows Of Harvard College High-throughput single cell barcoding
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8324353B2 (en) 2001-04-30 2012-12-04 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US8339645B2 (en) 2008-05-27 2012-12-25 Canon Kabushiki Kaisha Managing apparatus, image processing apparatus, and processing method for the same, wherein a first user stores a temporary object having attribute information specified but not partial-area data, at a later time an object is received from a second user that includes both partial-area data and attribute information, the storage unit is searched for the temporary object that matches attribute information of the received object, and the first user is notified in response to a match
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
US20130149337A1 (en) 2003-03-11 2013-06-13 City Of Hope Method of controlling administration of cancer antigen
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
WO2013123061A1 (en) 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
US20130287748A1 (en) 2010-12-09 2013-10-31 The Trustees Of The University Of Pennsylvania Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer
WO2013166321A1 (en) 2012-05-03 2013-11-07 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
WO2014031687A1 (en) 2012-08-20 2014-02-27 Jensen, Michael Method and compositions for cellular immunotherapy
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014096803A1 (en) 2012-12-21 2014-06-26 Immunocore Limited Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex
US20140219975A1 (en) 2011-07-29 2014-08-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
WO2014134165A1 (en) 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US20140301990A1 (en) 2013-03-21 2014-10-09 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015009604A1 (en) 2013-07-15 2015-01-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing anti-human papillomavirus antigen t cells
WO2015009606A1 (en) 2013-07-15 2015-01-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 e6 t cell receptors
WO2015018943A2 (en) * 2013-08-08 2015-02-12 Institut Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific cd8+ t-cells in patients with severe erosive oral lichen planus
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
US20150203817A1 (en) 2012-05-25 2015-07-23 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015136001A1 (en) 2014-03-11 2015-09-17 Cellectis Method for generating t-cells compatible for allogenic transplantation
WO2015161276A2 (en) 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2015184228A1 (en) 2014-05-29 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 e7 t cell receptors
WO2016016341A1 (en) 2014-07-29 2016-02-04 Cellectis EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2016044227A1 (en) 2014-09-15 2016-03-24 Abvitro, Inc. High-throughput nucleotide library sequencing
WO2016069283A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in cart cells and uses thereof
US20160208243A1 (en) 2015-06-18 2016-07-21 The Broad Institute, Inc. Novel crispr enzymes and systems
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
AU704601B2 (en) 1994-01-18 1999-04-29 Scripps Research Institute, The Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
EP0781331B1 (en) 1994-08-20 2008-09-03 Gendaq Limited Improvements in or relating to binding proteins for recognition of dna
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
ATE418340T1 (de) 1999-05-06 2009-01-15 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
US7189513B2 (en) 2001-03-23 2007-03-13 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus immunoreactive peptides
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP1708745B1 (en) 2003-12-23 2012-04-18 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
JP2008044848A (ja) 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
US8859218B2 (en) 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
ES2496916T3 (es) 2007-05-31 2014-09-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas
US20090117140A1 (en) 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
KR20090103571A (ko) 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
KR20090125628A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
KR20090125629A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
KR20160015400A (ko) 2008-08-22 2016-02-12 상가모 바이오사이언스 인코포레이티드 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
CN106957361A (zh) 2009-04-20 2017-07-18 阿波维塔公司 Hpv的e6蛋白的特异性抗体及其应用
ES2911246T3 (es) 2009-11-03 2022-05-18 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas
WO2011100058A1 (en) 2010-02-09 2011-08-18 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
DK2993183T3 (da) 2010-02-16 2020-03-30 Oesterreichische Akademie Der Wss Anti-hpv e7-antistoffer
KR101415554B1 (ko) 2010-09-13 2014-07-04 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련 질환 예방 또는 치료용 조성물
EP2567972A1 (en) 2011-09-12 2013-03-13 Adriacell S.p.A. Antibodies against E7 protein of Human Papilloma Virus (HPV)
ES2607148T3 (es) 2012-05-08 2017-03-29 The Johns Hopkins University Métodos y composiciones para infusión de poblaciones seleccionadas de linfocitos alogénicos con prendimiento transitorio para tratar cáncer
AU2014265331B2 (en) 2013-05-15 2019-12-05 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
CN103342738B (zh) 2013-07-24 2015-02-18 广州恒上医药技术有限公司 人乳头瘤病毒e6蛋白可诱发同源蛋白间交叉反应性抗体的精细表位肽
AU2014342020C1 (en) 2013-10-31 2019-09-05 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
WO2015143558A1 (en) 2014-03-27 2015-10-01 British Columbia Cancer Agency Branch T-cell epitope identification
CA2979493A1 (en) 2015-03-16 2016-09-22 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
WO2017011519A1 (en) 2015-07-13 2017-01-19 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
JP2018536436A (ja) 2015-12-04 2018-12-13 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
ES2983043T3 (es) 2015-12-18 2024-10-21 Sangamo Therapeutics Inc Alteración dirigida del receptor de células T
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
RU2020135968A (ru) 2018-04-05 2022-05-06 Джуно Терапьютикс, Инк. T-клеточные рецепторы и модифицированные клетки, экспрессирующие

Patent Citations (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5087616A (en) 1986-08-07 1992-02-11 Battelle Memorial Institute Cytotoxic drug conjugates and their delivery to tumor cells
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0452342B1 (en) 1988-12-28 1994-11-30 MILTENYI, Stefan Methods and materials for high gradient magnetic separation of biological materials
US5468614A (en) 1990-01-24 1995-11-21 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US6060273A (en) 1992-08-27 2000-05-09 Beiersdorf Ag Multicistronic expression units and their use
US6040177A (en) 1994-08-31 2000-03-21 Fred Hutchinson Cancer Research Center High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
WO1997030087A1 (en) 1996-02-16 1997-08-21 Glaxo Group Limited Preparation of glycosylated antibodies
US6207453B1 (en) 1996-03-06 2001-03-27 Medigene Ag Recombinant AAV vector-based transduction system and use of same
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
WO1998053060A1 (en) 1997-05-23 1998-11-26 Gendaq Limited Nucleic acid binding proteins
WO1998053059A1 (en) 1997-05-23 1998-11-26 Medical Research Council Nucleic acid binding proteins
WO1998053058A1 (en) 1997-05-23 1998-11-26 Gendaq Limited Nucleic acid binding proteins
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999018129A1 (en) 1997-10-02 1999-04-15 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6355424B1 (en) 1997-12-12 2002-03-12 Digene Corporation Assessment of human papillomavirus-related disease
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
WO2002016536A1 (fr) 2000-08-23 2002-02-28 Kao Corporation Detergent bactericide antisalissures, destine aux surfaces dures
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
US20020164328A1 (en) 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7446191B2 (en) 2001-04-11 2008-11-04 City Of Hope DNA construct encoding CE7-specific chimeric T cell receptor
US7354762B2 (en) 2001-04-11 2008-04-08 City Of Hope Method for producing CE7-specific redirected immune cells
US7265209B2 (en) 2001-04-11 2007-09-04 City Of Hope CE7-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US8324353B2 (en) 2001-04-30 2012-12-04 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
WO2003020763A2 (en) 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20070116690A1 (en) 2001-12-10 2007-05-24 Lili Yang Method for the generation of antigen-specific lymphocytes
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040110282A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
US20040109865A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US20130149337A1 (en) 2003-03-11 2013-06-13 City Of Hope Method of controlling administration of cancer antigen
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US20050123546A1 (en) 2003-11-05 2005-06-09 Glycart Biotechnology Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2006000830A2 (en) 2004-06-29 2006-01-05 Avidex Ltd Cells expressing a modified t cell receptor
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US7855275B2 (en) 2004-09-23 2010-12-21 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2006037960A2 (en) 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2537416A1 (en) 2007-03-30 2012-12-26 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2008121420A1 (en) 2007-03-30 2008-10-09 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
US20110003380A1 (en) 2007-12-07 2011-01-06 Stefan Miltenyi Sample Processing System and Methods
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
WO2010033140A2 (en) 2008-05-06 2010-03-25 Innovative Micro Technology Removable/disposable apparatus for mems particle sorting device
US8339645B2 (en) 2008-05-27 2012-12-25 Canon Kabushiki Kaisha Managing apparatus, image processing apparatus, and processing method for the same, wherein a first user stores a temporary object having attribute information specified but not partial-area data, at a later time an object is received from a second user that includes both partial-area data and attribute information, the storage unit is searched for the temporary object that matches attribute information of the received object, and the first user is notified in response to a match
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US20150164954A1 (en) 2009-11-10 2015-06-18 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US20110158957A1 (en) 2009-11-10 2011-06-30 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US20110301073A1 (en) 2010-05-17 2011-12-08 Sangamo Biosciences, Inc. Novel DNA-binding proteins and uses thereof
WO2012048341A1 (en) 2010-10-08 2012-04-12 President And Fellows Of Harvard College High-throughput single cell barcoding
WO2012048340A2 (en) 2010-10-08 2012-04-12 President And Fellows Of Harvard College High-throughput immune sequencing
US8911993B2 (en) 2010-12-09 2014-12-16 The Trustees Of The University Of Pennsylvania Compositions for treatment of cancer
US20130287748A1 (en) 2010-12-09 2013-10-31 The Trustees Of The University Of Pennsylvania Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US20140219975A1 (en) 2011-07-29 2014-08-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
WO2013123061A1 (en) 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
WO2013166321A1 (en) 2012-05-03 2013-11-07 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
US20150203817A1 (en) 2012-05-25 2015-07-23 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
WO2014031687A1 (en) 2012-08-20 2014-02-27 Jensen, Michael Method and compositions for cellular immunotherapy
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
WO2014096803A1 (en) 2012-12-21 2014-06-26 Immunocore Limited Method for predicting the off-target biding of a peptide which binds to a target peptide presented by a major histocompatibility complex
WO2014134165A1 (en) 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US20140301990A1 (en) 2013-03-21 2014-10-09 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015009604A1 (en) 2013-07-15 2015-01-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing anti-human papillomavirus antigen t cells
WO2015009606A1 (en) 2013-07-15 2015-01-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 e6 t cell receptors
WO2015018943A2 (en) * 2013-08-08 2015-02-12 Institut Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific cd8+ t-cells in patients with severe erosive oral lichen planus
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
WO2015136001A1 (en) 2014-03-11 2015-09-17 Cellectis Method for generating t-cells compatible for allogenic transplantation
US20170016025A1 (en) 2014-03-11 2017-01-19 Cellectis Method for generating t-cells compatible for allogenic transplantation
WO2015161276A2 (en) 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2015184228A1 (en) 2014-05-29 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 e7 t cell receptors
WO2016016341A1 (en) 2014-07-29 2016-02-04 Cellectis EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
WO2016044227A1 (en) 2014-09-15 2016-03-24 Abvitro, Inc. High-throughput nucleotide library sequencing
WO2016069283A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in cart cells and uses thereof
US20160208243A1 (en) 2015-06-18 2016-07-21 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor

Non-Patent Citations (106)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", JOHN WILEY & SONS
"Remington: The Science and Practice of Pharmacy, 21st ed.", 1 May 2005, LIPPINCOTT WILLIAMS & WILKINS
"The T Cell Factsbook, 2nd ed.", 2001, LEFRANC AND LEFRANC ACADEMIC PRESS
ALONSO-CAMINO ET AL., MOL THER NUCL ACIDS, vol. 2, 2013, pages e93
ANGELIKA B. RIEMER ET AL: "A Conserved E7-derived Cytotoxic T Lymphocyte Epitope Expressed on Human Papillomavirus 16-transformed HLA-A2 + Epithelial Cancers", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 38, 17 September 2010 (2010-09-17), pages 29608 - 29622, XP055207597, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.126722 *
BAE ET AL., BIOINFORMATICS, 2014
BORIS-LAWRIE; TEMIN, CUR. OPIN. GENET. DEVELOP., vol. 3, 1993, pages 102 - 109
BRASH ET AL., MOL. CELL BIOL., vol. 7, 1987, pages 2031 - 2034
BURNS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 8033 - 8037
CARLENS ET AL., EXP HEMATOL, vol. 28, no. 10, 2000, pages 1137 - 46
CAVALIERI ET AL., BLOOD, vol. 102, no. 2, 2003, pages 497 - 505
CHERVIN ET AL., J IMMUNOL METHODS, vol. 339, 2008, pages 175 - 84
CHICAYBAM ET AL., PLOS ONE, vol. 8, no. 3, 2013, pages e60298
CHO ET AL., LAB CHIP, vol. 10, 2010, pages 1567 - 1573
CHOTHIA ET AL., EMBO J., vol. 7, 1988, pages 3745
CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196
CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
COLIGAN, J. E. ET AL.: "Current Protocols in Immunology", 1999, JOHN WILEY & SONS, INC.
COOPER ET AL., BLOOD, vol. 101, 2003, pages 1637 - 1644
DAVILA ET AL., PLOS ONE, vol. 8, no. 4, 2013, pages e61338
DE CASTRO ET AL., NUCLEIC ACIDS RES., vol. 34, 1 July 2006 (2006-07-01), pages W362 - 5
DE FELIPE, GENETIC VACCINES AND THER., vol. 2, 2004, pages 13
DEFELIPE ET AL., TRAFFIC, vol. 5, 2004, pages 616 - 626
ENDO ET AL., BIOTECHNOL. ADV., vol. 21, 2003, pages 695 - 713
FEDOROV ET AL., SCI. TRANSL. MEDICINE, vol. 5, no. 215, December 2013 (2013-12-01)
FLATMAN ET AL., J. CHROMATOGR., vol. B 848, 2007, pages 79 - 87
FU ET AL., NAT BIOTECHNOL, 2014
GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414
GODIN ET AL., J BIOPHOTON., vol. 1, no. 5, 2008, pages 355 - 376
HAGA-FRIEDMAN ET AL., JOURNAL OF IMMUNOLOGY, vol. 188, 2012, pages 5538 - 5546
HEIGWER ET AL., NAT METHODS, vol. 11, no. 2, 2014, pages 122 - 3
HERMAN ET AL., J. IMMUNOLOGICAL METHODS, vol. 285, no. 1, 2004, pages 25 - 40
HO ET AL., J. IMMUNOL. METHODS, vol. 310, no. 1-2, pages 40 - 52
HOLLER ET AL., NAT IMMUNOL, vol. 4, 2003, pages 55 - 62
HOLLER ET AL., PROC NATL ACAD SCI USA, vol. 97, 2000, pages 5387 - 92
HOOGENBOOM ET AL.: "Methods in Molecular Biology", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37
HSU ET AL., NAT BIOTECHNOL, vol. 31, no. 9, pages 827 - 32
HUANG ET AL., METHODS MOL BIOL, vol. 506, 2009, pages 115 - 126
HUDECEK ET AL., CLIN. CANCER RES., vol. 19, 2013, pages 3153
JANEWAY ET AL.: "Immunobiology: The Immune System in Health and Disease, 3rd ed.", 1997, CURRENT BIOLOGY PUBLICATIONS, pages: 4,33
JOHNSTON, NATURE, vol. 346, 1990, pages 776 - 777
JORES ET AL., PROC. NAT'L ACAD. SCI. U.S.A., vol. 87, 1990, pages 9138
K. NILGES ET AL: "Human Papillomavirus Type 16 E7 Peptide-Directed CD8+ T Cells from Patients with Cervical Cancer Are Cross-Reactive with the Coronavirus NS2 Protein", JOURNAL OF VIROLOGY., vol. 77, no. 9, 1 May 2003 (2003-05-01), US, pages 5464 - 5474, XP055437988, ISSN: 0022-538X, DOI: 10.1128/JVI.77.9.5464-5474.2003 *
KABAT ET AL.: "Sequences of Proteins of Immunological Interest, 5th ed.", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688
KERRY ET AL., IMMUNOLOGY, vol. 114, 2005, pages 44 - 52
KERRY ET AL., J IMMUNOL, vol. 171, 2003, pages 4493 - 4503
KERRY ET AL., J. IMMUNOLOGY, vol. 171, no. 9, 2003, pages 4493 - 4503
KINDT ET AL.: "Kuby Immunology, 6th ed.", 2007, W.H. FREEMAN AND CO., pages: 91
KLEBANOFF ET AL., J IMMUNOTHER., vol. 35, no. 9, 2012, pages 651 - 660
KOCHENDERFER ET AL., J. IMMUNOTHERAPY, vol. 32, no. 7, 2009, pages 689 - 702
KOSTE ET AL., GENE THERAPY, 3 April 2014 (2014-04-03)
KOTB, CLINICAL MICROBIOLOGY REVIEWS, vol. 8, 1995, pages 411 - 426
KUBALL ET AL., BLOOD, vol. 109, 2007, pages 2331 - 2338
LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55
LEFRANC ET AL., DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, vol. 2, 2003, pages 55 - 77
LI ET AL., NAT BIOTECHNOL, vol. 23, 2005, pages 349 - 54
LI ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215
LLOYD ET AL., FRONTIERS IN IMMUNOLOGY, vol. 4, no. 221, 2013, pages 1 - 7
LUPTON S. D. ET AL., MOL. AND CELL BIOL., vol. 11, no. 6, 1991
MALI ET AL., SCIENCE, vol. 339, no. 6121, 2013, pages 823 - 826
MANURI ET AL., HUM GENE THER, vol. 21, no. 4, 2010, pages 427 - 437
MILLER, A. D., HUMAN GENE THERAPY, vol. 1, 1990, pages 5 - 14
MILLER; ROSMAN, BIOTECHNIQUES, vol. 7, 1989, pages 980 - 990
MULLEN ET AL., PROC. NATL. ACAD. SCI. USA., vol. 89, 1992, pages 33
OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249
OSBORN ET AL., MOL. THER., vol. 24, no. 3, 2016, pages 570 - 581
OSOL A: "Remington's Pharmaceutical Sciences, 16th ed.", 1980
PARK ET AL., TRENDS BIOTECHNOL., no. 11, 29 November 2011 (2011-11-29), pages 550 - 557
PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887
RIDDELL ET AL., HUMAN GENE THERAPY, vol. 3, 1992, pages 319 - 338
RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545
ROBBINS ET AL., J IMMUNOLOGY, vol. 180, no. 9, 2008, pages 6116 - 6131
ROSENBERG, NAT REV CLIN ONCOL., vol. 8, no. 10, 2011, pages 577 - 85
S. A. BROOKS AND U. SCHUMACHER: "Methods in Molecular Medicine, vol. 58: Metastasis Research Protocols, Vol. 2: Cell Behavior In Vitro and In Vivo", vol. 58, HUMANA PRESS INC., pages: 17 - 25
SADELAIN ET AL., CANCER DISCOV., vol. 3, no. 4, April 2013 (2013-04-01), pages 388 - 398
SANDER; JOUNG, NATURE BIOTECHNOLOGY, vol. 32, no. 4, pages 347 - 355
SANJANA ET AL., NAT. METHODS, vol. 11, 2014, pages 783 - 4
SCARPA ET AL., VIROLOGY, vol. 180, 1991, pages 849 - 852
SCATCHARD ET AL., ANN. N.Y. ACAD. SCI., vol. 51, 1949, pages 660
SCHLUETER, C. J. ET AL., J. MOL. BIOL., vol. 256, 1996, pages 859
See also references of EP3519433A1
SHARMA ET AL., MOLEC THER NUCL ACIDS, vol. 2, 2013, pages e74
SITARAMAN ET AL., METHODS MOL. BIOL., vol. 498, 2009, pages 229 - 44
SPIRIN, TRENDS BIOTECHNOL., vol. 22, 2004, pages 538 - 45
SWARTS, NATURE, vol. 507, no. 7491, 2014, pages 258 - 261
SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467
TANG ET AL., AM J TRANSL RES., vol. 7, no. 3, 2015, pages 460 - 473
TERAKURA ET AL., BLOOD, vol. 1, 2012, pages 72 - 82
TERAKURAET, BLOOD, vol. 1, 2012, pages 72 - 82
THEMELI ET AL., NAT BIOTECHNOL., vol. 31, no. 10, 2013, pages 928 - 933
TORIKAWA ET AL., BLOOD, vol. 119, 2012, pages 5697 - 5705
TSUKAHARA ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 438, no. 1, 2013, pages 84 - 9
TURTLE ET AL., CURR. OPIN. IMMUNOL., vol. 24, no. 5, October 2012 (2012-10-01), pages 633 - 39
VAN TEDELOO ET AL., GENE THERAPY, vol. 7, no. 16, 2000, pages 1431 - 1437
VERHOEYEN ET AL., METHODS MOL BIOL., vol. 506, 2009, pages 97 - 114
WADWA ET AL., J. DRUG TARGETING, vol. 3, no. 1 1 1, 1995
WANG ET AL., J IMMUNOTHER., vol. 35, no. 9, 2012, pages 689 - 701
WANG ET AL., J. IMMUNOTHER., vol. 35, no. 9, 2012, pages 689 - 701
WEISS; STOBO, J. EX. MED., vol. 160, no. 5, 1984, pages 1284 - 1299
WIGLER ET AL., CELL, vol. 2, 1977, pages 223
WILSON, SCIENCE, vol. 295, 2002, pages 2103
WOLFF ET AL., CANCER RES., vol. 53, 1993, pages 2560
WU ET AL., CANCER, no. 2, 18 March 2012 (2012-03-18), pages 160 - 75
XIAO A ET AL., BIOINFORMATICS, 2014
YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12139526B2 (en) 2015-12-03 2024-11-12 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
US11603519B2 (en) * 2017-02-06 2023-03-14 National Cancer Center Japan T-cell receptor
US20200010804A1 (en) * 2017-02-06 2020-01-09 National Cancer Center Japan Novel t-cell receptor
US11718657B2 (en) * 2017-06-20 2023-08-08 Immunocore Limited T cell receptors
US11427624B2 (en) * 2017-06-20 2022-08-30 Immunocore Limited T cell receptors
US12018062B2 (en) 2017-06-20 2024-06-25 Immunocore Limited T cell receptors
US12115216B2 (en) 2017-06-28 2024-10-15 Regeneron Pharmaceuticals, Inc. Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
US11559576B2 (en) 2017-06-28 2023-01-24 Regeneran Pharmaceuticals, Inc. Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
US10806780B2 (en) 2017-06-28 2020-10-20 Regeneron Pharmaceuticals, Inc. Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
WO2019005897A1 (en) * 2017-06-28 2019-01-03 Regeneron Pharmaceuticals, Inc. HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
JP2020537515A (ja) * 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
JP2023099142A (ja) * 2017-10-03 2023-07-11 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
CN111954679A (zh) * 2017-10-03 2020-11-17 朱诺治疗学股份有限公司 Hpv特异性结合分子
EP4215543A3 (en) * 2017-10-03 2023-10-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2019070541A1 (en) * 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
US11471489B2 (en) 2018-04-05 2022-10-18 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
US12202877B2 (en) 2018-04-19 2025-01-21 Board Of Regents, The University Of Texas System T cell receptors with mage-B2 specificity and uses thereof
WO2019204683A1 (en) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
US20210155941A1 (en) * 2018-06-22 2021-05-27 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
EP3833364A4 (en) * 2018-08-11 2022-07-13 Tcrcure Biopharma Corp. MODIFIED DUAL-FUNCTION T LYMPHOCYTES WITH HPV E6 SPECIFICITY AND PD-1 BLOCKADE
WO2020112815A1 (en) * 2018-11-27 2020-06-04 Duke University Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
US12139523B2 (en) 2018-11-27 2024-11-12 Duke University Anti-LMP2 TCR-T cell therapy for the treatment of EBV-associated cancers
US20220168346A1 (en) * 2019-03-04 2022-06-02 University Health Network T cell receptors and methods of use thereof
US12344654B2 (en) 2019-03-27 2025-07-01 Medigene Immunotherapies Gmbh Mage A4 T cell receptors
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
WO2020227483A1 (en) * 2019-05-08 2020-11-12 Bluebird Bio, Inc. Engineered t cells
US20230365649A1 (en) * 2020-10-02 2023-11-16 The Usa, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
WO2022099032A1 (en) * 2020-11-06 2022-05-12 Bioventures, Llc T cells and bifunctional protein against human papillomavirus
WO2023002204A1 (en) * 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
EP4384543A4 (en) * 2021-09-07 2025-06-11 Corregene Biotechnology Co., Ltd. ANTIGEN-BINDING PROTEINS AND USES THEREOF
WO2023077100A1 (en) * 2021-10-29 2023-05-04 Yafei Hou T cell receptor recognizing r175h mutation in p53 and its application
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
AU2022268348B2 (en) * 2021-11-10 2024-01-18 Tscan Therapeutics, Inc. Binding proteins recognizing hpv16 e7 antigen and uses thereof
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
WO2024148183A3 (en) * 2023-01-04 2024-08-15 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer
WO2024148178A3 (en) * 2023-01-04 2024-08-15 Board Of Regents, The University Of Texas System T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer

Also Published As

Publication number Publication date
JP2019536437A (ja) 2019-12-19
EP3519433A1 (en) 2019-08-07
US11072660B2 (en) 2021-07-27
CA3037086A1 (en) 2018-04-12
US20210363258A1 (en) 2021-11-25
CN110139873A (zh) 2019-08-16
MX2019003768A (es) 2019-06-24
KR20190062505A (ko) 2019-06-05
US20190225692A1 (en) 2019-07-25
AU2017338827B2 (en) 2023-08-31
MA46354A (fr) 2019-08-07
AU2017338827A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
US20210363258A1 (en) Hpv-specific binding molecules
US20230256018A1 (en) T cell receptors and engineered cells expressing same
CN108884140B (zh) 修饰的嵌合受体及相关组合物和方法
AU2016206457B2 (en) Antibodies and chimeric antigen receptors specific for ROR1
AU2018313952B2 (en) Methods and compositions for preparing genetically engineered cells
EP3664820B1 (en) Methods for producing genetically engineered cell compositions and related compositions
EP3766895A1 (en) Methods and compositions for adoptive cell therapy
CA3028002A1 (en) Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
EP3475706A1 (en) Mhc-e restricted epitopes, binding molecules and related methods and uses
CN112041430A (zh) 用于培养细胞的无血清培养基配制品及其使用方法
US20250283037A1 (en) Methods for stimulating and transducing t cells
CN121152813A (zh) 细胞免疫疗法的组合物和方法
HK40045337A (en) Methods and compositions for adoptive cell therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17787729

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3037086

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017338827

Country of ref document: AU

Date of ref document: 20171003

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019517952

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197012569

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017787729

Country of ref document: EP